Contents
Welcome Message...... 2
Organizing Committee...... 4
Floor Plan ...... 7
Agenda ...... 8
Scientific Program ...... 12
Dec.19th (Sat.) Â 601...... 12 Â 603...... 54 Â Young Doctor Session / Oral Presentation ...... 104
Dec.20th (Sun.) Â 601...... 92 Â 603...... 104 Â Young Doctor Session / Oral Presentation ...... 104
Official Sponsors ...... 136 Welcome Message
Dear olleagues and Fr ends
Welcome to the 6th nternat onal Wor sho on necolog c ncolog o the As an Soc et o necolog c ncolog (AS Wor sho 2020) n a an
As the res dent o AS cord all n te ou to the 6th Interna�onal Work sho on necolog c ncolog o AS h ch ll e held on Decem er 19th and 20th 2020 in CHANG YUNG-FA FOUNDATION Interna�onal Conven�on enter a e a an. AS as esta l shed leaders o a anese and Korean gynecologists in considera�on of the need for an Asian regional society dedicated to gynecologic cancer, and held its first mee�ng in Seoul in 2008. At present, gynecological oncology socie�es from 11 countries and regions have par�ci pated, and it has become a truly unified organiza�on. Six biennial mee�ngs and five interna�onal or sho s ha e een held to date ho e er th s ASGO Workshop 2020 in Taiwan will be the first t me or the congress to e held outs de o a an and orea. h s means that th s or sho ll propel ASGO out of its founders' zone, Japan and Korea, and begin to truly branch out across Asia. he de elo ment o surg cal techn ues and ne treatments n recent ears s remar a le and e must learn and acquire them without delay. Let the exchange of knowledge and experience with our As an colleagues e a s m ol o the AS Wor sho 2020
AS Wor sho 2020 ll arml elcome ou th numerous sc ent c rograms as ell as trad t onal a anese culture. We s ncerel loo or ard to meet ng ou at the 6th nternat onal Wor sho on necolog c ncolog o the As an Soc et o necolog c ncolog n 2020.
S ncerel ours
Daisuke Aoki, M.D., Ph.D. he Pres dent o As an Soc et o necolog c ncolog
2 Dear olleagues
On behalf of the organizing committee, we are honored to cordially invite you to par�cipate in the 6th Interna�onal Workshop on Gyneco log c ncolog o AS (AS Wor sho 2020) h ch ll e held on Decem er 19th 20th n A FA F DA nternat onal on ent on enter a e a an. Due to the D 19 andem c ASGO Workshop 2020 will be hosted in hybrid mee�ng.
ASGO Workshop has been contribu�ng to the research, preven�on and treatment o g necolog cal cancer. S nce commenced n 200 AS has made tremendous rogress ro d ng un ed com rehens e medical and surgical care to women with reproduc�ve tract cancers from diagnosis to comple�on of treatment. This year we will have speeches on topics covering in a variety of fields from dis�n gu shed s ea ers n As a and all o the orld to d scuss the er latest ad ances n necolog cal ncolog treatment and care.
This is the first �me ASGO Workshop is held outside of Japan and Korea. We believe that ASGO Workshop 2020 will certainly be one of the most valuable �me for all the par�cipants. Your out standing contribu�on and par�cipa�on will be crucial to the success of the conference. We sin cerely look forward to gree�ng you at the 6th Interna�onal Workshop on Gynecologic Oncology n a e .
S ncerel ours
Chih-Ming Ho, M.D.,Ph.D. AS Wor sho 2020 Organizing Commi�ee Chair A Pres dent
3 Organizing Committee
ASGO WORKSHOP
Executive committee members Pres dent Da su e Ao ( a an) Secretar eneral usu e o a ash ( a an) Pres dent lect reasurer ae Weon m ( orea) mmed ate Past Pres dent ee Sug u ( orea) Council members Andr Andr ono ( ndones a) Pres dent Da su e Ao ( a an) Du Soo ae ( orea) eer a hatla ( nd a) aren han ( ong ong) ren Dom ngo (Ph l nes) Pres dent lect reasurer ae Weon m ( orea) Seung heol m ( orea) Secretar eneral usu e o a ash ( a an) Suresh umarasam (Mala s a) Masa Manda ( a an) mmed ate Past Pres dent ee Sug u ( orea) Da d SP an (S nga ore) ung ahng Wang ( a an) dem ch Watar ( a an) Sar a an W la la ( ha land) ang ang ( h na) ong u ang ( h na)
Nominating committee members Sh ngo Fu ( a an) osh haru amura ( a an) Soon eom ang ( orea) uo on sh ( a an) oo un am ( orea) ee Sug u ( orea) Scientific Program Committee ung ahng Wang ha r ( a an) ng hang hang ce ha r ( a an) heng ang hou ( a an) Soon en uang ( a an) Wen Sh ung ou ( a an) ao n ( a an) Peng u Wang ( a an) Mu s en u ( a an) ung heng a ( a an) Wen Fang heng ( a an) an Shung eh ( a an) h en s ng u ( a an) Fu Sh ng u ( a an) Tze-Ho Chen ( a an) a a u nomoto ( a an) m o sh ma ( a an) ong Man m ( orea) ae Weon m ( orea)
TAGO Pres dent h h M ng o ( atha eneral os tal) Execu�ve Director ung ahng Wang ( a tung Mac a Memor al os tal) Peng u Wang ( a e eterans eneral os tal) ung sueh hou ( hang ung Memor al os tal and hang ung n ers t ollege o Med c ne) ng hang hang ( hang ung Memor al os tal and hang ung n ers t ollege o Med c ne) Wen-Fang Cheng (Na�onal Taiwan University Collage of Medicine) M ng Sh en en ( a e eterans eneral os tal) D rector Tang-Yuan Chu (Hualien Tzu Chi Hospital) Mu s en u ( r Ser ce eneral os tal) Cheng-Yang Chou (Na�onal Cheng Kung University College of Medicine) ao h ng ung ( h na Med cal n ers t and h na Med cal n ers t os tal) ae Fang u ( a e eterans eneral os tal) Keng-Fu Hsu (Na�onal Cheng Kung University College of Medicine) Bor-Ching Sheu (Na�onal Taiwan University Hospital) en hen ( a e eterans eneral os tal) Pao-Ling Torng (Na�onal Taiwan University Hospital) h a en uang ( atha eneral os tal) Wen Sh ung ou ( aohs ung eterans eneral os tal) Fu Sh ng u (Sho h an Memor al os tal) Hung-Cheng Lai (Transla�onal Epigene�c Center, Shuang Ho Hospital) uan ee an ( uan s eneral os tal) Execu�ve Supervisor an Shung eh ( h na Med cal n ers t ollege o Med c ne) Su er sor ua s Wu ( a e eterans eneral os tal) ao n ( aohs ung hang ung Memor al os tal) Soon en uang ( h Me Med cal enter) An en h ang ( aohs ung eterans eneral os tal) a M n heng ( ao eneral os tal) Chang-Yao Hsieh (Na�onal Taiwan University College of Medicine) Secretar eneral h h ong hang (Mac a Memor al os tal) ce Secretar eneral hen suan Wu ( aohs ung hang ung Memor al os tal) h en s ng u ( a chung eterans eneral os tal) n hang ( h na Med cal n ers t os tal) Tze-Ho Chen (Changhua Chris�an Hospital) Tze-Chien Chen (Mackay Memorial Hospital) u hen (Na�onal Taiwan University College of Medicine)
6 Floor Plan
張榮發基金會國際會議中心 6樓 配置圖僅供參考，攤位大小以實際尺寸為準 配置圖僅供參考，攤位大小以實際尺寸為準 張榮發基金會國際會議中心 6樓
601 VIP1 601 VIP2 VIP1 會議室 VIP2 大會報到處
大會報到處 點心區 點心區 學分簽到處 試片區 學分簽到處
603603 會議室會議室
A01 A01AZ AZ 610 A02 A03 A04 A05 A02羅氏 A03武田 A04東洋 A05百特 羅氏 武田 東洋 百特
Agenda
Date: December 19th 2020 (Sat.)
601 Room Topic Speaker Moderator 09 20 09 2 en ng remar s o AS Pres dent Dr. Da su e Ao 09 2 09 30 en ng remar s o S ce Pres dent Dr. ae Weon m 09 30 09 3 en ng remar s o A Pres dent Dr. h h M ng o 09 3 09 0 Time for Taiwan - My Beau�ful Island Prac�ce in gynecologic oncology during Covid 19 pandemics orea Dr. So om ang a an Dr. usu e o a ash 09 0 10 20 Dr. ung heng a nd a Dr. eer a hatla Mala s a Dr. Suresh umarasam a an Dr. heng hang hang
o el mmunothera or ad anced endometr al cancer 10 20 10 0 Dr. h a en uang Dr. ee Wen uang ( Industrial sec�on)
date on cer cal cancer surger a dom nal or 10 0 11 10 Dr. Se m Dr. ung ahng Wang m n mall n as e a roach 11 10 11 20 rea Update on treatment of metasta�c or relapsed 11 20 11 0 Dr. Pao ng orng Dr. Wen Fang heng cer cal cancer
ad cal trachelectom or earl stage cer cal 11 0 12 00 Dr. a a u nomoto Dr. ua s Wu cancer at 15-17 weeks of gesta�on 12 00 13 00 unch Anatomic dissec�on in nerve-sparing radical 13 00 13 20 Dr. Wu hou n Dr. u a h sterectom or cer cal cancer
Molecular characteriza�on and its clinical 13 20 13 0 Dr. ng hang hang Dr. Sh h hu o implica�on in endometrial cancer 13 0 13 0 rea Two-step sen�nel lymph node mapping strategy 13 0 1 10 Dr. Sang Wun m Dr. h ou hung uan n endometr al cancer stag ng
Ad u ant thera or earl endometr al cancer 1 10 1 30 Dr. m o sh ma Dr. a M n heng hen and ho and h
601 Room Topic Speaker Moderator 1 30 1 0 rea Treatment for stage 4 and metasta�c 1 0 1 00 Dr. ee Seung m Dr. h ong ue a endometr al cancer
1 00 1 20 ar an cancer surger 1st and 2nd debulking opera�on Dr. Masa Manda Dr. ung sueh hou
1 20 1 30 rea Personalized medicine- Maintenance therapy 1 30 1 0 Dr. a u se Dr. h a en uang n o ar an cancer
1 0 16 10 reatment or rela sed o ar an cancer Dr. eng heng su Dr. Pao ng orng
16 10 16 20 rea urrent role o m n mall n as e surger or 16 20 16 0 Dr. en hen Dr. Peng u Wang o ar an cancer
Big data analysis in popula�onal gynecologic 16 0 1 00 Dr. heng ao Dr. Wen Sh ung ou oncolog methods and outcomes 1 00 1 10 rea
1 10 1 30 Shared decision-making in real prac�ce Dr. hen suan Wu Dr. ao n
he th ASGO Biennial Mee�ng 1 30 1 3 See ou n ha land
9 Date: December 19th 2020 (Sat.) 603 Room Topic Speaker Moderator 09 20 09 2 en ng remar s o AS Pres dent Dr. Da su e Ao 09 2 09 30 en ng remar s o S ce Pres dent Dr. ae Weon m 09 30 09 3 en ng remar s o A Pres dent Dr. h h M ng o 09 3 09 0 Time for Taiwan - My Beau�ful Island Prac�ce in gynecologic oncology during Covid 19 pandemics orea Dr. So om ang a an Dr. usu e o a ash 09 0 10 20 Dr. ung heng a nd a Dr. eer a hatla Mala s a Dr. Suresh umarasam a an Dr. heng hang hang 10 20 10 0 Prec s on med c ne n g necolog c cancers Dr. Shu en hen Dr. or h ng Sheu Mechanism targe�ng homologous recombina�on 10 0 11 00 Dr. atsutosh DA Dr. Tze-Ho Chen deficiencies in ovarian cancer 11 00 11 10 rea 11 10 11 30 Biomarker and gene�c tes�ng for PARP inhibitor Dr. a M n heng Dr. M ng Sh en en Safety and QoL of Avas�n in Gyn cancer 11 30 12 00 Dr. ung sueh hou Dr. u M n e (Industrial sec�on) 12 00 12 30 S 10th Council mee�ng 12 30 13 00 A 9th Council mee�ng ol ng area o ma ntenance thera n recurrent 13 00 13 30 Dr. ng heng h ang Dr. ae Fang u ovarian cancer (Industrial sec�on) 13 30 13 0 PA P nh tors n o ar an cancer Dr. Sh h en su Dr. ao h ng ung 13 0 1 00 rea 1 00 1 20 mmuno ncolog n necolog cal Mal gnanc es Dr. en ue hen Dr. eng Fu su omar ers n mmuno oncolog or 1 20 1 0 Dr. Da d SP an Dr. ng hang hang necolog cal ancers 1 0 1 0 rea 1 0 1 10 ell thera n g necolog c cancers Dr. n hang Dr. an Shung eh
ra ected n n g necolog cal cancer 1 10 1 0 Dr. Wen Sh ung ou Dr. Fu Sh ng u (Industrial sec�on)
1 0 1 0 rea What's next for PARP inhibitors? PARPi resistance 1 0 16 20 and a s to o ercome Dr. h ong ue a Dr. uan ee an (Industrial sec�on) 16 20 1 0 Young doctor Session / Oral Presenta�on Dr. heng ang hou he th ASGO Biennial Mee�ng 1 0 1 See ou n ha land
10 Date: December 20th 2020 (Sun.)
601 Room Topic Speaker Moderator
he r g n o ar an ancer S ec es and 09 30 10 00 Dr. e M ng Sh h Dr. h h M ng o Precancerous andsca e
Iden�fica�on of BRCAness in clinical daily prac�ce: 10 00 10 30 Dr. h en Feng Dr. ang uan hu genes, phenotypes, and cases ( Industrial sec�on)
10 30 10 0 rea
Op�mize the chemotherapy in pla�num- 10 0 11 10 sensi�ve recurrent ovarian cancer and real world data Dr. ung sueh hou Dr. uan hong hao in Taiwan ( Industrial sec�on)
11 10 11 30 date n the treatment or uter ne sarcoma Dr. M o M am Dr. en hen
11 30 11 0 rea
a arosco c h ertherm c ntra er toneal 11 0 12 00 Dr. uan en uang Dr. Mu s en u chemothera
12 00 12 20 ancer dur ng Pregnac a g challenge Dr. Sar a an W la la Dr. h en s ng u
12 20 12 30 rea
he th ASGO Biennial Mee�ng 12 30 12 3 See ou n ha land
603 Room Topic Moderator
09 30 11 00 Young doctor Session / Oral Presenta�on Dr. Peng u Wang
11 00 11 10 rea
11 10 12 30 Young doctor Session / Oral Presenta�on Dr. Peng u Wang
he th ASGO Biennial Mee�ng 12 30 12 3 See ou n ha land
11 December 19 Sokbom Kang
urrent Pos t on ead enter or necolog c ancer at onal ancer enter Pro essor raduate School o ancer Sc ence and Pol c th 601 Room
December 19 ducat on M.D. .S. Ph.D. Seoul at onal n ers t ollege o Med c ne
Professional Experiences (Top 5): ha r ar an cancer comm ttee orean necolog c ncolog rou th
603 Room d tor al ad sor ournal o necolog c ncolog December 20 th 601 Room December 20 th 603 Room
12 Practice in gynecologic oncology during COVID-19 pandemics in Korea
So om ang
he standard o care n g necolog c cancers has een ne ta l ham ered the D 19 cr s s. As a result at ents and med cal sta s are ac ng un recedented challenges n treat ng cancer. h s cr s s has nterru ted health care del er or man patients with cancer, who often require frequent visits and extensive utilization of the health care s stem to manage the r d sease and treatment com l cat ons. h s ulnera le o ulat on aces an ncreased r s o se ere D 19 n ect on and mortal t ncreased r s ecause o dela ed cancer d agnos s or nterru t on o treatment necess tated se ere acute res rator s ndrome (SA S) o 2 n ect on recaut ons as ell as the dela or nterru t on o the r usual care or other med cal ro lems. ndeed rom Fe ruar to A r l 2020 h ch as the cr t cal er od or D 19 n South orea man cancer at ents experienced delayed treatment. In addition, health care providers are at risk for burnout, exhaustion, and emotional well-being disorders. The situation raised a need among the oncolog commun t or ro ess onal recommendat ons rom a rel a le source to assess the rapidly unfolding information frequently and objectively and place it into context for the care o th s un ue at ent o ulat on. hose recommendat ons co ered ssues o minimizing risk of patients, prioritization of patient care, health care team management, reco er lan and cl n cal research. Man o med cal soc et es announced the r o n gu del nes or management o cancer at ents nclud ng g necolog c cancers n order to e ect el con ront th s terr le s tuat on. o e er those gu del nes cannot e a l ed to e er countr across the glo e ecause o the d erent s tuat ons o D 19.
13 December 19 Yusuke Kobayashi
urrent Pos t on Ass stant Pro essor De artment o stetr cs and necolog e o n ers t School o Med c ne APA th 601 Room
December 19 ducat on 200 2011 raduate School o Med c ne e o n ers t 1996 2003 School o Med c ne su u a n ers t th 603 Room Professional Experiences (Top 5): 2020 Present Ass stant Pro essor De artment o stetr cs and necolog e o n ers t School o Med c ne 2019 Present December 20 Secretar eneral o As an Soc et o necolog c ncolog (AS ) 2019 Present Assoc ate d tor ournal o ar an esearch ( ) 201 Present
th Pr nc al d tor ournal o necolog c ncolog ( ) 601 Room 201 2019 ecturer De artment o stetr cs and necolog e o n ers t School o Med c ne December 20 th 603 Room
1 Practice in gynecologic oncology during COVID-19 pandemics in Japan
usu e o a ash
S nce Decem er 2019 hen the rst case o corona rus d sease 2019 ( D 19) as dent ed n Wuhan h na the n ect on case has ncreased str ngl . n a an as o o em er 26 there ere 136 1 cases o D 19 n ect on 2 021 deaths and 11 032 discharges from hospitals. To prevent the explosive spread of infection and to minimize the num er o se ere atal and the total num er o n ected cases there has een a strong encouragement to a o d the hree s (1. losed s aces th nsu c ent ent lat on 2. ro ded cond t ons th eo le 3. on ersat ons n a short d stance) to reduce the r s s of cluster development. This approach seemed to have prevented the excess strain on the med cal resource. o e er the num er o at ents s ncreas ng th the arr al o nter and t s necessar to recons der the s stem o healthcare del er . We re orted a case n our hos tal here D 19 n ect on as sus ected dur ng the treatment o g necolog cal tumors and a change n treatment as re u red. Along th ocus ng on the control o D 19 n ect on t s also essent al to de elo a ne s stem to manage cancer at ents n th s andem c. n a an the three oncolog soc et es colla orated to d ssem nate med cal ol c es or each t e o cancer. Although the treatment o t ons ar de end ng on the se er t o the e dem c and local and nst tut onal cond t ons the ollo ng three o nts should e cons dered n r nc le 1) lass the cases nto three categor es se ere (l e threaten ng and urgent) moderate (s gn cant dela s rognost c) and m ld ( ost onement o treatment or some t me or select on o another treatment does not s gn cantl change the rognos s) and cons der ost on ng or chang ng the treatment (2) ons der choos ng a treatment that re u res minimal hospital visits or hospitalization if the treatment is equally effective, (3) Consider us ng telemed c ne or ollo u and med cat on onl . ere ll ntroduce the treatment ol c or g necolog cal tumors n th s sess on. he s read o the D 19 e dem c has ra sed eth cal soc al and med cal ssues that cancer specialists have never experienced before. There are several points that we must take into account from a holistic standpoint in order to adjust practice; the extent o the D 19 e dem c n the reg on the hos tal s sa et s stem or ts med cal sta occurrence o D 19 nosocom al n ect ons the med cal resources de oted to D 19 at ents and the degree o mal gnanc and rogress on o each at ent. en dur ng the D 19 e dem c e ha e a res ons l t to ro de a ro r ate treatment to ensure cancer at ents are m n mall d sad antaged and e are re u red to select the most a ro r ate treatment n alance th the care o D 19 at ents.
1 December 19 Neerja Bhatla
urrent Pos t on P F SS D S F A D PA M F S S A th A D A S F M D A S S 601 Room W D D A
December 19 ducat on M S (A MS W D ) 19 2 MD S S A (A MS W D ) 19 F 2000 th
603 Room Professional Experiences (Top 5): FA M M A A MS W D S 19 9 A P S F MM (201 201 ) S A A A A F D A F A PA P S P ( F P ) 201 21) P S D A (201 16) December 20 P S D ASS A F A S S F D A (201 1 ) th 601 Room December 20 th 603 Room
16 Practice in Gynecologic Oncology during COVID-19 pandemic in India
eer a hatla
he D 19 andem c has a ru tl caused ma or changes n management o at ents th g necolog cal mal gnanc es n nd a. A com lete nat onal loc do n rom end March to Ma led to d sru t on n ongo ng treatment as ell as d cult or ne at ents to access cl n cal care. Moreo er there as e er resent concern regard ng sa et rom o d 19 n ect on or oth the at ents and the health ersonnel. n most hos tals a s gn cant ro ort on o the n rastructure and ersonnel ere d erted or o d care lea ng e er hos tal eds and o erat on theatres a a la le or oncolog care. he Assoc at on o naecolog c ncolog sts of India brought out recommendations for prioritizing care during the pandemic, and several u l cat ons addressed the ssue o acce ta le a t ng t mes or re ent e and curat e services. Cases with the highest probability of cure e.g., carcinoma cervix, germ cell tumours, ere to e managed at the earl est r or t at ents th slo gro ng tumours th good tumour olog e.g. lo r s endometr al cancers could e ad sed hormonal thera or 3 months h le h gh r s endometr al cancers ere ad sed surg cal management th n ee s. eoad u ant chemothera ( A ) as a good o t on or management o e thel al o ar an cancer n th s t me ut o ar an cancers l el to e less res ons e to chemothera were recommeded operation at the earliest. Patients already receiving external beam radiation thera ere to e ro ded rach thera at the earl est r or t . Whene er oss le h o ract onat on schedules ere encouraged. Surger es or recurrent cases and r s reduc ng re ent e surg cal thera es ere accorded the lo est surg cal r or t hene er oss le chemothera or rad othera o t ons ere cons dered or recurrence. A num er o onl ne sur e s ha e attem ted to uant the m act o the andem c on the ract ce o g necolog cal oncolog . An anal s s o three sur e s sho ed a decrease n the num er o at ents resent ng cessat on o reg strat on o ne at ents dela n n t at on o treatment. out ne surg cal nter ent ons decreased and onl emergenc surger es ere er ormed n t all . o d test ng cont nues to e mandator r or to surger and the use o ade uate ersonal rotect e e u ment as ensured. n the n t al hase o the andem c m n mal access surger es ere at a halt ut th gro ng e dence the ha e een resumed th recaut ons as recommended nternat onal gu del nes. reatment as de erred n man at ents h le man others ere o ered alternate non surg cal treatments .e. chemothera and rad othera . Ad anced cases o cer cal cancer rece ed h o ract onat on reg mens more o ten. arl stage endometr al cancers ere treated mostl la arotom . Man ere ound to ha e ntra er toneal s read o d sease normall an unusual nd ng. An ncreased num er o cases ere o ered hormonal treatment h le a a t ng surger . n o ar an cancer there as a sh t rom r mar c toreduct on to NACT. The number of cycles of NACT was often increased up to six cycles in many cases with nter al de ul ng surger e ng de erred. elemed c ne ser ces ere set u to ro de re and osto erat e gu dance and reduce n erson hos tal s ts. Follo u rotocols ere mod ed th most ado t ng a less re uent ollo u a roach. o conclude the andem c has had a s gn cant m act on oncolog care the ull m act o h ch ll e no n later.
1 December 19 Suresh Kumarasamy
urrent Pos t on onsultant naecolog cal ncolog st leneagles os tal Penang Mala s a th Ad unct l n cal Pro essor o al ollege o Surgeons n reland n ers t 601 Room ollege Du l n Mala s a am us
December 19 ducat on M S n ers t o M sore nd a (19 ) Masters n stetr cs naecolog n ers t o Mala a (1992) Mem ersh o the o al ollege o stetr c ans naecolog sts ondon (1992) Fello sh n nacolog cal ncolog n ted ngdom (199 ) th
603 Room Fello sh o the o al ollege o stetr c ans naecolog sts ondon (2009) Fello sh o the o al ollege o Ph s c ans o reland Ad undem (2011)
Professional experiences (Top 5): ounc l Mem er As an Soc et o naecolog cal ncolog Mem er ncolog omm ttee As a cean c Federat on o stetr cs naecolog December 20 ha rman naecolog cal ncolog Su comm ttee stetr cal naecolog cal Soc et o Mala s a Pres dent stetr cal naecolog cal Soc et o Mala s a (2012 2013) o Founder As a Pac c P oal t on. th 601 Room December 20 th 603 Room
1 Practice in Gynecological Oncology during Covid-19 pandemic in Malaysia
Suresh umarasam
Mala s a s a m ddle ncome countr n South ast As a th a o ulat on o 32. m ll on. he rst case o o d 19 n Mala s a as an m orted case rom Wuhan on 2 th anuar 2020. he rst Mala s an test ng os t e or o d 19 as re orted on 3rd Fe ruar 2020. As o 22nd o em er 2020 there ha e een con rmed cases o o d 19 th 1 9 reco er es and 335 deaths. 12,843 patients are currently under treatment. It is the country's policy to hospitalize all nd duals th a con rmed o d 19 d agnos s n a go ernment med cal ac l t e en the are as m tomat c. here ha e een three a es o o d 19 cases. he rst a e ended success ull th n less than 2 months. n earl March 2020 a second a e occurred ollo ng a rel g ous meet ng attended o er 16 000 eo le. Mala s a s currentl ac ng a th rd a e ollo ng a surge o cases n late Se tem er 2020. Due to a ra d ncrease n os t e cases and d cult n trac ng the contacts the go ernment o Mala s a m osed a nat on de Mo ement ontrol rder (M ) rom 1 th March to 12th Ma 2020. Dur ng the M se ere restr ct ons o mo ement ere n lace and onl essent al ser ces ere allo ed. W th an m ro ement n the s tuat on a gradual eas ng o restr ct ons resulted n a ond t onal Mo ement ontrol rder ( M ) h ch allo ed most us nesses to o en. h s as ollo ed a eco er Mo ement ontrol rder ( M ) rom 10th une 2020 th urther eas ng o restr ct ons. A surge n cases dur ng the th rd a e resulted n the go ernment re ert ng to the M n most states on 9th o em er 2020. h s s currentl due to run t ll 6th Decem er 2020. For the rst t o ee s o the M all elect e surger as cancelled and onl emergenc surger as carr ed out. Su se uentl sem elect e surger h ch ncluded g naecolog cal cancer surger as commenced. he M n str o ealth ssued gu del nes stat ng that essent al gynaecological services for malignancy should continue without disruption while optimizing un ersal recaut ons. he d rect e also recommended screen ng and test ng o at ents r or to elect e or sem elect e surger . S ec c gu del nes on ho to manage nd dual g naecolog cal mal gnanc es ere not ssued. nd dual g naecolog cal oncolog sts mod ed nternat onal gu del nes and recommendat ons de end ng on the c rcumstances n the r res ect e hos tals and reg ons. n general there as m n mal d sru t on n the adm n strat on o chemothera or rad othera . here as m n mal d sru t on o surger n non co d hos tals. n h r d hos tals ( .e. hos tals treat ng oth co d and non co d at ents) the amount o cancer surger that as oss le de ended on the a a la l t o hos tal eds and o erat ng t me h ch as o ten reduced as ell as the a a la l t o eds. he anaesthet c and g naecolog cal oncolog teams ould d scuss and agree surger could roceed or alternat e treatments eg. neoad u ant chemothera or rad othera ould e the re erred o t on de end ng on the resources a a la le at that o nt o t me. on urgent ollo u a o ntments ere de erred hen there ere l m tat ons n cl n c s ace or o num ers o med cal sta due to rede lo ment to co d ards or uarant ne following exposure to covid positive individuals. In the state of Sabah which severely affected o d 19 account ng or 0 o the countr s cases and 2 3 o the deaths unds ere ro ded the go ernment or surger o u l c hos tal at ents to e carr ed out n r ate hos tals. ra n ng o ello s n some hos tals as a ected less surger e ng carr ed out as ell as some ello s e ng tem orar l de lo ed to hel n the management o co d at ents. he nat onal P acc nat on rogram as also d sru ted hen schools ere closed.
19 December 19 Cheng-Chang Chang
urrent Pos t on De artment ha rman Assoc ate Pro essor o stetr cs and necolog r Ser ce eneral os tal at onal De ense Med cal enter a e th a an. 601 Room
December 19 ducat on Dr. hang rece ed h s MD degree rom the at onal De ense Med cal enter o a an n 199 the Ph.D. degree rom Postgraduate nst tute o Med cal Sc ence at onal De ense Med cal enter o a an n 201 . e ser ced n the a r orne troo as a m l tar med cal doctor (199 1996). e as tra ned n stetr cs and necolog s nce 1996 and th
603 Room necolog c ncolog (2006 2009) n r Ser ce eneral os tal ( S ) a an and ecame an accred ted necolog c ncolog st n 2013.
Professional Experiences (Top 5): 1. n 2003 he ent to hattanooga Women aser and ndosco c enter SA th Dr. u or the tra n ng o emale el c loor reconstruct on. December 20 2. n 200 he also mo ed to Sunn ale A SA or the tra n ng o da nc ro ot c surger and com leted the rst ro ot c g necolog c surger o a an n 200 . 3. Dr. hang s research ocused on the molecular s gnatures a roach to dent no el omar ers and otent al thera eut c targets n e thel al o ar an cancer.
th . e also nterested n the cl n cal a l cat on o art c al ntell gence n g necolog cal 601 Room cancer e aluat on and ntra artum card otocogra h . . n account o the D 19 andem c he has contr uted to re e the SA S o 2 n ect on n the regnanc and re roduct e s stem. December 20 th 603 Room
20 Practice in gynecologic oncology during COVID-19 pandemic in Taiwan
heng hang hang
he 2019 no el corona rus (2019 n o later named SA S o 2) s a andem c d sease orld de. S read ng o se ere acute res rator s ndrome corona rus 2 (SA S o 2) s cont nu ng at a ra d s eed. ll o 26 2020 there ha e een 9 1 313 con rmed cases and 1,404,542 deaths globally. Taiwan is close to mainland China and was expected to have the second-highest number of cases of SARS-CoV-2 due to its proximity to and the number of flights between China. Taiwan's government learned from the 2003 SARS experience and esta l shed a u l c health res onse s stem or ena l ng ra d act ons or the D 19. ll o 26 2020 there ha e een 62 con rmed cases and deaths. nderstand ng the act on tems ( order ontrol ase dent cat on and onta nment) that ere m lemented u c l n a an and assess ng these act ons e ect eness n re ent ng a largescale e dem c ma e nstruct e or other countr es. n our da l cl n cal ract ce e can get a at ent s tra el h stor rom the health nsurance card. An e er at ents ll e traced a out tra el occu at on contact and cluster h stor . he med cal con erence as con erted to a rtual meet ng. 1. ecommendat ons on the reduct on o n ect on rate nclud ng dent cat on o at ents D 19 ra d screen ng test de end ng on a a la le resources test ng at ents or treatment or surger and ased on cl n cal s m toms th n t o ee s str ct trac ng o at ents contacts esta l sh ng solated areas or D at ents clean D 19 ree o erat ng room or cancer surger or rom home se arated teams to ma nta n the workforce, social distance, travel restrictions, frequent sterilization of areas which are touched re uentl l m tat on o am l and r ends s t ng the hos tal. 2. ecommendat ons or out at ent cl n cs Ade uate rotect on e u ment ma nta n ng social distancing in outpatient waiting areas, minimize face-to-face appointments, tele hone deo consultat ons. 3. ecommendat ons on n at ent management estr ct ng the num er o s tors to none or s ngle onl and D des gnated ards ntens e care un ts o erat ng rooms. All surger er ormed n the D 19 andem c rres ect e o the no n or sus ected SA S o 2 status o the at ent should e cons der as h gh r s and rotect on o the surg cal team should e at the h ghest le el. . ncolog cal treatment gu del nes n s tuat ons here ca ac t s se erel l m ted following the guidelines apply in chemotherapy. Prioritization for radiotherapy is based on r nc les s m lar to chemothera at ents. Man o the gu del nes ocus on l m t ng at ent and sta nteract ons l m t ng the number and length of clinical visits and limiting exposure.
21 December 19 Chia-Yen Huang
urrent Pos t on Attend ng Ph s c an De artment o stetr cs and necolog atha eneral os tal a e a an th Ass stant Pro essor School o Med c ne Fu en athol c n ers t e 601 Room a e t a an
December 19 ducat on M.D. at onal a an n ers t School o Med c ne 1993 2000 MS at onal a an n ers t raduate nst tute o l n cal Med c ne 200 200 Ph.D. at onal h ao ung n ers t De artment o olog cal Sc ence echnolog 201 2020 th 603 Room Professional Experiences (Top 5): necolog c ncolog a arosco c Surger ancer enet cs o n ormat cs December 20 dem olog th 601 Room December 20 th 603 Room
22 Novel Immunotherapy for Advanced Endometrial Cancer
h a en uang
ndometr al cancer ( ) s the most common g necolog c cancer n de elo ed countr es nclud ng a an. n a an t s the 6th most common cancer n omen th nearl 2 00 ne l d agnosed cases annuall . he ma or t o s d agnosed at earl stage th a good prognosis. However, approximately one-fourth of patients are diagnosed with advanced disease. Despite excellent outcomes in early stage disease, patients presenting th ad anced stage or th aggress e h stolog c su t es ha e a h gher nc dence o recurrence and su se uentl shorter sur al. he standard treatment o ad anced metastat c or recurrent endometr al cancer is paclitaxel plus carboplatin. The response rate is about 40% to 62%, and OS is about 13 to 29 months. However, options for advanced disease after initial platinum–taxane thera are scarce. Data rom the ancer enome Atlas ( A) ro ect ha e ad anced our understand ng o the olog c heterogene t o endometr al cancer. h s ne no ledge has o ened u more o t ons or targeted thera or recurrent d sease. mmunothera or endometr al cancer s an emerg ng area o research and treatment es ec all or at ents th ad anced d sease. Se eral mmunothera related tr als or metastat c recurrent endometr al cancer are ongo ng. At resent there s onl one S FDA a ro ed mmunothera or the treatment o uter ne cancer. FDA granted accelerated approval to pembrolizumab plus lenvatinib for the treatment of patients with advanced endometr al carc noma that s not m crosatell te nsta l t h gh (MS ) or m smatch re a r de c ent (dMM ) and ho ha e d sease rogress on ollo ng r or s stem c thera ut are not cand dates or curat e surger or rad at on. n a s ngle arm hase 2 tr al the o ect e res onse rate as 3 at 2 ee s among unselected at ents th recurrent endometr al cancer and among the at ents th a res onse 6 . had a res onse that lasted or at least 12 months. es onses occurred n at ents ho had tumors thout h gh MS and n at ents th uter ne serous cancers. Based on the results, a randomized phase 3 trial of lenvatinib plus pembrolizumab versus doxorubicin or paclitaxel in patients with advanced endometrial cancer is ongoing ( 03 1 9).
23 December 19 Se-Ik Kim
urrent Pos t on esearch Pro essor omed cal esearch nst tute Seoul at onal n ers t os tal th De artment o stetr cs and necolog 601 Room Seoul at onal n ers t ollege o Med c ne Seoul e u l c o orea
December 19 ducat on 200 .3 2009.2 M.D. Seoul at onal n ers t ollege o Med c ne 2012.3 201 .2 M.S. Seoul at onal n ers t raduate School 201 .3 Ph.D. course Seoul at onal n ers t raduate School th
603 Room Professional Experiences (Top 5): nst tut onal ra n ng 2009.3 2010.2 nternsh Seoul at onal n ers t os tal Seoul at onal n ers t ollege o Med c ne 2010.3 201 .2 es denc De t. o stetr cs and necolog Seoul at onal n ers t os tal December 20 201 . 2020.9 Fello sh D s on o necolog c ncolog De t. o stetr cs and necolog Seoul at onal n ers t os tal
Pu l cat ons
th Proteom c D sco er o omar ers to Pred ct Prognos s o gh rade Serous ar an 601 Room arc noma m S ung M Dan ee S ee m S et al. ancers ( asel). 2020 12 90.
om ar son o sur al outcomes et een m n mall n as e surger and con ent onal o en surger or rad cal h sterectom as r mar treatment n at ents th stage 1 A2
December 20 cer cal cancer. m S ho Seol A m ee M m S et al. necol ncol. 2019 1 3(1) 3 12.
De elo ment o We ased omograms to Pred ct reatment es onse and Prognos s o thel al ar an ancer. th
603 Room m S Song M ang o S ee S ho m et al. ancer es reat. 2019 1(3) 11 .
Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. m S ee W ee M m S hung m W et al. necol ncol. 201 1 (2) 3 2.
2 Update on cervical cancer surgery- abdominal or minimally invasive approach
Se- m
For earl stage cer cal cancer rad cal h sterectom ( ) th lateral el c l m h node d ssect on s recommended. accom an ed ad u ant treatment s also a recommended treatment o t on or ul tumors n stage 2 or A2. n the era o m n mall n as e surger (M S) as commonl er ormed la arosco c surger or ro ot ass sted surger oth su orted e dence o oncolog c sa et n real orld cl n cal ract ce. However, a recent phase III randomized controlled trial (RCT) in patients with early- stage cer cal cancer named as the“Laparoscopic Approach to Carcinoma of the Cervix ( A ) tr al ”brought unexpected, discouraging results. Ramirez et al. reported that MIS or had h gher recurrence rates and orse o erall sur al com ared to o en surger among omen th F stage A1 (l m ho ascular n as on) to 1 cer cal cancer. We recognize that there are some controversies surrounding the LACC trial. Nevertheless, e are l ng n the ost A tr al era. As the sol tar le el 1 e dence the A tr al has alread s gn cantl n luenced real orld cl n cal ract ce. hen ho can e ada t to the change and hat should e do n the ost A tr al era F rst e ore re ect ng all M S and ts accom an ng ene ts e ha e to n est gate robust scientific evidence from additional RCTs elucidating the exact effect of MIS on sur al outcomes n earl stage cer cal cancer. on rmat on stud es that cons der the med cal c rcumstances o d erent countr es are arranted. n add t on ell conducted retros ect e stud es ma also ro de alua le nd ngs re lect ng real orld cl n cal ract ce. Second o t mal cand dates or M S should e eluc dated. A ter the A tr al some retros ect e stud es ha e ocused on to dent s ec c at ents or hom M S m ght enta l an es ec all lo r s . h rd de elo ment o surg cal techn ues to re ent tumor s llage dur ng M S s necessar . D ssem nat on rom the use o a uter ne manipulator, exacerbated by the intracorporeal colpotomy should be avoided. Lastly, g necolog c oncolog sts should e a are o the A tr al and u to date no ledge on M S or earl stage cer cal cancer. he results o the A tr al together th the r o n nst tut onal data should e d scussed th at ents e ore choos ng M S . n conclus on n order to sur e n the ost A tr al era e ha e to ee an accurate ns ght and u ld ro ust e dences on M S or treatment o earl stage cer cal cancer. Ad antages o M S should not e g en u at all ust ecause o the negat e results rom the A tr al. We ho e that M S cont nue to e m lemented rather than deca through the del cate at ent select on as ell as care ul surg cal techn ues.
2 December 19 Pao-Ling Torng
urrent Pos t on D rector De artment o stetr cs necolog s n hu r at onal a an n ers t os tal th 601 Room
December 19 ducat on 19 3 1990 at onal a an n ers t ollege o med c ne M.D. 199 200 at onal a an n ers t raduated nst tute o l n cal Med c ne Ph.D
Professional Experiences (Top 5): th
603 Room ul 1996 resent Attend ng Ph s c an De artment o stetr cs necolog at onal a an n ers t os tal Aug 2010 resent Assoc ate ro essor Med cal ollege o at onal a an n ers t 2013 resent ounc lor a an Assoc at on or M n mall n as e necolog ( AM ) 201 resent ounc lor a an Assoc at on o necolog c ncolog st ( A ) 2014 ~ present Executive Editor Gynecology and Minimally Invasive Therapy (GMIT) December 20 201 resent ounc lor a an o ot c Surger Assoc at on ( SA) 2016 resent ounc lor a an ndometr os s Soc et ( S) th 601 Room December 20 th 603 Room
26 Update on treatment of metastatic or relapsed cervical cancer
Pao ng orng
Pat ents th metastat c recurrent or ers stent cer cal cancer not amena le surger or rad othera ha e a er oor rognos s and the r ear o erall sur al ( S) rates range rom to 16 . Se eral hase tr als o d erent c s lat n ( DDP) ased doublets and a phase III randomized trial showing a trend in response rate, progression- free survival, and OS in favor of CDDP + paclitaxel (PTX) compared with other CDDP- based doublets. A phase III randomized trial, GOG 240, demonstrated a further significant improvement in overall survival when bevacizumab was incorporated to chemotherapy: th a med an o erall sur al (16. months) and rogress on ree sur al ( .2 months). The FDA has recently approved pembrolizumab for patients with recurrent or metastatic cer cal cancer n rogress on on or a ter chemothera hose tumors ere PD 1 os t e. nterest ng cl n cal researches on the use o mmune chec o nt nh tors n add t on to chemothera and oss l th rad othera that could act ate the ant tumor mmun t (called as asco al e ect) are st ll at the as c research hase ut rom s ng.
2 December 19 Takayuki Enomoto
Academ c Pos t ons Pro essor and ha rman De artment o stetr cs and necolog gata n ers t raduate School o Med cal and Dental Sc ence th S ec alt 601 Room necolog c ncolog necolog c Patholog ert cat ons necolog c ncolog l n cal tolog
December 19 Pro ess onal ra n ng and m lo ment 19 3 es dent n De artment o stetr cs and necolog sa a n ers t os tal 19 6 1991 s t ng Fello and uest esearcher n a orator o om arat e arc nogenes s at onal ancer nst tute Freder c ancer esearch and De elo ment enter Freder c MD 21 01 .S.A
th 1991 199 l n cal Fello n De artment o stetr cs and necolog sa a n ers t 603 Room os tal 1999 2002 Ass stant Pro essor n De artment o stetr cs and necolog sa a n ers t Facult o Med c ne 2002 200 Assoc ate Pro essor De artment o stetr cs and necolog sa a n ers t raduate School o Med c ne 200 2012 Pro essor De artment o stetr cs and necolog sa a n ers t os tal December 20 2012 resent Pro essor and ha rman De artment o stetr cs and necolog gata n ers t raduate School o Med cal and Dental Sc ence
Pro ess onal Mem ersh s orres ond ng Mem er Amer can Assoc at on or ancer esearch
th Act e Mem er Amer can Soc et or l n cal ncolog 601 Room Act e Mem er Soc et o necolog c ncolog Act e Mem er nternat onal Soc et or necolog c ancer Pres dent a anese necolog c ncolog rou Executive Board Member, Japanese Society of Obstetrics and Gynecology Executive Board Member, Japanese Society of Gynecologic Oncology Executive Board Member, Japanese Society for Clinical Cytology December 20 oard Mem er a anese Soc et o necolog cal ancer Screen ng ongress Pres dent o the th a an consort um 2016 ongress Pres dent o the 1 th a an necolog c ancer Meet ng 201 ongress Pres dent o the 61st Annual S Meet ng 2019 ongress Pres dent o the 29th a anese Soc et o necolog cal ancer Screen ng 2020 th
603 Room ongress Pres dent o the 3rd S Meet ng 2021
l n cal r al rou s Pres dent a anese necolog c ncolog rou a anese l n cal ncolog rou ncolog necolog c ancer nter rou
2 Radical trachelectomy for early stage cervical cancer at 15-17 weeks of gestation
a a u nomoto
D Standard treatment o earl stage cer cal cancer d agnosed dur ng regnanc has een rad cal h sterectom accom an ed mmed ate term nat on o the regnanc . o e er management n omen ho des re to reta n the r regnanc rema ns a s gn cant challenge rom oth oncolog cal and o stetr cal stand o nts. ne commonl used o t on is to delay the primary treatment of the cancer until the fetus can survive ex utero without s gn cant mor d t . n ortunatel a dela o treatment ma cause undue maternal r s . he second o t on s to conduct neo ad u ant chemothera dur ng the regnanc so that the cancer can e treated thout dela . here s a ust ed concern ho e er that exposure of the fetus to platinum-based chemotherapy in utero may increase its risk for uture cancer. ecentl rad cal trachelectom ( ) has een descr ed as a otent al o t on n cer cal cancer at ents ho ha e a strong des re to cont nue the r regnanc and et st ll treat the d sease thout dela . S S A dom nal rad cal trachelectom as success ull er ormed or e ght cases o stage 1 1 cer cal carc noma at 1 1 ee s o gestat on (under r tten n ormed consent). Planned cesarean sect on as er ormed at 3 ee s o gestat on n 3 cases and at 30 ee s o gestat on n one case and 33 ee s gestat on 2 cases. mergent cesarean sect on at 33 ee s o gestat on due to ntrauter ne n ect on as er ormed n one case. ont nuat on to ull term regnanc as lanned n one case. eneral anesthes a th ro o ol made man ulat on o the gra d uterus eas er than th the general anesthesia sevoflurane, which made the gravid uterus too relaxed to lift up. Prec se rocedure ll e sho n deo. S ur resent stud together th re ousl u l shed data suggests that a dom nal rad cal trachelectom or earl stage cer cal cancer at 1 1 ee s o gestat on ma ha e h gh ut l t o t ons or omen ho strongl des re to ha e the a .
29 December 19 Wu-Chou Lin
urrent Pos t on ha r o . . De artment h na Med cal n ers t os tal oard mem er a an Assoc at on or M n mall n as e n. ( AM ) th oard mem er o Formosa rog necolog Assoc at on (F A) 601 Room
December 19 ducat on 19 19 Med cal degree h na Med cal n ers t ( M ) 199 2000 Master o Med c ne School o Med c ne M . 2003 2012 Ph.D. o Med c ne School o h nese Med c ne M . th
603 Room Professional Experiences (Top 5): necolog cal oncolog necolog cal endosco c and m n mall n as e surger rog necolog ur nar ecal ncont nence Trans-sexual and pelvic reconstruction December 20 th 601 Room December 20 th 603 Room
30 Anatomic dissection in nerve-sparing radical hysterectomy for early cervical cancer
Wu hou n
Pelvic lymphadenectomy had been standardized in the procedure of radical h sterectom and so dose the la arosco c rad cal h sterectom angel 200 . ur el c l m hadenectom n t ated at the le el o 2cm a o e the urcat on o the common l ac artery. By following the external common iliac artery pathway the lymphadenectomy extend to the inguinal canal where the external iliac entered. Around the pubic ramus, e trac the o turator arter u ard to nternal common l ac than ac to the common l ac arter . h s cloc se (le t s de countercloc se or r ght s de) method of lymphadenectomy then enable us to exposed the bifurcation of the common iliac artery; the external iliac artery and vein; the psoas muscle; the genitofemoral nerve; the o l terated um l cal arter (su er or es cal arter ) the o turator e n arter and ner e. At th s le el the ara es cal s ace then can e d ssected remo ng the ad ose t ssue filling this virtual space until the internal obturator muscle is exposed with the endopelvic asc a s at the ottom. he d ssect on ena le us to dent the uter ne arter es cle artery, and even the deep uterine vein. The next step we go on and start to prepare the ararectal s ace dent ng o l terated um l cal arter on the lateral s de ureter on the med al s de and uter ne arter on the anter or s de. d ssect ng the so t t ssue around th s s ace do n ard to el c loor art al s m athet c trac ll e seen on the n ne o cloc os t on o the rectal all. Dur ng th s rocedure e should e caut ous o small arter ranches rom nternal l ac to rectal s de all. he d ssect on s sus end hen there are no small arter ranches seen. At th s le el e can clearl see the ascular art o card al l gment at the anter or the s m athet c ner e on the lateral s de o rectum and also the aras m athet c ner e com ng rom S2 S . tract on on the o l terated um l cus arter to the lateral s de e then are a le to d ssect along the ureter to ree the ureter. nt l the cross sect on o uter ne arter and ureter are met the ureteral ranch rom uter ne arter and e ound r ght at th s sect on. ndent ed th s ranch and care ul l gat on can a o d unnecessar leed ng h ch cause d cult es n the la arosco c surger and also dent the sure mar o the ureter tunnel entrance. he uter ne arter at th s o nt can e sect oned ollo round l gament and road l gament d ssect on rom the anter or face of the uterus until exposure of the anterior vaginal fascia up to 3 to 4cm of the cervix. h s d ssect on allo s the end o the ureter tunnel (ureter entrance n the tr gone) to e dent ed. he ureter tunnel s a c rcle n the orm o a dense connect e t ssue h ch s enclosed su er or es cle arter as su er or art and m ddle es cle arter as n er or art. he med al s de o the ureter tunnel s enhanced the es co uter ne l gaments h ch s const tute o essels rom the oster or ace o the ladder to the anter or ag nal
31 December 19
asc a. gat on o the esco uter ne l gaments rees the ladder and ureter rom anter or ace o ag na. gat on then cont nues th the su er or es cle arter as term nat on o the o en ng o the ureter tunnel anter or art. he oster or art o the ureter tunnel
th s o ened s m l l gat on o the m ddle es cle arter . As the d ssect on o the ureter 601 Room tunnel is complete, we can see the pelvic nerve plexus going from vagina sidewall upward to ards ladder h ch e are ntent to reser e. Also th s ste e had success ull push away the bladder and ureter from anterior face of vagina and surgery zone. After the ureter tunnel d ssect on the ascular art o the card al l gament can e clearl dent ed h ch nclude the es cle arter ag nal arter and the dee uter ne arter . hese essels December 19 then are nd dual sect oned close to the lateral el c all th caut ons. clam ng on the rema ned o the card al l gament u ard care ull d ssect the d stal end o essels along the lateral wall of vagina. The pelvic plexus formed by sympathetic nerve coming from hypogastric nerve and parasympathetic nerve from S2 to S4 is clearly exposed with its signature cross sign. Where as the pelvic plexus marked the crossing point; superiorly th
603 Room nner at on to the ladder and ag na n er orl nner at on to the rectum and u ard arm nner at on to the uterus. he onl ner e route need to e d ssected s the u ard arm h ch nner ate the uterus. h s method e can e sure that most o the other ne er nner at on to ards ladder ag na and rectum s reser ed. he d ssected cut out o the cross arm lea ng t the s gnature“ ”s gn. he uterosacral l gament or g nates n the all of the sacrum and extends forward to fuse with the posterior vaginal fascia on both sides December 20 o the uterus. n order to a roach the uterosacral l gament the Douglas ouch et een the two pararectal ligaments need to be opened. The external side of the uterosacral ligaments contained the inferior pelvic plexus witch we need to preserve also. Therefore, th tens on tract on and care ul d ssect on the uterosacral l gaments can e d ded nto
th an internal leaf and an external left. Then the internal leaf is sectioned to the proximal 601 Room end. A ter all the ste s the uterus th u to 2cm o ag na s ree to remo ed as n the trad t onal rad cal h sterectom ho e er th ner es nner at ng ladder ag na and rectum reser ed. December 20 th 603 Room
32 33 December 19 Ting-Chang Chang
urrent Pos t on Pro essor hang ung n ers t Med cal ollege onsultant attend ng h s c an De t. n hang ung Memor al os tal n ou Med cal th enter 601 Room
December 19 ducat on 19 19 1 achelor o Med c ne h na Med cal n ers t Med cal ollege a chung a an 1990 1991 Master o Pu l c ealth ar ard School o Pu l c ealth oston Massachusetts .S.A. th
603 Room 1990 1991 D s on o necolog c ncolog De artment o stetr cs and necolog r gham and Women s os tal and e ngland ro ho last c D sease enter oston Massachusetts .S.A.
Professional Experiences (Top 5): ce Pres dent As an necolog c ncolog rou 2016 resent December 20 Executive Board, Taiwan Precision Medicine Society, August 2019 – present Pres dent a an Prec s on Med c ne Soc et August 201 ul 2019 Executive Board, Taiwan Association of Obstetrics and Gynecology, October 2013 – present Executive Board, Taiwan Association of Gynecologic Oncologists, 2004 – present th 601 Room December 20 th 603 Room
3 Molecular characterization and its clinical implication in endometrial cancer
ng hang hang
et een anuar 2009 and Decem er 2013 a total o 6 9 endometr al cancer at ents as d agnosed at hang ung Memor al os tal n ou Med cal enter. 39 cases ho ul lled (1) endometr o d adenocarc noma h stolog (2) tumor d mens on n the ara n embedded block was equal to or exceeded 10 mm x 10 mm, (3) treated at this institute th com lete record and ( ) regularl ollo ed or at least e ears ere retr e ed. he r as c character st cs ere l sted n a le 1. he med an tumor d mens on measured 3 mm th the largest one measured 92 mm n length. All the 39 cases ere endometr o d carc noma h stolog call . Among these 1 3 o 39 ( 6.1 ) ere class ed as grade 1 n h stolog 1 grade 2 and 62 grade 3. he other cases ere not ment oned n the h stolog cal re ort. h rt n ne (39) cases had the r d sease rela sed dur ng ollo u er od. Among these cases encountered local rela se one th entrance (trocar) s te rela se th reg onal s te rela se other th no l m h node n ol ement 3 th reg onal l m h node recurrence onl one had oth reg onal node and reg onal s te rela se. 22 cases had the r rst rela se at d stant s tes nclud ng cases sho ed lung rela se 3 th a dom nal ( ntra er toneal rela se) out o the el s one th d stant one rela se the others sho ed mult le rela se s tes n ol ng d stant locat ons. ne cases sho ed ers stent d sease a ter the r r mar thera . POLE mutation was noted in 44 (11.1%) of the study cases while mutated exon 9 was noted in 25 cases, mutated exon 13 in 15 cases, mutated 14 in 5 cases and mutated 11 in one case. Exon 10 mutation was not observed in our study cases. All the noted mutations ere m ssense mutat on. he mean and med al age o P mutated at ents ere 6.1 ears and ears com ar ng th 2. and 3 ears n at ents th P unmutated ( ld t e) tumor ( 0.031). F grade F stage cl n cal and atholog cal l m h node status r mar thera and t e o recurrence ere not stat st call s gn cant et een the t o grou s. Among the mutated one at ent had local recurrence 6.3 months a ter r mar d agnos s o a F A d sease another one had mult le d stant recurrence 2 . months a ter d agnos s o a F 3 2 d sease. oth ere sur ed a ter treatment or recurrence. he other one as a 9 ears oman ho sho ed an A d sease th an cm tumor at diagnosis and had never experienced disease free after diagnosis. The patient received surger and chemothera and d ed o d sease 1 months a ter n t al d agnos s as the onl at ent th P mutated endometr a cancer ho d ed o d sease. t suggests that under current management o endometr o d endometr al cancer at ent th somat c P mutated tumor sho ed a tendenc o etter sur al than those th no P mutat on. We then extended our study to define the other molecular markers among these patients, focused on the immunohistochemical expression of miss-match repair deficiency, estrogen rece tor rogesterone rece tor and 3 status. he nteract on o these mar ers and cl n cal s gn cance s to resent at the meet ng.
3 December 19 Sang-Wun Kim
urrent Pos t on Se . 2020 resent ce D rector o onse ancer enter M Se . 2019 resent D rector o nst tute o Women s e Med cal Sc ence M th Mar. 201 resent D rector o Women s ancer enter onse ancer enter 601 Room Mar. 2016 resent Pro essor. D s on o necolog c ncolog De artment o stetr cs and necolog onse n ers t ollege o Med c ne Seoul South orea
December 19 ducat on 1991 199 M.D. onse n ers t ollege o Med c ne Seoul orea 2000 2006 M.S. onse n ers t ollege o Med c ne Seoul orea 2006 2009 Ph.D. onse n ers t ollege o Med c ne Seoul orea th
603 Room Professional Experiences (Top 5): Mar. 2012 Dec. 2013 s t ng Scholar San ord urnham Med cal esearch nst tute San D ego A SA orean Soc et o stetr cs and necolog Secretar general (2009 2011 10) Amer can Assoc at on o ancer esearch (AA ) Act e mem er (201 resent) orean ancer Assoc at on mem er (200 resent) December 20 orean Soc et o necolog c ncolog and ol osco mem er (200 resent) orean Soc et o necolog c ndosco and M n mall n as e Surger mem er (200 resent) th 601 Room December 20 th 603 Room
36 Two-step sentinel lymph node mapping strategy in endometrial cancer staging
Sang Wun m
Background: Fluorescence mage gu ded sent nel l m h node (S ) o s us ng t o ste ma ng techn ue ncor orated se uent al n ect on o ndoc an ne green ( ) nto lateral cornu o uterus ollo ed cer cal n ect on. l n cal outcome as com ared to that o con ent onal cer cal method (one ste ). Methods: Pat ents th F stage endometr al cancer ho under ent la arosco c or ro ot c stag ng o erat on nclud ng S o s ollo ed l m hadenectom rom Ma 201 to Decem er 201 ere retros ect el re e ed. Pat ent character st cs reo erat e mag ng S detect on attern atholog cal result, adjuvant treatment, and recurrence locations were analyzed. Results: A total o 199 at ents rece ed one ste (n 123) and t o ste (n 6) S o s . Paraaort c S s ere more re uentl dent ed n the t o ste grou . o er and u er araaort c S s ere dent ed n 6 .1 and 3 .2 res ect el n the t o ste grou and n 1 . and . n the one ste grou ( 0.001). he num er o araaort c S s har ested as su er or n the t o ste grou ( 0.001). Moreo er trend o a h gher ro ort on o at ents th metastat c araaort c S as sho n n the t o ste grou ( .9 ) than n the one ste grou (1.6 ) ( 0.0 6). he metastat c araaort c S s ere ound n .9 o the t o ste grou and 2. o the one ste grou . n detect ng metastas s sens t t es o the one and t o ste methods ere 91. and 100.0 negat e red ct e alues ere 99.0 and 100.0 alse negat e rates ere .3 and 0 and accurac ere 99.1 and 100.0 res ect el . he one ste methods dent ed onl 3 out o araaort c metastas s and m ssed araaort c metastas s. o e er there as no m ssed araaort c metastas s n t o ste grou . ecurrence as o ser ed n t o at ents (2.6 one ag nal ault and one adrenal gland) n the t o ste and se en at ents ( . ) nclud ng three nodal recurrences n the one ste method. Discussion: o ste S ma ng m ro ed araaort c S detect on rate a no n t all o the con ent onal cer cal n ect on. Pro er e aluat on o aort c l m h node status ll ass st n the ta lor ng o ad u ant thera and re ent under treatment o at ents th solated araaort c metastas s.
3 December 19 Kimio Ushijima
urrent Pos t on ha rman Pro essor urume n ers t School o Med c ne De artment o stetr cs and necolog th 601 Room
December 19 ducat on 19 3 M.D. urume n ers t School o Med c ne urume a an 1990 Ph.D. urume n ers t School o Med c ne urume a an
Professional Experiences (Top 5): th
603 Room 1992 1999 Sen or stu De artment o urume n ers t School o Med c ne 2000 200 Ass stant Pro essor urume n ers t 200 201 Assoc ate Pro essor urume n ers t Ma 201 Pro essor and ha rman De artment o urume n ers t School o Med c ne December 20 th 601 Room December 20 th 603 Room
3 Adjuvant therapy for early endometrial cancer – when and how and why?
m o sh ma
he r s actors or recurrence o endometr al cancer ( ) s dec ded atholog cal s ec men a ter stag ng surger . at ents has some r s actors such as dee m ometr al n as on l m ho ascular s ace n as on ad u ant thera s conducted e en n earl stage cases (stage and ). n h gh grade carc noma h stolog c t e tsel ould e a r s actor. s ec all the d agnos s o uter ne serous carc noma ould e a s gn cant oor rognost c actor e en n less m ometr al n as on. M F (M croc st c longated and Fragmented) attern ould e a ne atholog c r s actor. As the strateg o ad u ant thera or at ents th ntermed ate r s actors rad at on thera ( ) s a standard treatment and chemothera ( ) s a l ed or onl or the ad anced cases n estern countr es nclud ng most As an countr es. n the other hand s stem c has een done or most at ents as an ad u ant thera n a an s nce 1990 s. here ma e some oss le reasons or th s trend. n a an g necolog c cancer at ents are treated not onl h gh olume center. Although there ere so man ad anced cer cal cancer at ents ne rad at on ac l t es ere not arranged enough and less num er o rad o oncolog st. So there ere less room or at ents. a anese g necolog st are am l ar th es ec all lat num agents n o ar an cancer treatment. So thout de n te e dence the trend ere s ted to . F rst e dence o s 2033 tr al. sho ed sl ghtl longer sur al than n intermediate high risk patients. The choice of drugs are cyclophosphamide, doxorubicin, and cis-platin (CAP), then doxorubicin plus cis-platin (AP), now the dominant combination is paclitaxel and carboplatin (TC). JGOG 2043 is a prospective randomized control study to seek the best combination among AP, TC, and docetaxel and cis-platin (DP) including ad anced stage at ent. here as no s gn cant d erence o sur als et een these three reg mens. t s d cult to ans er h ch s the etter strateg or as the ad u ant thera or earl stage th ntermed ate r s actors. e ertheless has d erent olog cal eature rom cer cal cancer and has s m lar eature as o ar an cancer. has onl temporary toxicity, or does not increase local recurrence rate or show worse survival. here ore ma e a reasona le treatment strateg e en n earl endometr al cancer.
39 December 19 Hee-Seung Kim
urrent Pos t on Assoc ate Pro essor De artment o stetr cs and necolog th Seoul at onal n ers t ollege o Med c ne e u l c o orea 601 Room
December 19 ducat on 1. 1996 199 Premed cal School Seoul at onal n ers t 2. 199 2002 achelor Seoul at onal n ers t ollege o Med c ne 3. 2009 2011 Master Seoul at onal n ers t ollege o Med c ne . 2013 201 Doctor Seoul at onal n ers t ollege o Med c ne th 603 Room Professional Experiences (Top 5): 1. Mar 2003 Fe 200 es dent at De artment o stetr cs and necolog n Seoul at onal n ers t os tal 2. Mar 200 Aug 2009 Fello sh at De artment o stetr cs and necolog n Seoul at onal n ers t os tal December 20 3. Se 2009 Se 201 omm ss oned ro essor at De artment o stetr cs and necolog n Seoul at onal n ers t os tal . Se 201 Aug 2016 l n cal ass stant ro essor at De artment o stetr cs and necolog n Seoul at onal n ers t os tal
th . Se 2016 Assoc ated ro essor at De artment o stetr cs and necolog n Seoul 601 Room at onal n ers t ollege o Med c ne December 20 th 603 Room
0 Treatment for stage 4 and metastatic endometrial cancer
ee Seung m
reatment o t on s l m ted or stage and metastat c endometr al cancer ecause o extent of metastasis and aggressive feature of tumor biology. Thus, it is no longer difficult to a l the com nat on o surger rad othera and chemothera e ect el and ro erl or the d sease. n th s re e e ll ntroduce the role o each treatment or m ro ng rognos s o stage or metastat c endometr al cancer. n terms o surger man stud es ha e sho n that aggress e and de ul ng surger ma e hel ul n m ro ng sur al n at ents th ad anced or recurrent endometr al cancer suggest ng o t mal c toreduct on as a a ora le rognost c actor. o e er the role neoad u ant chemothera s contro ers al or ad anced endometr al cancer contrar to o ar an cancer due to a lac o e dence. s ec all the reg men o the rst l ne chemothera has een esta l shed as the combination of paclitaxel-carboplatin through GOG-0209 and JGOG-2043. Moreover, addition of trastuzumab to paclitaxel-carboplatin has been shown to improve survival in patients with advanced or recurrent endometrial cancer who had HER-2/neu expression. Although bevacizumab showed the potential to treat recurrent endometrial cancer, the com nat on to the chemothera eut c reg men a led to m ro e sur al n those th ad anced or recurrent endometr al cancer. ecentl d erent t es o mmune chec o nt nh tors are e ng n est gated as monothera or com nat on thera th targeted agents or ad anced or recurrent endometr al cancer. When e cons der the e ect o mmune chec o nt nh tors ma e maximal for patients with advanced or recurrent endometrial cancer in whom mismatch repair genes are deficient or the expression of PD-1/PD-L1 is positive, precision medicine using immune checkpoint inhibitors will be the next strategy for treating advanced or recurrent endometr al cancer n the near uture.
1 December 19 Masaki Mandai
urrent Pos t on Pro essor and ha rman De artment o necolog and stetr cs oto n ers t raduate School o Med c ne th 601 Room
December 19 ducat on MD PhD oto n ers t
Professional Experiences (Top 5): 2000 2002 esearch ello acc ne esearch enter S th
603 Room 2013 201 Pro . ha rmen nda n ers t Facult o Med c ne sa a December 20 th 601 Room December 20 th 603 Room
2 Ovarian cancer surgery- 1st and 2nd debulking operation
Masa Manda
ecentl there u l shed results o se eral m ortant researches on the surger or o ar an cancer. F rst n stud ( 00 1221 ) the ene t o s stemat c el c and araaort c l m hadenectom n the surg cal treatment o at ents th ad anced o ar an cancer ho had undergone macrosco call com lete resect on and had normal l m h nodes oth e ore and dur ng surger has een e aluated randoml ass gned to e ther undergo or not undergo l m hadenectom . Among at ents ho under ent l m hadenectom the med an num er o remo ed nodes as . he med an o erall sur al or med an rogress on ree sur al as not s gn cantl d erent et een the grou s suggest ng l m hadenectom n these at ents ha e no ene t ut assoc ated th ncreased osto erat e com l cat ons. ll d scuss on the role o d ssect on n r mar de ul ng surger or . Second the role o secondar c toreduct e surger n recurrent o ar an cancer ( ) has een e aluated n 2 large . he result o 0213 ( 00 6 1) has een u l shed. n th s stud at ents th lat num sens t e th n est gator determ ned resecta le disease were randomized to undergo secondary surgical cytoreduction and then receive lat num ased chemothera or to rece e lat num ased chemothera alone. Ad u ant chemotherapy and use of bevacizumab were at the discretion of the investigator. Complete gross resect on as ach e ed n 6 o the at ents ass gned to surger . Plat num ased chemotherapy with bevacizumab followed by bevacizumab maintenance was administered to o the at ents o erall and as e uall d str uted et een the t o grou s. he hazard ratio for death (surgery vs. no surgery) was 1.29 (95% confidence interval [CI], 0.97 to 1. 2 P 0.0 ) h ch corres onded to a med an o erall sur al o 0.6 months and 6 . months res ect el nd cat ng that surger does not result n longer o erall sur al than chemothera alone. Also the nal result o A D S P stud ( 01166 3 ) as resented n AS 2020. n th s stud Pts th lat num sens t e th a os t e AGO-score were randomized to second-line chemotherapy alone vs. cytoreductive surgery ollo ed the same chemothera . A com lete resect on as ach e ed n n surger grou . Pr mar end o nt anal s s sho ed med an S o 3. mos th and 6.2 mos thout surger ( 0. 6 9 0. 9 0.9 0.03) demonstrat ng a mean ng ul sur al ene t o surger n . D scuss on ll e made or these 2 contrad ctor results. he role o neo ad u ant chemothera ( A ) has cont nuousl een e aluated n se eral tr als. 9 1 and S stud es ha e alread demonstrated non n er or t o A and recentl nal result o ne tr al to com are et een r mar de ul ng surger (PDS) and A or stage has een u l shed rom a an ( 0602 M 000000 23). o S or A as 1.0 2 90 0 3 1.326 and one s ded non n er or t alue as 0.2 . om lete resect on as ach e ed n 12 (1 1 ) o PDS and 31 ( 1 ) o PDS ± DS n the PDS arm and n 6 ( 3 130) o DS n the A arm and the non n er or t o A as not con rmed suggest ng that A ma not al a s e a su st tute or PDS. hese con l ct ng results o P sho ed some d cult to e aluate the role o surger n . Also the suggest that the result ma e a ected the use o ne drugs or the extent of surgery. Personalization rather than standardization in surgical treatment ould e another m ortant ssue. 3 December 19 Ka-Yu Tse
urrent Pos t on l n cal Assoc ate Pro essor th 601 Room
December 19 ducat on M S ( he n ers t o ong ong) F AM ( ) ( he ong ong Academ o Med c ne) MMedSc ( he n ers t o ong ong) ert ( n ncolog ) ( o al ollege o stetr c ans and naecolog sts ) th
603 Room F ( o al ollege o stetr c ans and naecolog sts )
Professional Experiences (Top 5): 1. De ul ng surger n o ar an cancer 2. o ot ass sted surger n g naecolog cal cancer 3. hemothera n g naecolog cal cancer December 20 . argeted thera and mmunothera n g naecolog cal cancer . as c sc ence research th 601 Room December 20 th 603 Room
Personalized medicine – maintenance therapy in ovarian cancer
a u se
ar an cancer s the e ghth commonest o cancer deaths among omen n the orld. he gold standard treatment or ad anced d seases has een surger and lat num ased chemothera s nce late 19 0s. o e er t rema ns a lethal d sease. More than hal o the at ents th ad anced o ar an cancer recur and a out 2 are res stant to lat num at rst rela se. W th more understand ng n cancer olog and ad ance n molecular techolog man cancers are no treated ased on the r genet c ro les nstead o the r anatom c or g n. Accord ng to the at onal ancer nst tute ( ) the de n t on o rec s on med c ne s an a roach to at ent care that allo s doctors to select treatments that are most l el to hel at ents ased on a genet c understand ng o the r d sease. h s s the reason that rec s on med c ne s also called ersonal sed med c ne . Prec s on med c ne s la ng a more and more m ortant role n o ar an cancer. he most successful example is poly-ADP-ribose polymerase inhibitors (PARPi), which patients th A 1 or 2 mutat on or homologous re a r de c enc ould ene t most rom the treatment n e ther rontl ne l ne or recurrent sett ng. o e er there are st ll t alls n the d agnos s and the res stance mechan sms to PA P st ll need to e eluc dated. n 2017 the US Food and Drug Adminstration (FDA) also approved the use of pembrolizumab in patients with DNA mismatch repair deficiency, which was the first ever personalized mmunothera that as a ro ed ased on molecular changes. n th s lecture the current status o rec s on med c ne n o ar an cancer the methods o gu d ng th s a roach and the challenges ll e d scussed.
December 19 Heng-Cheng Hsu
urrent Pos t on Attend ng h s c an at onal a an n ers t os tal s n hu ranch d tor al Fello nternat onal ournal o necolog cal ancer th 601 Room
December 19 ducat on Fello sh 201 ul 201 un at onal a an n ers t os tal stetr cs necolog es denc 2011 ul 201 un at onal a an n ers t os tal stetr cs necolog Phd Program n l n cal Med c ne 201 Se at onal a an n ers t raduate nst tute o l n cal Med c ne ndergraduate School 2003Se 2010 un a e Med cal n ers t th
603 Room School o Med c ne
Professional Experiences (Top 5): Attend ng h s c an at onal a an n ers t os tal s n hu ranch d tor al Fello nternat onal ournal o necolog cal ancer December 20 th 601 Room December 20 th 603 Room
6 Treatment for relapsed ovarian cancer
eng heng su
Most at ents th ad anced e thel al o ar an cancer ll de elo recurrence o d sease. he res onse o the at ents ho recur de end on the lat num ree nter al (PF ). he onger the PF the more l el that the at ents res ond to urther treatment. For those th a PF o 12 months 30 m ght res ond to retreatment th lat num. For those that ha e a PFS 2 months 60 0 m ght res ond. Also su se uent res onses to chemothera are mostl shorter com ared to that rom the re ous res onse. n the end des te ad ancement o treatment n e thel al o ar an cancer at ents st ll encounter chemores stance h ch leads to atal t . reatment th those th re ractor res stance s st ll challeng ng. ere e re e the management o treatment n rela sed o ar an cancer.
December 19 Yi-Jen Chen
urrent Pos t on D rector Pro essor De artment o S School o Med c ne at onal ang M ng n ers t a e a an th d tor al oard ournal o the h nese Med cal Assoc at on (S F 2.1 ) 601 Room h e D s on o necolog De artment o stetr cs and necolog a e eterans eneral os tal a an
December 19 ducat on Med cal Doctor o Med c ne at onal ang M ng n ers t a e a an Postgraduate PhD o nst tute o l n cal Med c ne raduate School th
603 Room at onal ang M ng n ers t a e a an oard ert cat on n necolog c ncolog a an . 200 APA necolog cal ndosco c entre eacher 201
Professional Experiences (Top 5): 1. sa W uang M Wang P uang S Chen YJ* s eh S . Dc 3 romotes cell December 20 adhes on and enhances endometr os s de elo ment. Pathol. 201 Fe 2 (2) 1 9 202. (S 6.021 Patholog ) 2. Chen YJ*. uang S eh Fu su F sa W hang Wang P Posto erat e ma ntenance le onorgestrel releas ng ntrauter ne s stem and endometr oma
th recurrence. A randomized controlled study. Am J Obstet Gynecol. 2017 Jun;216(6):582. 601 Room e1 2.e9. (S 6. 02 S ) 3. uang S Chen YJ* hou hen uang S sa W an hang u F en MS Wang P hao ee ang M . strogen nduced ang ogenes s promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. J ell Mol Med. 201 .1 ( ) 13 1 (same contr ut on th corres ondence)
December 20 . Chen YJ Wang P cam o u F en MS hao . S ngle ort com ared th conventional laparoscopic-assisted vaginal hysterectomy: a randomized controlled trial. stet necol. 2011 A r 11 ( ) 906 12. (S . 2 S ) . Chen YJ uang u F en MS Wang P hou u hao ang M . estrogen nduced e thel al mesench mal trans t on o endometr al e thel al cells th
603 Room contr utes to the de elo ment o adenom os s. Pathol. 2010 o 222(3) 261 0. (S 6.021 Patholog )
Current role of minimally invasive surgery for ovarian cancer
en hen
Accord ng to the u del nes 2020 De ul ng surger s the n t al treatment recommendat on or at ents th cl n cal stage or d sease. Although de ul ng surger s the standard o care th s recommendat on s ased on retros ect e data. n general the rocedures should e art o the surg cal management o at ents th o ar an Fallo an tu e or r mar er toneal cancer n an e ort to ull stage at ents and to achieve maximal debulking to less than 1-cm residual disease or resection of all visible d sease n a ro r ate c rcumstances. Surg cal de ul ng s o t mal the res dual tumor nodules are less than 1 cm in maximum diameter or thickness; the goal is resection to R0. Extensive resection of upper abdominal metastases is recommended for patients who can tolerate th s surger . n select at ents m n mall n as e rocedures ma e used to assess hether de ul ng surger s eas le. A recent tr al assessed hether la arosco can e used to determ ne de ul ng surger ll e ut le ( ecause at ents actuall ha e d sease that cannot be optimally debulked to less than 1 cm). A maximal effort should be made to remo e all gross d sease ecause the more com lete the de ul ng the etter the outcomes. The surgical guidelines emphasize that an open laparotomy should be used for at ents th sus ected mal gnant o ar an cancer the treatment lan n ol es surg cal stag ng r mar de ul ng nter al de ul ng or secondar de ul ng surger . he surg cal gu del nes also state that at ents cannot e o t mall de ul ed us ng m n mall n as e techn ues the should e con erted to an o en rocedure. eoad u ant thera can e considered if maximal debulking cannot be achieved .
9 December 19 Cheng-I Liao
urrent Pos t on D rector o necolog De artment o stetr cs and necolog aohs ung eterans eneral os tal a an th 601 Room
December 19 ducat on M.D. at onal ang M ng n ers t a an
Professional Experiences (Top 5): 1. oard ert ed a an oard o stetr cs necolog 2. Su s ec alt ert cat on o necolog c ncolog th
603 Room 3. Ass stant Pro essor December 20 th 601 Room December 20 th 603 Room
0 Big data analysis in populational gynecologic oncology- methods and outcomes
heng ao
We collected data d erent a to sol e the d erent ro lems s nce our anc ent ancestors. As technolog ad ances the s eed and so h st cat on o data collect on has ncreased dramat call result ng n an un mag na le ncrease n the amount o data. D erent s ec al occu at ons egan to use data to red ct mar et demand and m ro e their service quality. In the medical industry, we are also expanding our data-related ser ces th n th s trend. ancer threatened human l e. We treat our at ents accord ng the cl n cal tr als. ut less than o the cancer o ulat on as ncluded n tr als. t does not ma e sense. ence the n ted States egan the Sur e llance dem olog and nd esults (S ) rogram s nce 19 3 us ng deta led cancer reg strat on data and stat st cal anal s s to e ect el reduce the huge m act o cancer. n order to lan cancer re ent on and control ro ects the a an M n str o ealth and Wel are esta l shed a cancer reg strat on s stem or hos tals adm n strat e order n 19 9 re uest ng the summar data on e dem olog d agnos s and treatment o ne cancer cases. ther countr es also u lt se eral s m lar s stems to ach e e the r s ec c demands. o to use these nds o data to sol e the cl n cal ssues s art cularl m ortant. We ll sho the use ul methods and the r mar results o g necolog c oncolog rom the d erent data ase. he data ase not onl can ass st the cl n c an n ormulat ng the at ent s treatment d rect on ut also ro des rele ant n ormat on to ass st the health un t to de lo the uture med cal resources more e ect el . At the same t me the data anal s s can hel the cl n cal sta to gure out the nade uac es o current med cal record s stem and ro de suggest ons or uture m ro ement. t also can hel us to ach e e the goal o rec s on med c ne.
1 December 19 Chen-Hsuan Wu
urrent Pos t on D rector o D s on o necolog c ncolog n aohs ung hang ung Memor al os tal th 601 Room
December 19 ducat on 1. MD degree s nce une 30 2002 aohs ung Med cal n ers t aohs ung c t . 2. Post raduate ducat on PhD and date o hang ung n ers t 3. Academic Appointment (lnclude Teaching Experience): Assistant Professor of Kaohsiung hang ung Memor al os tal s nce ul 201 th 603 Room Professional Experiences (Top 5): 1. Attend ng h s c an o De artment o stetr cs and necolog aohs ung hang ung Memor al os tal (s nce an. 1 2009 resent) 2. oard o S ec al st o a anese Assoc at on o stetr cs and necolog S nce cto er 200 resent December 20 3. esearch Fello sh o D s on o De artments o Patholog ncolog and necolog stetr cs ohns o ns n ers t School o Med c ne ( ul 1 2011 to ct. 31 2012) . D rector o D s on o necolog ncolog De artment o stetr cs and necolog aohs ung hang ung Memor al os tal (s nce ul 1 2016 resent)
th . oard o S ec al st o a anese Assoc at on o encolog ncolog st s nce Ma 601 Room 2016 resent December 20 th 603 Room
2 Shared decision-making in real practice
hen suan Wu
Shared dec s on ma ng (SDM) has ecome ncreas ngl m ortant n health care. SDM occurs hen a health care ro der and a at ent or together to ma e a health care decision that is best for the patient. Health care providers explain treatments and alternat es to at ents and hel them choose the treatment o t on that est al gns th the r re erences as ell as the r un ue cultural and ersonal el e s. he o t mal dec s on ta es nto account e dence ased n ormat on a out a a la le o t ons the ro der s knowledge and experience, and the patient's values and preferences. The core elements o SDM are r s commun cat on and alues clar cat on. alues clar cat on cons ders oth at ent alues and at ent re erences. Pre erences are ncl nat ons to ard or a a rom an o t on. alues are the underl ng eel ngs that hel determ ne re erences. o e er des te sc ent c e dence e ect e m lementat on strateg es and a rom nent os t on on the health ol c agenda SDM s not del m lemented n rout ne ract ce so ar. Making SDM a reality is really a complex task, in this talk, we will share our experience a out ho to a l t nto e er da ract ce and ho to ac l tate the m lementat on n cl n cal s tuat ons.
3 December 19 Shu-Jen Chen
urrent Pos t on h e Sc ent c cer and o Founder A enom cs o. td. th 601 Room
December 19 ducat on Ph.D. ochem str rg n a ommon ealth n ers t chmond rg n a SA M.S. ochem str at onal a an n ers t School o Med c ne a e a an .S. Pharmac a e Med cal ollege a e a an th
603 Room Professional Experiences (Top 5): 201 Present S and o ounder A enom cs 2009 201 Assoc ate Pro essor De artment o omed cal Sc ences hang ung n ers t a an 2006 2009 Assoc ate esearch Fello Molecular Med c ne esearch enter hang ung n ers t December 20 2001 2006 n est gator Molecular olog rou eader a en otechnolog nc. 199 2001 Pr nc le n est gator otechnolog and Pharmaceut cal esearch D s on at onal ealth esearch nst tutes ( ) a an 199 199 Sen or esearch Sc ent st De artment o ochem str S at u alo
th SA 601 Room 1993 199 esearch Ass stant Pro essor De artment o Ph s olog S at u alo SA 19 9 1993 Postdoctoral Fello De artment o eurosc ence a lor Med cal ollege SA December 20 th 603 Room
Precision medicine in gynecologic cancers
Shu en hen
Ad anced g necolog c mal gnanc es nclud ng o ar an uter ne cer cal ag nal and ul ar cancer ear a d smal rognos s and const tute a ma or challenge or ade uate treatment strateg es. Des te ntense research e orts and thera eut c ad ances g necolog c cancers rema n a lead ng cause o cancer deaths unt l recent ears. er the last decade e ha e tnessed ho a su t e s ec c a roach to o ar an cancers has dramat call changed management nclud ng hat surger s er ormed and h ch or an ad u ant treatment s needed. en more m ortantl ra dl e ol ng technolog es such next-generation sequencing (NGS) have allowed us to translate our knowledge in cancer genom cs and harmacolog nto more rec se more e ect e and more creat e cancer care. By analyzing and targeting molecular alterations, molecular guided treatments graduall ecome a a le o t on or the management o ad anced g necolog c cancers. h s tal ll llustrate ho S ased genet c test ng and assoc ated omar ers such as A1 2 mutat ons and homologous recom nat on de c enc ( D) ha e een used or the management o g necolog c cancers.
December 19 Katsutoshi Oda
urrent Pos t on Pro essor D s on o ntegrat e enom cs raduate School o Med c ne he n ers t o o o th D rector De artment o l n cal enom cs he n ers t o o o os tal 601 Room
December 19 ducat on 199 es dent De artment o he n ers t o o o ( o o) a an 199 raduate student raduate School o Med c ne o o 2001 De artment o necolog Sa tama ancer enter 2002 De artment o o o th
603 Room 200 Post doctoral esearch Fello ancer esearch nst tute n ers t o al orn a San Franc sco A SA 200 De artment o o o 2013 Ass stant Pro essor ( ecturer) De artment o o o 201 Assoc ate Pro essor De artment o raduate School o Med c ne o o 2020 resent Pro essor D s on o ntegrat e enom cs raduate School o Med c ne December 20 o o
Professional Experiences (Top 5): 1. ha r erson o the comm ttee o ranslat onal esearch ( ) n a anese necolog c
th ncolog rou ( ) 601 Room 2. Pr nc al n est gator o n est gator n t ated cl n cal tr al A mult center hase stud o la ar ma ntenance thera or h gh grade o ar an cancer th os t e omar er by exome sequencing. JapicCTI-184036 3. ert ed cl n cal genet c st n a anese oard o Med cal enet cs and enom cs l n cal enet cs
December 20 . ounc lor n a anese ancer Assoc at on ( A) and a an Soc et o l n cal ncolog ( S ) and he a an Soc et o uman enet cs ( S ) . ert ed g necolog c oncolog st n a an Soc et o l n cal ncolog th 603 Room
6 Mechanism targeting homologous recombination deficiencies in ovarian cancer
atsutosh da
n add t on to la ar ra ar has een a ro ed as a ma ntenance thera n a an (PMDA Pharmaceut cals and Med cal De ces Agenc ) or ne l d agnosed ad anced r mar o ar an cancer as ell as lat num sens t e rela sed o ar an cancer ho are n a com lete or art al res onse to lat num ased chemothera . n add t on PMDA also a ro es n ra ar or D os t e ad anced o ar an cancer ho are treated th three or more r or chemothera reg mens. om an on d agnost cs or D os t t s the Myriad myChoice CDx as either tumor BRCA mutated (tBRCAm) and/or a high genomic nsta l t score ( S 2 or h gher). ra ar has een a ro ed or r mar or rst l ne ma ntenance o ad anced o ar an cancer regardless o D status as long as the are sens t e to lat num ased chemothera . o e er PA A 1 stud has strongl suggested that Pos t e D status (regardless o BRCA status) by Myriad myCHoice CDx is associated with the sensitivity to olaparib with bevacizumab in a maintenance setting. here ore D status as ell as t Am (germl ne o somat c Am) ll gather much attent on as a omar er or a PA P nh tor. PARP inhibitors block the enzyme activity of poly ADP ribose polymerase (PARP) and prevent base excision repair, which leads to accumulation of double strand breaks. As HRD- os t e cancer cells cannot correctl re a r dou le strand rea s D os t e cancer cells are sens t e to PA P nh tors. n add t on PA P tra ng s another mechan sm o PA P inhibitors. Trapping PARP1 and PARP2 to the sites of DNA damage (DNA-PARP complex) causes cytotoxicity in cells. The PARP trapping potency is distinct among PARP inhibitors (talazoparib, niraparib, olaparib, rucaparib and veliparib). This difference may be associated th the ant tumor act t and ad erse e ents. In addition to GIS, evaluated by Myriad myChoice CDx, mutational signatures may re lect the D status. Mutat onal s gnatures are com osed o su st tut on atterns o nucleotides (using the six substitution subtypes: C>A, C>G, C>T, T>A, T>C, and T>G) in cancer tissues, which reflect a process of oncogenesis and exogenous/endogenous mutagen exposures.“ A s gnature” s a s ec c mutat onal s gnature h ch s assoc ated th D nclud ng A mutat ons. In this symposium, mechanisms of PARP inhibitors will be reviewed with explanation of the strateg to e aluate D n cancers.
December 19 Ya-Min Cheng
urrent Pos t on Su er ntendent uo eneral os tal th 601 Room
December 19 ducat on De artment o Med c ne ollege o Med c ne at onal heng ung n ers t a an . . 1st to 3rd ear res dent n De artment o . at onal heng ung n ers t os tal th
603 Room h e res dent n De artment o . at onal heng ung n ers t os tal necolog ncolog Fello n De artment o . at onal heng ung n ers t os tal Fello sh o at onal ancer enter o o a an P D cand date o nst tute o l n cal Med cal esearch Pro essor o stetr cs and necolog Med cal ollege and os tal at onal heng December 20 ung n ers t
Professional Experiences (Top 5): D rector o each ng enter at onal heng ung n ers t os tal
th ce ha r or Student A a rs School o Med c ne Med cal ollege at onal heng ung 601 Room n ers t D rector o a an Assoc at on o necolog ncolog ( A ) D rector o a an Assoc at on o stetr cs necolog ( A ) D rector o a an Assoc at on or m n mall n as e necolog ( AM ) December 20 th 603 Room
Biomarker and genetic testing for PARP inhibitor
a M n heng
he stud result o S 1 re ealed the use o ma ntenance thera th ola ar ro ded a su stant al ene t th regard to rogress on ree sur al among omen th ne l d agnosed ad anced o ar an cancer and a A1 2 mutat on. he stud result o PA A 1 or at ents th ad anced o ar an cancer rece ng rst l ne standard therapy including bevacizumab, the addition of maintenance olaparib provided a s gn cant rogress on ree sur al ene t h ch as su stant al n at ents th D os t e tumors nclud ng those thout a A mutat on. hese stud es o nted out the m ortance o gene test or S . urrentl a a la le D tests are use ul or red ct ng l el magn tude o ene t rom PA P s ut etter omar ers are urgentl needed to etter dent current homologous recom nat on ro c enc status and strat S management
9 December 19 Hung-Hsueh Chou
urrent Pos t on Attend ng h s c an D s on o g necolog c oncolog De artment o n hang ung Memor al os tal th 601 Room
December 19 ducat on M.D. De artment o Med c ne ollege o Med c ne a e Med cal n ers t a e a an
Professional Experiences (Top 5): th
603 Room 1. Attend ng h s c an D s on o g necolog c oncolog De artment o n hang ung Memor al os tal 2. Assoc ated Pro essor hang ung Med cal School hang ung n ers t 3. Mem er o Stand ng omm ttee a anese Assoc at on o ncolog cal oncolog st . Mem er o omm ttee o Postgraduate ra n ng a a r December 20 th 601 Room December 20 th 603 Room
60 Safety and QoL of Avastin in Gyn Cancer
ung sueh hou
he rat onale to use an ant ang ogenet c treatment n cancer s related to the resence of hypoxia in cancer tissue; the reduction of oxygen induces the transcription of vascular endothel al gro th actor rece tor ( F ) on the endothel al cells su se uentl the nd ng o c rculat ng ascular endothel al gro th actor ( F) th the rece tor leads to rol erat on o ne essels romot ng tumor gro th. Bevacizumab, a humanized monoclonal IgG antibody that targets VEGF-R, has been one o the rst and most n est gated ant ang ogenet c drugs and se eral e dences demonstrated ts e cac also n and . Bevacizumab is approved for the first-line treatment of AOC, fallopian tube, and primary peritoneal cancers due to the results of two randomized controlled Phase III trials. It is also the rst and onl target thera a ro ed o rst l ne com nat on s stem c treatment based on a randomized controlled Phase III trial. he nternat onal olla orat e ar an eo lasm r al ( ) and the necolog c ncolog rou rotocol ( 021 ) demonstrated an m ro ement o rogress on ree sur al (PFS) ma nl n the h gh r s o ulat on the “h gher r s ” as de ned as at ent th a F stage tumor su o t mal de ul ed (res dual d sease a ter DS 1 cm) or stage IV. Gynecologic Oncology Group protocol (GOG-0240) proved Bevacizumab the standard o care to rolong PFS and S n cer cal cancer. Despite recent studies confirmed, the truth of bevacizumab plays a pivotal role in the o ar an and cer cal cancer lead ng to the e entual de elo ment o mal gnant d seases. n th s as s these agents are generall atent o ed or used n some thera eut c treatment. Follo the regulator o o s m lar drug entrance the sa et and e cac or g n at ents care s the ma n o nt e should mon tor. ere e d scuss the as s o and the log c eh nd the a ro al o these agents n the treatment o cancers as ell as the r e aluat on n d erent ers ect es and rules.
61 December 19 Ying-Cheng Chiang
urrent Pos t on 1. Attend ng Ph s c an De artment o stetr cs and necolog at onal a an n ers t os tal th 2. Ass stant ro essor De artment o stetr cs and necolog ollege o 601 Room Med c ne at onal a an n ers t
December 19 ducat on 1. M.D. School o Med c ne ollege o Med c ne at onal a an n ers t 2. Ph.D. raduate nst tute o l n cal Med c ne ollege o Med c ne at onal a an n ers t th
603 Room Professional Experiences (Top 5): 1. Attend ng h s c an De artment o stetr cs and necolog at onal a an n ers t os tal un n ranch 2. Attend ng h s c an De artment o stetr cs and necolog at onal a an n ers t os tal 3. Ad unct nstructor De artment o stetr cs and necolog ollege o Med c ne December 20 at onal a an n ers t 4. Visiting Scholar, Department of Obstetrics and Gynecology, Anschutz Medical Campus, n ers t o olorado Den er . D rector De artment o stetr cs and necolog at onal a an n ers t os tal
th unl n ranch 601 Room December 20 th 603 Room
62 Evolving Area of Maintenance Therapy in Recurrent Ovarian Cancer
ng heng h ang
ar an cancer s one o the lead ng causes o death rom g necolog c mal gnanc . Des te h gh res onse rate to standard lat num ased chemothera man at ents recur su se uentl and re eated recurrence th decreased lat num sens t t ollo s. o rolong rogress on ree nter al o o ar an cancer targeted thera arose as ma ntenance therapy in the past decade. Bevacizumab, an anti-vascular endothelial growth factor (VEGF), as rst used. Pol (adenos ne d hos hate r ose) ol merase (PA P) nh tors has een e ol ng after. Inhibition of PARP, an enzyme required in single-stranded DNA break repair, has ro en to e e ect e n cancers that n ol e D A re a r mechan sm de ects. n 201 ola ar ecame the rst PA P nh tor to e a ro ed or the ma ntenance treatment o recurrent e thel al o ar an allo an tu e or r mar er toneal cancer n at ents ho are n com lete or art al res onse to lat num ased chemothera th cl n cal e dence o Stud 19 and S 2. In 2017, niraparib was approved based on the results of NOVA trial, a randomized, dou le l nd lace o controlled hase . A tr al demonstrated n ra ar s gn cantl rolonged rogress on ree sur al n at ents th recurrent lat num sens t e h gh grade serous o ar an allo an tu e or r mar er toneal cancer regardless o A mutat on or homologous recom nat on de c enc ( D) status. t also suggests that n ra ar s an e ect e ne o t on th a managea le tolera l t ro le.
63 December 19 Shih-Tien Hsu
urrent Pos t on h e D s on o necolog De artment o stetr cs and necolog a chung eterans eneral os tal th 601 Room
December 19 ducat on MD School o h nese Med c ne h na Med cal n ers t MS raduate nst tute o ntegrated Med c ne h na Med cal n ers t PhD raduate nst tute o as c Med c ne h na Med cal n ers t th
603 Room Professional Experiences (Top 5): Attend ng Ph s c an De artment o stetr cs and necolog a chung eterans eneral os tal ecturer School o Med c ne h na Med cal n ers t December 20 th 601 Room December 20 th 603 Room
6 PARP inhibitors in ovarian cancer
Sh h en su
Pol ADP ose Pol merase nh tors (PA P ) ere rstl l censed or ma ntenance treatment n recurrent lat num sens t e e thel al o ar an cancer at ents. he recent three hase tr als sho ed that there s a role or PA P also n rst l ne sett ng as ma ntenance thera a ter lat num res ons e chemothera . e ertheless the u l shed tr als ra sed se eral uest ons on hat s the est treatment accord ng to the molecular status tumor h stolog and the res onse to lat num. Follo ng the re ous tal professor Wu, the published data was summarized to discuss clinical decision making on hat could e the est se uence or com nat on o treatments on ne d agnosed ad anced o ar an cancer or the three molecular ro les (the carr ers o a A mutat on ( Amut) those th a de c enc n homologous recom nat on s stem ( d) and those th a ro c ent homologous recom nat on s stem ( )).
6 December 19 Jen-Ruei Chen
urrent Pos t on Sen or Attend ng Ph s c an D s on o necolog cal ncolog De artment o Mac a Memor al os tal a e a an th 601 Room
December 19 ducat on MD. De artment o Med c ne h na Med cal ollege a chung a an graduated n 199
Professional Experiences (Top 5): National Board of Medical Examiners Diploma of R.O.C. (No. 28012) th
603 Room at onal oard o stetr cs and necolog o . . . ( o. 26 2) oard o a an Assoc at on o necolog c ncolog ( o. 00 ) oard o a an Soc et o Per natolog ( o. 3 0) December 20 th 601 Room December 20 th 603 Room
66 Immuno-Oncology in Gynecological Malignancies
en ue hen
mmuno oncolog also no n as cancer mmunothera s a ne eld o cancer thera . t s an art c al st mulat on o the mmune s stem to treat cancer re en orce the immune system's natural killing ability to recognize and destroy the cancer cells. After understand ng the current as c no ledge o mmunolog cancer mmunolog has also een ell stud ed n recent t o decades. n 2013 Dan el S. hen and ra Mellman re e ed“ he cancer mmun t c cle” n the ournal called mmun t e e and o nted out some uture ne n est gat ons o cancer mmunothera . n 201 Amer can mmunolog st ames P. All son and a anese mmunolog st asu u on o rece ed the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negat e mmune regulat on. The carcinogenesis is characterized by the accumulation of a consecutive genetic alterat ons and the loss o normal cellular regulator a o tos s rocesses. hese e ents lead the expression of neoantigens, differentiation antigens, or cancer testis antigens. Presentation o ant gens and ound to ma or h stocom at l t class (M ) molecules on the sur ace o cancer cells ll ma e them sho d erent mmun t character st cs rom normal somat c cells. he h othes s o cancer mmunothera s that cancer cells ha e un ue tumor ant gens or molecules resents on the r cell sur ace. A ter act at ng the mmuno s stem immune cells (T-cell, B-Cell, nature killer cells or dendritic cells) could recognize the unique cancer ant gen or molecular and roceed destro unct on to cancer cells. urrentl man researches had re orted the r e orts n cancer mmunothera es. n summar the are“ ellular mmunothera (Dendr t c cell thera A cell thera )” “Ant od thera ( nclud ng cell rogrammed death ath a s)” “ to ne thera ( nter eron nterleu n)” “ om nat on mmunothera ” “Pol sacchar de ” and man ne molecular olog cal elds h ch are also under n est gat on. he goal o cancer mmunothera s to n t ate or re n t ate a sel susta n ng c cle o cancer mmun t ena l ng t to am l and ro agate ut not so much as to generate unrestra ned auto mmune n lammator res onses. Am l ng the ent re c cle ma ro de ant cancer act t ho e er t ro a l causes the otent al cost o un anted damage to normal cells and t ssues. Fortunatel man o the cancer mmunothera a roaches re ort sa et ro les that are m lder and more managea le than trad t onal ( .e. surger rad at on or chemothera ) or targeted ( .e. oncogene centr c) cancer thera es. n th s r e tal the conce t o cancer mmun t c cle ll e re e ed. St mulat ng and nh tor actors n each ste s o mmun t c cle ll also e resented or understand ng the oss le a l cat on o these actors n current cancer mmunothera es. F nall ll ocus on the current e dence or cl n cal tr als o the agents med c ne that connect ons et een u to date cancer mmunothera es and g necolog cal cancer treatments.
6 December 19 David SP Tan
urrent Pos t on Sen or onsultant Med cal ncolog st Assoc ate Pro essor ong oo n School o Med c ne th 601 Room
December 19 ducat on Dr David Tan graduated with an intercalated BSc in Experimental Pathology (1st Class onours) and M S th D st nct on rom u s ng s and St homas School o Med c ne n ers t o ondon . e undertoo tra n ng n nternal med c ne at ammersm th os tal and u s and St homas os tals n ondon. e as a arded a ancer esearch th
603 Room ( ) l n cal esearch Fello sh n 200 at he nst tute o ancer esearch ondon here he o ta ned h s PhD n oncolog . e com leted h s s ec al st tra n ng n med cal oncolog at he o al Marsden os tal ondon and com leted a ello sh at the Pr ncess Margaret ancer entre n ers t o oronto anada n Drug De elo ment and naecolog c ncolog e ore return ng ac to S nga ore.
December 20 Professional Experiences (Top 5): 2020 resent o ha r er cal ancer esearch et or ( ) o the necolog c ancer nter rou ( ) 2019 resent ha r o the As a Pac c necolog c ncolog r als (AP ) rou
th 2019 resent Sc ent c omm ttee Mem er or the uro ean Soc et o Med cal 601 Room ncolog ( SM ) naecolog cal ancers Su omm ttee 201 resent Sc ent c omm ttee Mem er or the uro ean Soc et o Med cal ncolog ( SM ) argeted Ant cancer hera es ( A ) on erence 201 resent As an Soc et o necolog c ncolog (AS ) ounc l Mem er and Pres dent o the necolog c ancer rou S nga ore ( S) December 20 th 603 Room
6 Biomarkers in Immuno-oncology for Gynecological Cancers
Da d SP an
n recent ears mmunothera has trans ormed the treatment landsca e o cancer. n art cular mmune thera target ng mmune chec o nt rece tors such as rogrammed cell death 1 (PD 1) and rogrammed cell death l gand 1 (PD 1) are among the most rom s ng a roaches ha ng demonstrated cl n cal act t n a de ar et o tumors nclud ng o ar an cer cal and endometr al cancers. n th s tal the current e dence or red ct e omar ers o res onse to mmunothera eut c a roaches n g necolog c mal gnanc es ll e d scussed.
69 December 19 Cherry Yin-Yi Chang
urrent Pos t on D rector o endosco c d s on de artment o n h na Med cal n ers t os tal 201 no th D rector o the e dence ased med c ne center o h na Med cal n ers t 601 Room os tal 201 no Ass stant Pro essor Med cal School h na Med cal n ers t os tal a chung a an
December 19 ducat on PhD h na Med cal n ers t School o Pu l c ealth a an 200 2013 MP n ers t o M ch gan School o Pu l c ealth. Ann Ar or SA 200 200 MS h na Med cal n ers t School o Med c ne a an 2001 2003 MD h na Med cal n ers t School o Med c ne a an 19 199 th 603 Room Professional Experiences (Top 5): Mem er o the oard o D rector o a an Assoc at on o o stetr cs and necolog Mem er o a an Assoc at on o necolog ncolog Mem er o the oard o Su er sors or a an Assoc at on or M n mal n as e necolog December 20 th 601 Room December 20 th 603 Room
0 Cell therapy in gynecologic cancers
herr n hang
necolog c cancer s common and ro lemat c d sease or omen. Surger chemothera and rad at on are the ma n strateg es o the treatment or g necolog cancer. e ertheless the rognos s o some g necolog cancers are not m ro ed lot. n recent ears there s da n that target thera es are a l ed n the treatment o o ar an cancer and the sur al s rolonged n stud es. o e er e st ll need more ne nno at ons or the treatment o g necolog cancer to m ro e outcome o at ents and cellular thera s graduall gra ng sc ent st s attent on. Some orms o cell thera ha e een ro osed around s nce the 19 0s to treat certa n t es o cancer. n 201 o the rst A cell thera es to treat leu em a as a m lestone o the cell thera a l ed n treat ng cancer. S nce then glo al n estment n cell thera s ncreas ng and cancer cell thera has ecome one o the most rom s ng a roaches or cancer treatment. n human od mmune cells no n as ller cells are aga nst cancer due to the r a l t to nd to mar ers no n as ant gens on the sur ace o cancer cells. ellular mmunothera es can be utilized in several ways to fight with cancers, such as Tumor-Infiltrating Lymphocyte ( ) hera ng neered ell ece tor ( ) hera h mer c Ant gen ece tor ( A ) ell hera atural ller ( ) ell hera ect. A l cat on o cellular mmunothera on g necolog cancer ere re orted ut data as l m ted. ut ancer mmunothera s e ol ng u c l . nderstand ng the omar ers o res onse to th s thera and dent ng mechan sms to o ercome mmune su ress on and counter regulat on are cr t cal n the uture stud es.
1 December 19 Wen-Shiung Liou
urrent Pos t on De ut D rector o stetr cs and necolog n aohs ung eterans eneral os tal th 601 Room
December 19 ducat on Se . 19 3 ul 1990 at onal De ense Med cal enter a an . . .
Professional Experiences (Top 5): Dec 2003 an 200 s t ng Scholar or g necolog c oncolog tra n ng n Stan ord th
603 Room n ers t ul 200 an 2013 D rector o ancer enter n aohs ung eterans eneral os tal ul 2016 201 Manages the su er sor n a an Assoc at on o necolog c ncolog sts Se 2012 Se 2019 D rector o o stetr cs and necolog n aohs ung eterans eneral os tal December 20 th 601 Room December 20 th 603 Room
2 Trabectedin in gynecological cancer
Wen Sh ung ou
ra ected n s a D A nd ng agent th a un ue ant tumor mechan sm o act on targeting the transcription-coupled nucleotide excision repair (NER) system. Trabectedin traps members of the NER mechanism forming large complexes that inhibit NER activity result ng n s ngle strand D A rea s. hese rea s su se uentl stall re l cat on or s leading to double-strand DNA breaks and resulting in cell death. Trabectedin exerts its act on nd ng to the 2 os t on o guan ne n the D A m nor groo e and th s ends the D A to ards the ma or groo e there nh t ng nduc le transcr t on. Due to ts e ect on tumor assoc ated macro hages and h st oc tes tra ected n s ostulated to ha e mmunomodulator e ects on the tumor m croen ronment. Trabectedin in combination with pegylated liposomal doxorubicin (T + PLD) is approved n the uro ean n on and man other countr es or treatment o at ents th recurrent platinum-sensitive ovarian cancer. These drug entities, with non-overlapping toxicities, can nduce D A rea s lead ng to cell a o tos s through d erent mechan sms o act on. he A1 rote n s m ortant n the re a r o these D A rea s a the transcr t on coupled NER complex and hence mutations in BRCA1 are likely to be associated with better treatment res onse. he r mar unct on o A2 s n homologous recom nat on ( ) med ated the assem l o AD 1 on dsD A. n AD 1 mutant east stra ns tra ected n d s la ed h ersens t t su ort ng act e dur ng the rocess ng re a r o the drug nduced les ons. ther se le om osarcoma ( MS) s a common h stolog c su t e o so t t ssue sarcomas (S S) most o h ch ar se n the uterus. Although uter ne le om osarcomas (u MS) account for fewer than 5% of all uterine malignancies, they represent approximately half of all uter ne sarcomas. he treatment o metastat c u MS rema ns a cons dera le challenge. First- and second-line chemotherapy options include fixed dose rate gemcitabine plus docetaxel which achieves an objective response in approximately 30% of patients, single- agent gemcitabine, which achieves an objective response in approximately 20% of patients, and doxorubicin-based treatment, with similar objective responses. Systemic treatment o t ons are l m ted or at ents th u MS a ter anthrac cl ne a lure. n se eral ros ect e cl n cal tr als and retros ect e anal ses tra ected n has demonstrated rolonged d sease control n at ents th MS or l osarcoma ( PS). he post hoc subset analysis of data from a large randomized phase 3 trial, women with uLMS ho had rece ed r or anthrac cl ne treatment ach e ed a s gn cant m ro ement n PFS with trabectedin compared with dacarbazine. The observed efficacy and toxicity profile o tra ected n as s m lar to that re orted n the o erall MS and PS o ulat on. h s su set anal s s con rms the a l t o tra ected n to ach e e cl n call mean ng ul d sease control rates or rolonged treatment er ods there su ort ng ts use or omen th ad anced u MS.
3 December 19 Chyong-Huey Lai
urrent Pos t on ce Pres dent n ou hang ung Memor al os tal D rector necolog cal ancer esearch enter hang ung Memor al os tal th ha r erson As an necolog c ncolog rou 601 Room D st ngu shed Pro essor hang ung n ers t De artment o Med c ne
December 19 ducat on at onal a an n ers t ollege o Med c ne s t ng l n cal Fello necolog c ncolog De t. o stetr c g necolog ale n ers t School o Med c ne .S.A. s t ng l n cal Fello necolog c ncolog De t. o stetr cs necolog th
603 Room olum a Pres ter an Med cal enter ollege o Ph s c an and Surgeon olum a n ers t .S.A.
Professional Experiences (Top 5): a hao A uang sueh S n uang S hao F u ong hou hang hang . uman a lloma rus genot e n cer cal cancer a o ulat on December 20 ased stud . nt ancer 200 120 1999 2006. ( F 6. 13； 2 21 ； ) corres ond ng author a hang uang sueh S hao A n hao F uang S uang Wu uang hang . ole o P genot e n rognos s o cer cal cancer undergo ng
th ； ；
601 Room r mar surger . l n ncol 200 2 362 363 .( F 2 .00 21 ) corres ond ng author hou hang en g Ma S sueh S hang uang hao A Wu Wu YC, Lin CT, Huang KG, Lai CH.* Low value of 2-fluoro-2-deoxy-d-glucose positron emission tomogra h n r mar stag ng o earl stage cer cal cancer r or to rad cal h sterectom . ； ； December 20 l n ncol 2006 2 123 12 .( F 2 .00 21 ) corres ond ng author en g Ma S hou sa S sueh S hang ong See n W hen JT, Huang KG, Lui KW, Lai CH.* Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron em ss on tomogra h n cer cal cancer. l n ncol 2003 21 36 1 .( F 2 .00 ； 21 ； ) corres ond ng author th 603 Room n g hang Wang o en Wu Wang hen uang g S ung SM hang a . M ometr al n as on de th n endometr al cancer d agnost c accuracy of diffusion-weighted MR imaging at 3.0 T: initial experience at 3.0 T. Radiology 2009 2 0 92. ( F .296； 2 126； AD A M D M D A MA ) corres ond ng author
What's next for PARP inhibitors? PARPi resistance and ways to overcome
h ong ue a
t s ell no n that tumor cells th D A re a r de ect e.g. A1 2 mutat on are more sens t e to PA P nh tors (PA P ) through the mechan sm o s nthet c lethal t . Se eral PAP nh tors ha e een a ro ed or o ar an cancer nd cat ons nclud ng ola ar n ra ar and ruca ar . o e er PA P res stance s not unusual n cl n cal ract ce. Some A1 2 de c ent at ents a l to res ond to PA P h le some other at ents ac u re PA P res stance th rolonged oral adm n strat on o PA P nh tors. omologous recom nat on re a r de c enc ( D) as a rere u s te o s nthet c lethal t la s a cr t cal role n ll ng tumor cells. As ou can see PA P are much more e ect e n homologous recom nat on re a r de c ent tumor cells than n homologous recom nat on re a r ro c ent cells. here ore omologous recom nat on re a r restorat on ecomes the redom nant reason o PA P res stance. ar ous actors such as D A re l cat on or rotect on re ers on mutat ons e genet c mod cat on restorat on o ADP r os lat on (PA lat on) and harmacolog cal alterat on ma lead to PA P res stance. h s tal ll ocus on the underl ng mechan sms o PA P nh tor res stance and r ng out the otent al strateg es (e.g. PA P com nat ons a roach) to o ercome PA P res stance and ncrease PA P sens t t .
December 19 Young Doctor Session/Oral Presentation
Chia-Lin Chou
urrent Pos t on th
601 Room Attend ng Ph s c an D s on o olorectal Surger h Me Med cal enter December 19
ducat on M.D. degree 199 200 a e Med cal n ers t School o Med c ne a e a an Ph.D degree 201 9 no at onal Sun at sen n ers t nst tute o omed cal Sc ence
th aohs ung a an 603 Room
Professional Experiences (Top 5): a arosco c colorectal surger Da nc o ot c surger ransanal m n mal n as on surger ( AM S) December 20 Transanal total mesorectal excision (TaTME) Anal surger th 601 Room December 20 th 603 Room
6 Clinical Impact and Prognostic Factors of Oophorectomy for Ovarian Metastasis from Colorectal Cancer: a single institution experience
o c l n cal m act and Prognost c Factors o o horectom or ar an Metastas s rom olorectal ancer a s ngle institution experience Authors h a n hou1 2 u Feng an1 h n heng1 h en Feng 3 h eh ang6 uo Feng uang6 A l at on 1 D s on o olorectal Surger De artment o Surger h Me Med cal enter a nan a an. 2 nst tute o omed cal Sc ences at onal Sun at sen n ers t aohs ung a an 3De artment o Patholog h Me Med cal enter a nan a an. De artment o Med cal esearch h Me Med cal enter a nan a an at onal nst tute o ancer esearch at onal ealth esearch nst tutes a nan a an 6 De artment o stetr cs and necolog h Me Med cal enter a nan a an.
ac ground ar an metastases ha e re ousl een re orted as occurr ng n 2 o omen th metastat c colorectal cancer ( ). he current stud a med to n est gate the character st cs and rognos s o surg cal treatment or o ar an metastas s rom colorectal cancer and to esta l sh an o t mal management lan. Methods and esults h s s a s ngle nst tut on retros ect e stud o at ents th th o ar an metastases rom 2000 to 2019. 2 Pat ents ho under ent r mar tumor resect on and oo horectom ere collected or anal s s. We e aluated at ent d sease and treatment related actors assoc ated th o erall sur al rom n t al d agnos s o th o ar an metastas s. he med an age at d agnos s as 9.9 (range 2 2) ears. All o the at ents resented th ad anced tumor (at least 3) and almost all at ents had an os t e tumor. n total 0 (96.2 ) at ents had moderatel d erent ated adenocarc noma 2 (3. ) oorl d erent ated adenocarc noma and (9.6 ) muc nous adenocarc noma. Moreo er 22 (42.3%) patients experienced bilateral ovarian involvement. The peritoneum (44.2%) was the most common concurrent metastat c s te ollo ed the l er ( 0. ) and lung (11. ). he med an sur al t me a ter surger as 21 (9 con dence nter al 2) months. urat e resect on ( 0) as ach e ed n 16 (30. ) at ents. Degree o res dual tumor s s gn cantl assoc ated th o erall sur al n the un ar ate and mult ar ate anal s s ( 0.001 and 0.029). onclus on n care ull selected at ents curat e resect on or o ar an metastas s s e ect e and could o er otent al long term sur al.
December 19 Young Doctor Session/Oral Presentation
Malika Kengsakul
urrent Pos t on th
601 Room ecturer De artment o stetr cs and naecolog Pan anantha h hu hon rathan Med cal enter Sr na har n rot n ers t ha land December 19
ducat on ert cate o Med cal Pro c enc n naecolog cal ndosco 2020 D loma o the ha oard o naecolog cal ncolog 201
th D loma o the ha oard o stetr cs necolog 201 603 Room ha Med cal cense 2010
Professional Experiences (Top 5): naecolog cal ncolog st December 20 th 601 Room December 20 th 603 Room
Extra-nodal Involvement of Diffuse Large B-cell Lymphoma Mimics Locally Advanced Cervical Cancer: A Case Report and Literature Review
Authors 1Mal a engsa ul 2 ar tsara Wongtong 3 heethat Mong ornthong an ttha tsom ut A l at on 1 3 De artment o stetr cs and necolog Pan anantha h hu hon rathan Med cal enter Sr na har n rot n ers t ontha ur ha land 2De artment o Med c ne Pan anantha h hu hon rathan Med cal enter Sr na har n rot n ers t ontha ur ha land
ac ground D use large cell l m homa (D ) s the most common su t e o non odg n lymphoma (NHL). Approximately, 40% of DLBCL originates from extra-nodal sites. The common or g nal s tes are gastro ntest nal tract test s central ner ous s stem reast mediastinum, skin and bone. Extra-nodal involvement of female genital tract organ was reported however, it is extremely rare. Methods and esults We resented a case o an act e 63 ear old mult arous meno ause oman. ur at ent under ent an nc dental cer cal o s dur ng her annual chec u . A ee later she as re erred to our hos tal or urther treatment. er ro s onal d agnos s as locall ad anced cervical cancer. However, the initial cell type was atypical cell cannot exclude malignancy. The pelvic examination reviewed a whole infiltrative dark red, hard consistency cervix and short fornices. Her rectovaginal examination was normal, no parametrial involvement was observed. Other physical examinations were normal. The initial tissue slides were reviewed and a re eat cer cal o s and endocer cal curettage as er ormed. Dur ng a month o n est gat on she de elo ed mult le l m hadeno ath and s gn cant e ght loss. he Scan sho ed d use th c en ng all o gall ladder th sus ected o n as on o ad acent l er mult le ntraa dom nal and gro n l m hadeno ath s lenomegal and m n mal asc tes. he nal mmunoh stochem str re ort as d use large cell l m homa. Marro and one o s stud es ere negat e. he d agnos s as d use large cell l m homa Ann Ar or stage . he at ent as re erred to hematolog st and rece ed courses o P (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone). After second courses of R-CHOP, the cervix appeared normal. The patient showed a complete response and rema ned n rem ss on. he resentat on treatment and cl n cal outcome o our case and re ous u l shed cases ere re e ed and d scussed. onclus on o the emale gen tal tract s rare. he d ers t o d sease man estat on can m m c r mar neo lasms. A h gh le el o sus c on and mult d sc l nar a roach are mandator to er orm a t mel d agnos s and an a ro r ate treatment to m ro e the outcome and a o d unnecessar surger or rad at on. e ords hematologic malignancy, cervical cancer, large B-cell lymphoma, extra-nodal n ol ement
9 December 19 Young Doctor Session/Oral Presentation
Se-Ik Kim
urrent Pos t on th
601 Room esearch Pro essor omed cal esearch nst tute Seoul at onal n ers t os tal De artment o stetr cs and necolog Seoul at onal n ers t ollege o Med c ne Seoul e u l c o orea December 19
ducat on 200 .3 2009.2 M.D. Seoul at onal n ers t ollege o Med c ne 2012.3 201 .2 M.S. Seoul at onal n ers t raduate School
th 201 .3 Ph.D. course Seoul at onal n ers t raduate School 603 Room
Professional Experiences (Top 5): nst tut onal ra n ng 2009.3 2010.2 nternsh Seoul at onal n ers t os tal Seoul at onal n ers t ollege o Med c ne December 20 2010.3 201 .2 es denc De t. o stetr cs and necolog Seoul at onal n ers t os tal 201 . 2020.9 Fello sh D s on o necolog c ncolog De t. o stetr cs and necolog Seoul at onal n ers t os tal th
601 Room Pu l cat ons Proteom c D sco er o omar ers to Pred ct Prognos s o gh rade Serous ar an arc noma m S ung M Dan ee S ee m S et al. ancers ( asel). 2020 12 90.
December 20 om ar son o sur al outcomes et een m n mall n as e surger and con ent onal o en surger or rad cal h sterectom as r mar treatment n at ents th stage 1 A2 cer cal cancer. m S ho Seol A m ee M m S et al. necol ncol. 2019 1 3(1) 3 12.
th De elo ment o We ased omograms to Pred ct reatment es onse and Prognos s o 603 Room thel al ar an ancer. m S Song M ang o S ee S ho m et al. ancer es reat. 2019 1(3) 11 .
Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. m S ee W ee M m S hung m W et al. necol ncol. 201 1 (2) 3 2.
0 Low Adoption Rate of iRECIST Guidelines in Recurrent Gynecologic Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors Se m MD Mar a ee MD PhD ae Weon m MD PhD A l at on De artment o stetr cs and necolog Seoul at onal n ers t ollege o Med c ne Seoul 030 0 e u l c o orea
ntroduct on Two immune checkpoint inhibitors, pembrolizumab (pembro) and nivolumab (nivo), have een erm tted the orean Food and Drug Adm n strat on n treatment o recurrent g necolog c cancers s nce o em er 201 . urrentl S (mod ed S 1.1 or mmune ased thera eut cs) s a a la le or res onse e aluat on n cl n cal tr als and practice also. We aimed to present real-world experience with pembro and nivo regarding res onse e aluat on n t o tert ar hos tals. Mater als and Methods We dent ed at ents th recurrent o ar an cer cal and endometr al cancers treated th mmune chec o nt nh tor monothera et een o em er 201 and Ma 2020. We excluded patients who were enrolled in clinical trials. Through the review of patients’ med cal records cl n co atholog c character st cs and res onse data ere collected. umor res onse as e aluated oth the S 1.1 and S gu del nes. esults n total 9 at ents ere ncluded n th s anal s s ( 1 or em ro and 1 or n o). Mean at ent age as .6 ears and med an treatment l nes and c cles or em ro n o ere (range 3 9) and (range 1 2 ) res ect el . Pem ro n o treatment as st ll ongo ng n 6 at ents. Among 3 at ents ho sho ed rogress e d sease (PD) S 1.1 1 ( 0.0 ) at ents sto ed em ro n o thout mag ng F h le 21 at ents (60.0 ) ere regarded as PD S and cont nued em ro n o th mag ng F . erall the o ect e res onse rate as . and med an rogress on ree sur al (PFS) as 3.0 months ho e er these alues urther decreased to 6. and 1.9 months res ect el hen S 1.1 as str ctl a l ed. onclus on he ado t on rate o S n at ents th recurrent g necolog c cancers as 60.0 . ur stud results demonstrate the necess t o mag ng ollo u or con rmat on o res onse rather than d rect d scont nuat on o the drugs as recommended the S .
1 December 19 Young Doctor Session/Oral Presentation
Se-Ik Kim
urrent Pos t on th
601 Room esearch Pro essor omed cal esearch nst tute Seoul at onal n ers t os tal De artment o stetr cs and necolog Seoul at onal n ers t ollege o Med c ne Seoul e u l c o orea December 19
ducat on 200 .3 2009.2 M.D. Seoul at onal n ers t ollege o Med c ne 2012.3 201 .2 M.S. Seoul at onal n ers t raduate School
th 201 .3 Ph.D. course Seoul at onal n ers t raduate School 603 Room
Professional Experiences (Top 5): nst tut onal ra n ng 2009.3 2010.2 nternsh Seoul at onal n ers t os tal Seoul at onal n ers t ollege o Med c ne December 20 2010.3 201 .2 es denc De t. o stetr cs and necolog Seoul at onal n ers t os tal 201 . 2020.9 Fello sh D s on o necolog c ncolog De t. o stetr cs and necolog Seoul at onal n ers t os tal th
601 Room Pu l cat ons Proteom c D sco er o omar ers to Pred ct Prognos s o gh rade Serous ar an arc noma m S ung M Dan ee S ee m S et al. ancers ( asel). 2020 12 90.
December 20 om ar son o sur al outcomes et een m n mall n as e surger and con ent onal o en surger or rad cal h sterectom as r mar treatment n at ents th stage 1 A2 cer cal cancer. m S ho Seol A m ee M m S et al. necol ncol. 2019 1 3(1) 3 12.
th De elo ment o We ased omograms to Pred ct reatment es onse and Prognos s o 603 Room thel al ar an ancer. m S Song M ang o S ee S ho m et al. ancer es reat. 2019 1(3) 11 .
Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. m S ee W ee M m S hung m W et al. necol ncol. 201 1 (2) 3 2.
2 Impact of Adjuvant Radiotherapy on Survival Outcomes in Intermediate-risk, Early-stage Cervical Cancer: Analyses Regarding Surgical Approach of Radical Hysterectomy
Authors Se m MD1 ae un m MD 2 Mar a ee MD PhD1 ae Weon m MD PhD1 A l at on 1De artment o stetr cs and necolog Seoul at onal n ers t ollege o Med c ne Seoul 030 0 e u l c o orea 2De artment o stetr cs and necolog Seoul Metro ol tan o ernment Seoul at onal n ers t oramae Med cal enter Seoul 0 061 e u l c o orea
ntroduct on h s stud a med to n est gate the m act o ad u ant rad othera ( ) on sur al outcomes n at ents th ntermed ate r s earl stage cer cal cancer ho under ent rad cal h sterectom ( ). Mater als and Methods From the cer cal cancer cohorts o t o tert ar hos tals at ents th 2009 F stage A ho under ent r mar et een 2010 and 201 ere dent ed. Pat ents th ntermed ate r s actors that met the Sedl s cr ter a ere ncluded. Sur al outcomes ere com ared et een the at ents ho rece ed ad u ant (stud grou n 3) and those ho d d not rece e ad u ant treatment (control grou n 30). esults om ared to the control grou the stud grou sho ed s gn cantl etter recurrence ree sur al ( FS ear sur al rate .6 s. 61.0 P 0.009). n mult ar ate anal s s ad u ant as assoc ated th a s gn cantl lo er r s o d sease recurrence (ad usted 0.2 1 9 0.0 2 0. 09 P 0.010). n a su grou that under ent o en (n 33) ad u ant sho ed a trend to ard m ro ed FS th orderl ne stat st cal s gn cance (ad usted 0.09 9 0.009 1.02 P 0.0 3). o e er n a su grou o m n mall n as e surger (n 0) ad u ant d d not m ro e FS. onclus on m lementat on o ad u ant s gn cantl reduced the d sease recurrence rate n at ents th ntermed ate r s stage A cer cal cancer treated r mar l th surger . Sur al ene t rom ad u ant d ered accord ng to the surg cal a roach.
3 December 19 Young Doctor Session/Oral Presentation
Alka Dahiya
urrent Pos t on th
601 Room 3rd ear M h res dent (Post graduate) De artment o necolog c ncolog hr st an Med cal ollege ellore. nd a December 19
ducat on achelor o Med c ne achelor o Surger (M S) MS stetr cs and necolog (201 201 )
th M h necolog c ncolog (201 t ll date) 603 Room
Professional Experiences (Top 5): 1. 3 ear tra n ng n stetr cs and necolog (Post graduat on 201 201 ) 2. 1 ear sen or res denc n stetr cs and necolog (201 201 ) 3. 2 ear tra n ng n necolog c ncolog (201 t ll date) December 20 . ral a er resentat on on ndometr os s and mal gnanc ts ntr gu ng relat onsh n A 2019 . ne u l cat on n . th 601 Room December 20 th 603 Room
Primary Peritoneal Carcinoma and Ovarian Carcinoma : Similar Yet Different
Al a Dah a A t Se ast an A raham Peed ca l notha homas An tha homas achel hand
ac ground Pr mar er toneal carc noma(PP ) s an aggress e e thel al mal gnanc laced th o ar an and allo an tu e cancer under a roader s ectrum o d sease Muller an carc noma shar ng common her tage. F rst descr ed S erdlo n 19 9 PP s st ll cons dered an en gma th a de ata le or g n and s one o the most challeng ng mal gnanc es to treat. ur stud a ms at de elo ng a etter understand ng o th s ent t through a deta led com arat e anal s s o cl n co atholog cal character st cs and sur al outcomes o PP th the h stolog call and o ten cl n call nd st ngu sha le ad anced serous o ar an cancer ( ). Methods and esults Pros ect el ma nta ned cl n cal data ase at hr st an Med cal ollege ellore as re e ed (01 anuar 2010 to 31 Ma 2020). A retros ect e com arat e anal s s as done et een PP (n 69) and (n 1 1) at ents ha ng h gh grade serous stage d sease. nde endent test and h s uare test ere used as a ro r ate. Stat st cal s gn cance as laced at 0.0 . Progress on ree sur al (PFS) and o erall sur al ( S) was calculated using Kaplan Meir curves. Multivariate Cox regression model was used to assess the e ect o nde endent ar a les on sur al. Pat ents th PP had a h gher rate o ar t ( 0.0 9) re ous h sterectom ( 0.0 9) oorer er ormance status ( 0.000) shorter s m tom to treatment nter al ( 0.02 ) larger asc tes ( 0.000) h gher rate o nter al c toreduct on ( 0.00) and lo er surg cal complexity score (p=0.00). The median PFS was 19 months in both PPC and OC patients ( 0. 62). he med an S or PP as months s months n ( 0. 0 p=0.416). In multivariate Cox regression analysis suboptimal cytoreduction (HR 2.51, 0.001) had a s gn cant m act on S h le a shorter PFS as assoc ated th ( 1.6 0.02 ) DS ( PDS 0. 0.002) and su o t mal de ul ng ( 1. 6 0.00 ). When matched or treatment modal t PP at ents ho under ent ( DS) had a su er or PFS (HR OC: 1.66, P=0.032) than the OC IDS subgroup. In multivariate Cox regression anal s s ar an cancer ( 1. P 0.020) and su o t mal c toreduct on ( 2.060 0.006) rema ned s gn cantl assoc ated th a h gher recurrence rate h le res dual d sease ( 3.33 P 0.001) and lac o ad u ant chemothera ( 3. 11 P 0.03 ) lead to a shorter S. onclus on We ound some s gn cant d erences n the cl n co atholog cal ro les o PP and . Though insignificant PPC had an inferior overall survival congruous with existing evidence. Data on PP cont nues to mature and ts oss l t o e ng a d st nct d sease ent t th mult ocal or g n cannot e ruled out.
December 19 Young Doctor Session/Oral Presentation
Anusha Kamath
urrent Pos t on th
601 Room Ass stant Pro essor De artment o stetr cs necolog All nd a nst tute o Med cal Sc ences ag ur. December 19
ducat on raduated rom Smt . . Mun c al Med cal ollege Ahmeda ad n 2011. Passed Master o Surger ( stetr cs naecolog ) rom . Med cal ollege
th Ahmeda ad ( l os tal Ahmeda ad ) n 201 . 603 Room nder ent one ear tra n ng at u arat ancer esearch nst tute
Professional Experiences (Top 5): Sen or res dent n M S Med cal ollege l os tal andh nagar ( ul Decem er201 ) December 20 Ass stant Pro essor at u arat ancer and esearch nst tute Ahmeda ad (Fe ruar 201 Present) AP cert ed tra n ng n Pa n and Pall at e care Ass stant Pro essor at P Sal e Med cal ollege ag ur(Fe March 2019) Ass stant Pro essor De artment o stetr cs necolog A MS ag ur ( ul 2019 th
601 Room Present) December 20 th 603 Room
6 HPV INFECTION AND VACCINE: Knowledge, Attitude And Perception Among Medical Graduates In India
Authors Dr Anusha amath(Ass stant Pro essor) Dr An ta ada (Assoc ate Pro essor) Dr P ush ansal (Ass stant Pro essor) Dr ot aghel (Sen or res dent) Dr Shuch ta Mundle (Add t onal Pro essor) A l at on All authors are a l ated th the All nd a nst tute o Med cal Sc ences ag ur
ac ground De elo ng and under de elo ed countr es ear ng more than 0 o the glo al urden of cervical cancer. It can largely be prevented by prevention and treatment of sexually transm tted n ect ons such as and uman Pa lloma rus ( P ). oth condom usage and rotect e noculat on ( P acc ne) ma e cons dered as r mar re ent on s nce cer cal cancer screen ng onl detects the re n as e les ons. At resent t o acc nes l censed glo all are a a la le n nd a a uadr alent acc ne ardas l mar eted Merc and a bivalent vaccine, Cervarix marketed by Glaxo Smith Kline. The WHO recommends the P acc ne as the ma n a roach or the re ent on o cer cal cancer to e adm n stered prior to first sexual contact especially in adolescent girls. The most important step in creat ng an e ect e co erage rogram s to de elo accurate orms o commun cat on and n ormat on a out P so that eo le understand the m ortance o re ent on and ro lems assoc ated th th s rus. S nce the acc ne s most e ect e hen adm n stered prior to sexual contact, it is essential to inform the youth about the availability of this acc ne. Most o the stud es or no ledge a areness and ract ce o P n ect on and acc nat on are a med at omen n the commun t . h s stud attem ts to assess the a areness among med cal graduates stud ng at ar ous nst tut ons s read o er Southern and entral nd a. Mater als and methods he current stud s des gned as a cross sect onal o ser at onal stud or nal ear med cal graduates at ar ous med cal colleges across nd a. he recru tment o art c ants as done ur os e sno all ng techn ue o er a er od o t o months. he data collect on as done through an onl ne uest onna re generated th the hel o oogle Forms. esults Mean age o the art c ants as 21. 3 ( 1.33) ears th a range et een 20 and 2 ears (n 3 ). 196 ( . ) art c ants ne that cer cal cancer s the second most common cancer among omen n nd a and 3.6 ne all the r s actors or cer cal cancer. Approximately 51.6% were aware of the conditions that may be associated with P and 69.2 ere a are o the ar ous methods o rotect on rom P n ect on. no ledge a out the t es o acc ne a a la le n nd a and the dosage schedule as oor. onclus on Med cal schools should mod the r curr cula to nclude teach ng methods a med at m ro ng P acc nat on and ts related n ormat on. here s a need or a ell des gned P educat on rogram ntegrated nto a nat onal cer cal cancer re ent on and control rogram or greater u ta e o acc nat on.
December 19 Young Doctor Session/Oral Presentation
Rahul Deepak Modi
urrent Pos t on th
601 Room Asst. Pro essor naecolog cal ncolog A MS sh esh nd a December 19
ducat on M S MD stetr cs naecolog (P M hand garh) Fello naecolog cal ncolog ( Ahmeda ad)
th M. h naecolog cal ncolog ( ata Memor al os tal Mum a ) 603 Room
Professional Experiences (Top 5): Pro . Sh ngo Fu ra el rant A ard or S 2019 Pro . Shash ant ele nternat onal necolog cal ncolog cal Fello sh • JRD Tata Award for academic excellence December 20 • Exceptional service Award – Bombay Leprosy Project th 601 Room December 20 th 603 Room
Insight into 'Gynaecological Oncology' Training in India: Perspectives of In-Training Candidates
Authors Mod ahul ar Parm ta erma Palla A l at on naecolog cal ncolog A MS sh esh nd a
ac ground n the last decade g naecolog cal oncolog has seen an enormous gro th and ract ce chang ng re orms a ter ts nce t on almost our decades ago. ar ous soc et es across the glo e ha e de elo ed structured tra n ng rogram or tra nees n g naecolog cal oncolog . nd a had started ts structured tra n ng rogram o 3 ears s nce 2011 although ello sh s did exist prior. There are more than 15 centres in India, averagely training 1 to 2 candidates er ear h ch ncludes oth go ernment and r ate sector. ra n ng ar es rom reg on to reg on across the countr de end ng on actors such as a a la l t o ad anced tra n ng ac l t es mentorsh durat on o course and cancer urden. We a med to stud tra nee profile, satisfaction levels and future expectations of in-training candidates across India. To our knowledge, this is the only study from Asian subcontinent in this context. Methods We de elo ed al dated and adm n stered a cross sect onal e ased ( oogle orms) sur e uest onna re to all the tra nees n g naecolog cal oncolog across nd a l sted n our d rector . uest onna re as sent to them n the rst ee o August 2020. Data collected was analysed using Google sheets. Results were expressed as percentages of total responses received excluding unattended responses. Inferences were drawn from the content s ec c res onses. esults h rt n ne n tra n ng cand dates across the countr res onded o h ch ma or t ( 1. ) ere emales. Most o the tra nees ( ) ere rom un ers t teach ng hos tal run ded cated cancer care centres h ch see a h gh urden o cases. Almost t o th rds (6 .1 ) were extremely satisfied with their training while 28% were just satisfied. Most of the trainees were satisfied with the surgical exposure (64%) and academic activities (61%) at the r centres. es ondents had a s ec al nterest n c toreduct e surger es ( S) 1 and ro ot cs 2 h le 9 and suggested or a ded cated ello sh res ect el n same ost com let on o tra n ng. nl sho ed s ec al nterest n re ent e oncolog and related ad ances. nan mousl (9 ) suggested that tra nees should e ade uatel exposed to gynaecological oncology in their post-graduate training of obstetrics and g naecolog h le 92 suggested harmon sat on o tra n ng curr culum across the countr . onclus on Majority of trainees expressed satisfaction although there is a greater need for uniformifization of training curriculum in gynaecological oncology in India. An interesting nd ng o ncl nat on o n tra n ng cand dates to ards c toreduct e surger es and ro ot cs emerged, inferring building in future - high quality training standards in these complex surger es th needed resources and n rastructure. S ec al em has s should e la d on or creat ng a areness on m ortance and u ld ng an nterest n re ent e oncolog ser ces among tra nees n nd a.
9 December 19 Young Doctor Session/Oral Presentation
Rahul Deepak Modi
urrent Pos t on th
601 Room Asst. Pro essor naecolog cal ncolog A MS sh esh nd a December 19
ducat on M S MD stetr cs naecolog (P M hand garh) Fello naecolog cal ncolog ( Ahmeda ad)
th M. h naecolog cal ncolog ( ata Memor al os tal Mum a ) 603 Room
Professional Experiences (Top 5): Pro . Sh ngo Fu ra el rant A ard or S 2019 Pro . Shash ant ele nternat onal necolog cal ncolog cal Fello sh • JRD Tata Award for academic excellence December 20 • Exceptional service Award – Bombay Leprosy Project th 601 Room December 20 th 603 Room
90 Experience of Virtual Learning in the Times of Pandemic in India and it's Future Perspectives : Observations from 'Gynaecological Oncology' Trainee Survey
Authors Mod ahul erma Palla ar Parm ta A l at on naecolog cal ncolog A MS sh esh nd a
ac ground n these un recedented t mes o D 19 andem c surg cal educat on and tra n ng has een se erel d sru ted. Surg cal s lls are rone to deca . Promot ng rtual learn ng and simulation based platforms can expand training opportunities beyond the walls of hospital. Such measures ma m t gate the d m n shed surg cal and cl n cal s lls caused d sru t on o tra n ng. he oreseea le goal should e to u ld res l ent tra n ng standards res stant to d sru t on as one caused D 19. We a med to stud the erce t ons o n tra n ng candidates in gynaecological oncology in India regarding their present experience of virtual learn ng and uture ers ect es to ncor orate these tra n ng modal t es n standard academ c curr cula. Methods We developed and validated a survey questionnaire using a three member expert team. he sur e as adm n stered through a cross sect onal e ased ( oogle orms) lat orm to all the tra nees n g naecolog cal oncolog across nd a l sted n our d rector n the rst ee o August 2020. Data collected as anal sed us ng oogle sheets. esults ere expressed as percentages of total responses received excluding unattended responses. n erences ere dra n rom the content s ec c res onses. esults h rt se en tra nees across the countr res onded. Ma or t (9 .2 ) o the tra nees conceded that D 19 had s gn cantl m acted the r tra n ng o h ch suggested that hands on surg cal tra n ng as the most a ected 1 erce ed an m act on academ c tra n ng and onl suggested an m act on cl n cal tr al learn ng. All res ondents ere cont nu ng academ c tra n ng through e nars onl ne case resentat ons and tumour oards. one o the res onses a ored rtual learn ng o er or e u alent to eds de cl n cs and ace to ace nteract ons. Almost three ourths ( ) o tra nees suggested cont nu ng onl ne lat orms n ost D t mes. Presentl onl 3 o 16 centres rom res onses rece ed had s ll la and s mulat on tra n ng ac l t es. rtual anatom cal learn ng ac l t as a a la le onl n a s ngle centre across the countr . ada er c d ssect on ( 9 ) as a re erred cho ce o er s mulat on modules n tra n ng cand dates to re ent s ll deca . elemed c ne cl n cs ere run 1 o 16 centres n the countr ut onl o tra nees ere sat s ed th telemed c ne ser ces. onclus on A os t e res onse or onl ne teach ng modules as rece ed among tra nees n g naecolog cal oncolog n nd a although ace to ace learn ng and ed s de cl n cs ere more alued. here as a modest re erence or s mulat on ased s ll tra n ng h le cada er c d ssect on la tra n ng as o er helm ngl acce ted. ncreas ng re erence or onl ne lat orms as seen n the sur e m l ng greater need or urther m ro ement n e ased nteract e ser ces ensur ng a smoother trans t on.
91 December 19 Ie-Ming Shih
urrent Pos t on chard W. e nde D st ngu shed Pro essor o D rector Women s Mal gnanc Program S dne mmel th om rehens e ancer enter 601 Room
December 19 ducat on ear Degree nst tut on D sc l ne 19 1 19 M.D. a e Med cal n ers t Med c ne 19 9 1993 Ph.D. n ers t o Penns l an a omed cal Sc ence ( atholog ) 199 199 es dent ohns o ns os tal Anatom c Patholog th
603 Room 199 199 l n cal Fello ohns o ns os tal necolog c Patholog 199 2000 es. Fello ohns o ns Med c ne Molecular ancer enet cs
Professional Experiences (Top 5): d tor al oard the W lass cat on o umours (Female gen tal tumours) th d t on (2020) December 20 Principal Investigator, NIH/NCI Special Program of Research Excellence of ovarian cancer D rector necolog c D sease esearch Program ohns o ns n ers t School o Med c ne Attending pathologist in gynecologic pathology expertise
th Pu l sh more than 360 eer re e ed a ers n M ancer ell P AS Sc ence ancet 601 Room ncolog ature and ature Med c ne with an H-index > 100, citations > 40,000.
esearch e s te .g necolog cancer.org December 20 th 603 Room
92 The Origin of Ovarian Cancer Species and Precancerous Landscape
e M ng Sh h
nl e other human cancers n h ch all r mar tumors ar se de no o o ar an e thel al cancers are r mar l m orted rom e ther endometr al or allo an tu e e thel um. he re a l ng arad gm n the genes s o h gh grade serous carc noma ( S ) the most common o ar an cancer os ts de elo ment n allo an tu es through ste se tumor rogress on. n recent ears rogress has een made not onl n gather ng tera tes o om cs data ut also n deta l ng the h stolog c molecular correlat ons re u red to loo nto and ma e sense o the t ssue or g n o S . h s emerg ng arad gm s chang ng man acets o o ar an cancer research and rout ne g necolog ract ce. he recancerous landsca e n allo an tu es conta ns mult le concurrent recursor les ons nclud ng serous tu al ntrae thel al carc noma (S ) th genet c heterogene t ro d ng a lat orm or S e olut on. Mathemat cal models m l that a rolonged t me (decades) ela ses rom a earance o a P 3 mutat on the earl est no n molecular alterat on to a earance o a S ollo ed a shorter s an (6 ears) or rogress on to a S . enet c red s os t on accelerates the tra ector ut th s t me l ne ma allo or earl d agnos s o S and S reasona l ollo ed an ntent on to cure surger . n th s resentat on ll d scuss the recent ad ances o th s tu al arad gm and ts olog cal and cl n cal m l cat ons alongs de the rom se and challenge o stud ng recancerous les ons o S .
ote he content o th s resentat on n art can e do nloaded rom htt s do . org 10.1016 .a ath.2020.09.006
93 December 19 Chien-Feng Li
urrent Pos t on ha r De artment o Patholog h Me Med cal enter a an o nt A o ntment n est gator at onal nst tute o ancer esearch th at onal ealth esearch nst tutes 601 Room
December 19 ducat on aohs ung Med cal n ers t aohs ung a an M.D. 199 2002 Med c ne at onal Sun at sen n ers t aohs ung a an Ph.D. 2009 2012 omed cal Sc ences
Professional Experiences (Top 5): th
603 Room o nt A o ntment Pro essor nst tute o Med cal Sc ence and echnolog at onal Sun at sen n ers t Pro essor De artment o otechnolog Southern a an n ers t o Sc ence and echnolog a an o nt A o ntment Assoc ate n est gator at onal nst tute o ancer esearch at onal ealth esearch nst tutes a an December 20 th 601 Room December 20 th 603 Room
9 Identification of BRCAness in clinical practice: genes, phenotypes, and cases
h en Feng
DNA double strand breaks (DSB) are the most cytotoxic DNA lesions. DSB triggers chromosomal a errat on and cell death re a r mach ner can not e act ated. he a l t to restore DS s de ends on the unct on o the homologous recom nat on re a r ( ) s stem h ch co es the res ect e undamaged homologous D A o the s ster chromat d to reconstruct the corru ted dou le strand dur ng S and 2 hase. note the status o tumors s rele ant or treatment select on as ts de ect red cts sens t t to lat num drugs and PA P nh tors (PA P ). Accord ngl test ng or a errat ons o re a r as a red ct e omar er o thera res onse has ecome an area o art cular cl n cal nterest. he a a la l t o PA P ra ses o erall a areness and an ncreas ng a a la l t o A1 2 genet c test ng as ell as those genes n ol ng . Wh le e an test ng has een de elo ed to e aluate status n cancer h ch s gn cantl m a rs the ts access l t . Furthermore l ttle s no n a out the de c enc status n a anese h gh grade serous o ar an cancer ( S ). We thus ll not onl ntroduce the conce ts o genet c test ng n the resent tal ut ll also share the re alence o A1 2 and other genes mutat on as ell as de c enc n a anese S .
9 December 19 Hung-Hsueh Chou
urrent Pos t on Attend ng h s c an D s on o g necolog c oncolog De artment o n hang ung Memor al os tal th 601 Room
December 19 ducat on M.D. De artment o Med c ne ollege o Med c ne a e Med cal n ers t a e a an
Professional Experiences (Top 5): th
603 Room 1. Attend ng h s c an D s on o g necolog c oncolog De artment o n hang ung Memor al os tal 2. Assoc ated Pro essor hang ung Med cal School hang ung n ers t 3. Mem er o Stand ng omm ttee a anese Assoc at on o ncolog cal oncolog st . Mem er o omm ttee o Postgraduate ra n ng a a r December 20 th 601 Room December 20 th 603 Room
96 Optimize the chemotherapy in platinum-sensitive recurrent ovarian cancer and real world data in Taiwan
ung sueh hou
Worldwide, ovarian cancer is the sixth most common cancer and the seventh most common cause of cancer deaths in women. At the time of presentation, approximately 0 o omen ha e ad anced d sease. Des te standard treatment o n t al de ul ng surger ollo ed chemothera most at ents rela se a ter ach e ng a com lete clinical response. Disease that responds to first-line therapy but relapses ≥ 6 months a ter com let on o n t al lat num ased thera s cons dered lat num sens t e. hemothera re treatment s an m ortant as ect n the o erall management o at ents th lat num sens t e recurrent o ar an cancer ( ). n at ents th recurrent o ar an cancer the A A 2.2 tr al sho ed superior efficacy with a platinum–paclitaxel doublet versus platinum alone, establishing com nat on chemothera n th s sett ng. S m larl the A A 2. tr al sho ed s gn cantl longer rogress on ree sur al th a car o lat n gemc ta ne dou let ersus carboplatin alone. A meta-analysis of individual patient data from four randomized trials con rmed the role o lat num dou lets n th s sett ng sho ng m ro ed rogress on ree sur al and o erall sur al ersus s ngle agent lat num across all at ent su grou s. Subsequent randomized phase 3 trials have compared different chemotherapy dou lets nclud ng the A PS A A 2.9 tr al h ch sho ed s gn cantl longer progression-free survival with a carboplatin–pegylated liposomal doxorubicin doublet versus carboplatin–paclitaxel, without impairing quality of life. The carboplatin–pegylated liposomal doxorubicin regimen has become widely used in recurrent ovarian cancer because of its more favorable therapeutic index (particularly the lower incidences of alo ec a h ersens t t react ons and sensor neuro ath ) and dos ng schedule. Ant ang ogen c strateg es com ned th chemothera re resent an m ortant de elo ment n s stem c thera or o ar an cancer. Se eral ant ang ogen c agents ha e sho n e cac n lat num sens t e recurrent o ar an cancer. he latest hase 3 1 tr al sho ed that or omen th recurrent o ar an cancer el g le or lat num re treatment, a carboplatin–pegylated liposomal doxorubicin-bevacizumab experimental reg men led to longer rogress on ree sur al than the car o lat n gemc ta ne bevacizumab standard regimen established in the OCEANS trial. To our knowledge, this is the first phase 3 trial comparing two bevacizumab-containing regimens in recurrent o ar an cancer. Furthermore o erall sur al as s gn cantl m ro ed th eg lated liposomal doxorubicin containing experimental therapy, with an increase in median overall sur al o more than months these results suggest that car o lat n eg lated l osomal doxorubicin–bevacizumab is a new standard regimen for patients with recurrent ovarian cancer su ta le or lat num ased and ant ang ogen c treatment.
9 December 19 Mikio Mikami
urrent Pos t on Pro essor De artment o stetr cs and necolog o a n ers t School o Med c ne sehara anaga a a an th 601 Room
December 19 ducat on 19 M.D. e o n ers t School o Med c ne 1991 Ph.D. e o n ers t School o Med c ne
Professional Experiences (Top 5): th
603 Room 1991 1992 eseach Fello a olla ancer esearch Foundat on ( SA) ( resent San ord urnham Med cal esearch nst tute) 199 199 Fello De artment o stetr cs and necolog e o n ers t os tal 199 200 h e Ph s c an Department of Obstetrics and Gynecology, National Hospital Organization Sa tama at onal os tal December 20 2003 2006 s t ng Assoc ate Pro essor e o n ers t School o Med c ne 2006 Pro essor De artment o stetr cs and necolog o a n ers t School o Med c ne
th Professional Organizations 601 Room 2006 D rector a an Soc et o necolog c ncolog ( S ) 200 D rector a an necolog c ncolog rou ( ) 201 D rector a an Soc et o necolog c and stetr c and M n mal n as e hera ( S ) 201 D rector a an Soc et o stetr cs and necolog ( S )
December 20 2016 ha rman o u del ne comm ttee o S 2019 ha r o th cal omm ttee o S th 603 Room
9 Update in the treatment for uterine sarcoma
M o M am
he Fourth d t on o the a anese u del nes or reatment o ter ne od eo lasm as u l shed n 201 (1) ( necol ncol. 2020 an 31(1) e1 ). h s gu del ne ncludes 9 cha ters he t tle o cha ter s reatment o uter ne carc nosarcoma and uter ne sarcoma. h s cha ter ncludes o er e s and cl n cal uest ons and recommendat ons on the treatment or uter ne sarcoma ( 3 0). l n cal uest ons on ter ne sarcoma n th s cha ter are as ollo s 3 . What surg cal methods and osto erat e ad u ant thera are recommended or uter ne le om osarcoma 39. What surg cal methods and ad u ant thera are recommended or endometr al stromal sarcoma ( SS) 0. What treatments are recommended or unresecta le ad anced or recurrent SS le om osarcoma n th s resentat on recent n ormat on on the d agnos s and treatment or uter ne sarcoma ll e u dated n add t on to cl n cal uest ons and recommendat ons descr ed n our a anese gu del ne on uter ne sarcoma (1 3). e erence 1. necol ncol. 2020 an 31(1) e1 htt s do . org 10.3 02 go.2020.31.e1 2. u del nes ter ne neo lasma ers on1.2021 cto er 20 2020 3. S e Academ Masterclass n necolog cal ncolog
99 December 19 Kuan-Gen Huang
urrent Pos t on Pres dent o a an Assoc at on or M n mal n as e necolog th 601 Room
December 19 ducat on a e Med cal ollege graduated n 19
Professional Experiences (Top 5): D rector o necolog cal ncolog hang ung Memor al os tal a an (201 2020) th
603 Room Pres dent o a an Assoc at on or M n mal n as e necolog (201 2020) December 20 th 601 Room December 20 th 603 Room
100 Laparoscopic Hyperthermic Intraperitoneal Chemotherapy
uan en uang
M n mall n as e surger s ncreas ng the role o treatment n the gastro ntest nal and g necolog cal cancer at ents. a arosco has reduced mor d t aster reco er and s m lar oncolog c outcomes hen com ared th la arotom . toreduct e surger ( S) and h ertherm c ntra er toneal chemothera ( P ) as de elo ed as the treatment o r mar or secondar er toneal mal gnanc es. he gold standard o c toreduct e surger s the remo al o gross tumours and peritoneum. The peritoneal cancer index (PCI) was used to score the extent of peritoneal n ol ement at the t me o surger de ned as P o 10 or less. he com leteness o c toreduct on ( ) score as used to class the resect on status o the er tonectom at ents. he o t mal c toreduct on s score 0 and 1 hereas score 2 and 3 are des gnated as ncom lete c toreduct on. P as er ormed at 1. 3℃ . ecentl the la arosco c S com ned th P s eas le and sa e n the treatment of gastrointestinal and gynecological cancer with the peritoneal cancer index (PCI) of 10 or less. Gynecologic cancer does not have data of the laparoscopic randomized control tr al stud ng o S th P ut there s rom s ng uture de ends on re ousl limited experience.
101 December 19 Sarikapan Wilailak
urrent Pos t on Pro essor o stetr cs necolog De ut Dean or Academ cs ulture amath od os tal Mah dol th n ers t ang o ha land 601 Room
December 19 ducat on 19 2 .Sc. (Med cal Sc ence) Facult o Sc ence hulalong orn n ers t ang o ha land 19 M.D. Facult o Med c ne hulalong orn n ers t ang o ha land 19 raduate D loma n l n cal Sc ence ( . ) Facult o Med c ne th
603 Room amath od os tal Mah dol n ers t ang o ha land 1990 D loma ha oard o stetr cs and necolog 199 ert cate s t ng Fello n necolog c ncolog at ohns o ns os tal Mar land .S.A. 199 D loma ha Su oard o necolog c ncolog 201 D loma at onal De ence ollege he at onal De ence ourse lass 9 December 20
Professional Experiences (Top 5): omm ttee ha r o ncolg As a cean a Federat on o stetr cs and naecolog (A F )
th nternat onal Federat on o stetr cs and g necolog (F ) omm ttee or naecolog c 601 Room ncolog ounc l Mem er As an Soc et o necolog c ncolog (AS ) and As an necolog c ncolog rou (A ) Past Pres dent o the ha necolog c ancer Soc et ( S) d tor al Ad sor o the ournal o necolog c ncolog ( ) December 20 th 603 Room
102 Cancer During Pregnancy: A Big Challenge
Sar a an W la la
Cancer during pregnancy is a rare event, occurring approximately once per 1,000 regnanc es annuall (0.0 to 0.1 o all mal gnant tumors). he most common mal gnanc es assoc ated th regnanc are melanoma reast cancer cer cal cancer l m homas and leu em as res ect el . Ph s olog cal changes dur ng regnanc nclud ng hormonal changes mmunolog cal suppression and increased permeability and vascularization of pregnancy, effect the olog o cancer that occurs dur ng regnanc . he dent cat on o cancer dur ng regnanc s challeng ng. Ph s olog cal changes that occur dur ng regnanc can dela ro er n est gat on o an underl ng neo lasm. S gns and s m toms commonl seen n cancer ma o erla and e mas ed h s olog cal changes that occur dur ng regnanc . here ore careta ers m ght eas l attr ute the s m toms o an und agnosed cancer to regnanc tsel and do not roceed th urther n est gat on hen needed. n add t on concerns about the exposure of the fetus to inherent risks of complementary examination, such as ionizing radiation, contrasts and surgical/anesthetic procedures, might make h s c ans less rone to mmed atel roceed th the n est gat on o those s m toms. ommonl used tumor mar ers A 1 3 S A 12 and AFP le els are ncreased n regnanc and conse uentl are not rel a le. here s ro ust e dence regard ng the sa et o surg cal rocedures and use o anesthet cs n regnant omen. he r s o maternal death s not ncreased nor s t assoc ated th rth de ects. St ll the r s o m scarr age s sl ghtl ele ated (1 2 ) es ec all dur ng the rst tr mester. here s also an ncrease r s n the l el hood o lo rth e ght and remature del er (1. 2 t mes relat e r s ). ad othera s not rout nel recommended dur ng regnanc and should e ost oned unt l a ter ch ld rth hene er oss le. Most chemothera eut c agents ha e lo molecular e ght and cross the lacenta. t should e a o ded dur ng the rst tr mester. hemothera dur ng the second and th rd tr mester s cons dered relat el sa e. he h s olog cal changes that occur dur ng regnanc such as h er olem a enhanced renal he at c el m nat on and reduced al um n le els ma nter ere th the harmaco net cs o the chemothera eut cs. ancer n regnanc s also cons dered as an emot onal challenge for pregnant women and their family. The pregnancy period is characterized by s cholog cal stress o uncerta nt a out the mothers health and that o the a . o ach e e the est oss le outcomes o oth mother and a e en though th s cond t on s rare e must e are that mult d sc l nar care dur ng and a ter regnanc s cruc al.
103 December 19 Young Doctor Session/Oral Presentation
Roopjit Kaur Sahi
urrent Pos t on th
601 Room es dent (P ) De artment o stetr cs and necolog M hand garh December 19
ducat on Post raduate Med cal ducat on n stetr cs necolog Ma 201 resent o ernment Med cal ollege and os tal hand garh nd a
th MD ( achelor o Med c ne and achelor o Surger ) ul 2011 Mar 201 603 Room o ernment Med cal ollege and os tal hand garh nd a gh School ( rade 11 12) A r l 2009 Mar 2011 Sacred eart Sen or Secondar School hand garh nd a gh School ( rade 9 10) Mar 2006 Mar 2009 St. ose h s on ent School alandhar nd a December 20
Professional Experiences: eg stered Med cal Pract t oner A r l 201 Present Pun a Med cal ounc l th
601 Room Med cal cer A r l 201 Mar 201 lo al os tal alandhar nternsh an 2016 Mar 201 o ernment Med cal ollege and os tal hand garh. l n cal lect e Ped atr c e hrolog ct 2016 o 2016 December 20 December 20 Massachusetts eneral os tal ar ard Med cal ollege oston th th 603 Room 603 Room
10 Characterizing Adnexal Masses Using IOTA Logistic Regression Models, RMI and IOTA ADNEX Ultrasound Models: Experience of a Tertiary Care Centre in India
Authors Sah oel Sehgal A A l at on De t o stetr cs and necolog M hand garh nd a
ntroduct on Accurate assessment of an adnexal mass, whether benign or malignant, is important to decide the course of its clinical management. Ultrasonography by an expert examiner (subjective assessment) has been the best method to pre-operatively differentiate benign from malignant adnexal masses. However, expertise for assessment of an adnexal mass may not be available at all centers and prediction of ultrasound findings could vary between different examiners. Certain scoring systems have been developed with an effort to make ultrasound examination more objective. We have characterized the functioning of certain such models as RMI (Risk of Malignancy Index), IOTA og st c regress on models and A AD th th s research stud . Mater al Method t s a cross sect onal d agnost c stud h ch used ros ect el collected cl n cal and ultrasound data. Women aged between 14-75 years with an adnexal mass were included. Women th un locular th n alled c st not re u r ng surg cal nter ent on omen d agnosed th endometr os s P D and ecto c regnanc and omen not consent ng to e a art o the stud were excluded from the study. All omen enrolled n the stud under ent a trans ag nal trans a dom nal ultrasound. he examiner analyzed the mass using morphological and blood flow variables, keeping in mind the ultrasound terms and definitions defined for adnexal masses by IOTA. The reference standard was the h sto atholog cal d agnos s ost surger . Per ormance o the models as determ ned us ng measures o d scr m nat on and cal rat on. D scr m nator er ormance as calculated us ng cur es and A . D agnost c er ormance as assessed us ng sens t t s ec c t PP P and accurac th the r corres ond ng 9 con dence nter als. A alue 0.0 as cons dered stat st call s gn cant. esult the 9 at ents enrolled 2 (2 ) ere mal gnant nclud ng ( . ) orderl ne masses 11 (12.3 ) r mar n as e masses 9 (10 ) metastat c masses and 6 ( 2 ) ere en gn. Pred ct e arameters o 1 At cut o alue 12.1 sens t t 0. s ec c t 0.96 PP 0.92 P 0.9 Accurac 0.93 2 At cut o alue 6. sens t t 0.92 s ec c t 0.91 PP 0. 9 P 0.96 Accurac 0.91 M At cut o alue 9 . sens t t 0. s ec c t 0.9 PP 0. P 0.9 Accurac 0.90 AD At cut o alue13. sens t t 0. s ec c t 0.96 PP 0. P 0.96 Accurac 0.91 onclus ons A AD has a good d agnost c er ormance. Although t does su class the mal gnant mass et t does not ha e a good red ct e alue h le d erent at ng orderl ne rom earl stage o ar an cancer. 2 and AD had the est screen ng results amongst all models. These models could be highly useful in non-oncology referral centers or centers lacking expert ultrasound examiners to assess adnexal masses.
10 December 19 Young Doctor Session/Oral Presentation
Wen-Hsuan Lin
urrent Pos t on th
601 Room he th ear res dent o de artment o stetr cs necolog n Mac a Memor al os tal December 19
ducat on M.D. de artment o med c ne Mac a med cal college th 603 Room December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
106 Retrospective Analysis of Malignant Ovarian Germ Cell Tumor in MMH
Authors n Wen suan A l at on hang h h ong
ac ground o com are sur al e ect o the d erent treatment o mal gnant o ar an germ cell tumor. Ped atr c an and necolog st ha e d erent management or mal gnant o ar an germ cell tumor nclude stag ng s stem o erat on methods the cr ter a to er orm chemothera and chemothera reg men. Methods and esults Mater al and methods A retros ect e re e o med cal records nclude cl n cal and atholog cal data o the at ent o mal gnant germ cell tumor n Mac a Memor al os tal between 1997~2017 were performed. We analyzed distribution of histology, stage, the treatment outcomes n d erent surg cal treatment and e ther to er orm chemothera a ter surger or not. We also re staged the at ents n ed atr c grou rom stage system to FIGO stage system and analyze the progression free survival rate in different staging system. Treatment outcomes were analyzed by progression free survival rate, using a lan Me er method. esults In total, we analyzed 87 patients with malignant germ cell tumor. Of these patients, 67 cases are managed necolog st and 20 cases Ped atr c an. he med an age at d agnos s as 21 ears (2 ). he most common t e o h stolog s mmature teratoma ( .1 n 1). he rogress on ree sur al rate n S grou S o ar an c stectom ert l t s ar ng stag ng o erat on and com lete stag ng o erat on ere 100 100 .6 and 100 res ect el ( 0. com are S and ert l t s ar ng stag ng o erat on). Progress on ree sur al rate n P ( leom c n eto os de c s lat n) as 9 . and n ( leom c n eto os de car o lat n) as . ( 0.00 6). onclus on Fert l t s ar ng stag ng o erat on at least s standard surg cal methods as gu del ne recommendat on n adults. o e er less aggress e surg cal methods such as un lateral sal ngo oo horectom as ed atr c an s management ha e s m lar sur al rate. P reg men s an e ect e rst l ne chemothera and ha e etter sur al com are to reg men.
10 December 19 Young Doctor Session/Oral Presentation
Anila, (Tresa) Alukal
urrent Pos t on th
601 Room Fello sh tra nee n necolog cal ncolog December 19
ducat on M S MS ( stetr cs necolog ) D
th Professional Experiences (Top 5): 603 Room 1. Fello sh tra nee n necolog cal ncolog reg onal ancer entre h ru anantha uram erala nd a 2. Sen or es dent o ernment Med cal ollege hr ssur erala nd a 3. MS stetr cs necolog o ernment Med cal ollege hr ssur erala nd a . M S o ernment Med cal ollege h ru anantha uram erala nd a December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
10 Significance of LEEP Specimen Dimension in Predicting Margin Positivity and Persistent Disease for CIN
Authors An la resa Alu al ema P Suchetha S Dhan a D nesh Ale amma Mathe agathnath r shna hara Somanathan S aran th A l at on De t o necolog cal ncolog eg onal ancer entre h ru ana
ntroduct on er cal ntrae thel al neo las a ( ) s the recursor les on o cer cal cancer. ntreated high-grade CIN significantly increases the risk of developing invasive cancer. Conization is the main treatment. Loop electrosurgical excision procedure (LEEP) is the most common conization method used. The study aims to assess the risk factors associated with positive marg n and ers stent d sease a ter P or Mater al Method A total o 1 6 at ents ho under ent P dur ng 2011 201 ncluded n the stud . We analyzed the socio-demographic characteristics, colposcopy details, histopathology, d mens ons o P s ec men (th c ness length olume) . Pers stent d sease as h stolog call con rmed re eat P or h sterectom . esult Marg n os t t as seen n 33.3 o at ents. Pers stent d sease as ound n 26.2 o at ents on re eat P or h sterectom . here as s gn cant assoc at on et een marg n os t t and s ede score o and more a h gh grade les on on F P score nner marg n n ol ement P done n a s ngle ass. he cut o or marg n os t t as length o 0. 13 cm and th c ness o 0.3 cm. S gn cant assoc at on et een res dual d sease and marg n os t t ostmeno ausal status s ede score o and more h gh grade les on on F P score nner marg n n ol ement as o ser ed. he chance o res dual d sease as less the cone s ec men had m n mum length o 0. cm and m n mum th c ness o 0.6 cm. onclus ons Postmeno ausal omen and nner marg n os t t are m ortant red ct e actors or marg n os t t . Such at ents ha e a h gh chance o res dual d sease and should e e ther e t on close ollo u or cons der a re eat rocedure.
109 December 19 Young Doctor Session/Oral Presentation
Anila, (Tresa) Alukal
urrent Pos t on th
601 Room Fello sh tra nee n necolog cal ncolog December 19
ducat on M S MS ( stetr cs necolog ) D
th Professional Experiences (Top 5): 603 Room 1. Fello sh tra nee n necolog cal ncolog reg onal ancer entre h ru anantha uram erala nd a 2. Sen or es dent o ernment Med cal ollege hr ssur erala nd a 3. MS stetr cs necolog o ernment Med cal ollege hr ssur erala nd a . M S o ernment Med cal ollege h ru anantha uram erala nd a December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
110 CLINICAL PROFILE AND SURVIVAL OUTCOME OF ENDOMETRIAL CANCER WITH P 53 MUTATION
Authors An la resa Alu al Suchetha S ema P Dhan a D nesh S aran th S ndhu a r Ale amma Mathe Ash n umar A l at on De t o necolog cal ncolog eg onal ancer entre h ru ana
ntroduct on Molecular mar ers are m ortant rognost c actors n tumor d ssem nat on and earl recurrence o endometr al cancers along th age stage h stolog cal t e grade de th o m ometr al n ltrat on l m ho ascular n as on nodal n ol ement cer cal n ol ement. P 3 mutat on s an m ortant rognost c actor or oth serous and endometr o d cancers. he stud a ms to com are the cl n cal ro le and o erall sur al o endometr al cancers th and thout P 3 mutat on Mater al Method 63 at ents ho under ent surg cal stag ng or arc noma endometr um ere ncluded in the study.TP53 mutation status was determined based on p53 expression by Immunohistochemistry (IHC) as a p53 wild or p53 mutant type. Data analyzed for the cl n cal ro le 3 mutat on status on h stolog cal attern tumor grade stage o the d sease l m h node s read recurrence attern treatment rece ed t o ear d sease ree sur al and o erall sur al. esult ecurrence as noted n 12. at ents a ter 2 ears ollo u o h ch at ents had p53 mutation. Significant association was seen between p53 expression and high grade tumours, cervical involvement, myometrial invasion, adnexal involvement. The two-year o erall sur al o the 3 ld t e as 9 .1 and the 3 mutant t e as 92 . he t o ear d sease ree sur al or the 3 ld t e as 93.9 and the d sease ree sur al o the 3 mutant ar et as . . he 2 ear d sease ree sur al or endometr o d carc noma th 3 ld t e as 100 and 3 mutant ar et as 6.2 ( alue 0.033). onclus ons to assess somat c 3 mutat on should e done n all endometr al cancers rres ect e o the r h stolog . h s ma hel to dent the aggress e tumors es ec all among the endometr o d tumors there hel n lann ng ad u ant treatment and ollo u .
111 December 19 Young Doctor Session/Oral Presentation
Aswathy G Nath
urrent Pos t on th
601 Room Sen or es dent De t naecolog cal ncolog December 19
ducat on M S MS ( ) D F WS P naecolog cal ncolog
th Professional Experiences (Top 5): 603 Room 1. Sen or es dent De t naecolog cal ncolog h ru anantha uaram S nce anuar 2019 2. Fello sh n naecolog cal ncolog h ru anantha uaram Se tem er 2016 to Se tem er 201 3. Ass stant Pro essor De t ster cs naecolg S M Med cal college ar ala December 20 . l n cal assoc ate De t ster cs naecolg S Pattom h ru anantha uaram . un or es dent De t ster cs naecolg o t. Med cal ollege h ru anantha uram th 601 Room December 20 December 20 th th 603 Room 603 Room
112 Long Term Quality Of Life, Survival Outcome and Complications After Pelvic Exenteration for Gynecological Malignancies
Authors Dr As ath ath Dr ema P Dr Suchetha S Dr S aren th Dr Dhan a D Dr agath r shna A l at on h ru anantha uram
Background: Pelvic exenteration is a radical surgical treatment that removes all organs rom a erson s el c ca t . he rocedure lea es the erson th a ermanent colostom and ur nar d ers on. h s surger as n t all ntroduced as a all at e rocedure Brunschwing in 1948. Later exenteration procedure was considered as a therapeutic procedure for recurrent as well as advanced cases of carcinoma cervix, endometrium, vulva and ag na ecause o m ro ed sur al rate assoc ated th rocedure. F e ear o erall survival after pelvic exenteration ranges between 25 to 50 %. Recent developments in cancer tr als as ell as treatment a roach s g ng ncreased m ortance to ual t o l e so as to ncrease the num er o long term sur ors a ter treatment. A ms and ect es 1. To study functional quality of life in patients after pelvic exenteration for gynaecological mal gnanc es 2. o assess o erall and d sease ree sur al as ell as mmed ate and long term mor d t after pelvic exenteration Methods and esults ong term ual t o l e as ros ect el assessed dur ng ollo u s ts ( une 201 to Se tem er 2019) th the hel o 30 uest onna re and FA uest onna re ( al dated to local language) th ade uate erm ss on to use. Sur al outcomes and com l cat ons ere assessed retros ect el . ncluded 32 at ents who underwent pelvic exenteration for gynaecological malignancies, from January 2006 to Decem er 2016. Post o erat e com l cat ons ere graded accord ng to the la en D ndo grad ng. erall and d sease ree sur al as calculated us ng a lan Me er method and log ran test or stat st cal s gn cance. Med um ollo u er od as months. 1.2 has ade uate ollo u to ears. ut o 32 at ents 13 ere al e. ear as ell as ear o erall sur al as 3 . th a S o . . ear d sease ree sur al as 33.2 th a S o . . Med an S as 1 months th a S 9. 6 9 22.2 9. .Med an DFS as 1 months th a S o 6. 3 9 1. 2 2 . . 10 at ents had grade2 mmed ate com l cat ons and at ents hade grade3 late com l cat ons. A erage glo al health status role unct on ng emot onal unct on ng and h s cal unct on ng scores ere a o e 0 or all at ents and s m tom score as less than 0 onclus on Even though pelvic exenteration is a morbid and complicated surgery, it is associated with sur al outcome o 3 . at ears and the rocedure s ell tolerated th good Pro er counsell ng e ore surger regard ng ma or conse uences o th s rad cal surger s m ortant
113 December 19 Young Doctor Session/Oral Presentation
Aswathy G Nath
urrent Pos t on th
601 Room Sen or es dent De t naecolog cal ncolog December 19
ducat on M S MS ( ) D F WS P naecolog cal ncolog
th Professional Experiences (Top 5): 603 Room 1. Sen or es dent De t naecolog cal ncolog h ru anantha uaram S nce anuar 2019 2. Fello sh n naecolog cal ncolog h ru anantha uaram Se tem er 2016 to Se tem er 201 3. Ass stant Pro essor De t ster cs naecolg S M Med cal college ar ala December 20 . l n cal assoc ate De t ster cs naecolg S Pattom h ru anantha uaram . un or es dent De t ster cs naecolg o t. Med cal ollege h ru anantha uram th 601 Room December 20 December 20 th th 603 Room 603 Room
11 Vulvo-Vaginal Melanoma: 10-Year Experience From a Tertiary Care Center in India
Authors Dr As ath ath Dr S aren th Dr ema P Dr Suchetha S Dr Dhan a D Dr agath r shna A l at on h ru anantha uram
ac ground Melanomas are second most common ul ar cancer. Melanomas are tumors ar s ng rom gmented melanoc tes. Annual age ad usted nc dence rate o ul o ag nal melanomas n As ans s 1.03. nc dence o ag nal melanoma s st ll lo er com ared to ul al melanoma ut the are o er aggress e nature th oor rognos s. he deal management o ul o ag nal melanoma s st ll un no n. As the nc dences o these cancers are er less there are l m ted num ers o stud es to ormulate an deal treatment strateg or the same. he purpose of this study is to analyze the outcome of patients diagnosed with vulvo vaginal melanoma n a ma or tert ar care center n South nd a. Methods and esults etros ect e anal s s o case records o at ents ho under ent treatment or o s ro en ul o ag nal melanoma rom anuar 2006 to anuar 2016. Parameters assessed ere soc o demogra h c data o at ents age o d agnos s cl n cal resentat on d agnost c e aluat on treatment rocedures ost o erat e com l cat ons and ollo u data. erall and d sease ree sur al as calculated us ng a lan Me er method and log ran test for statistical significance. Data was analyzed after grouping patients into two categories metastat c grou and otent all curat e grou on the as s o status o d sease resentat on. the 12 at ents n the otent all curat e grou had ag nal melanoma and had ul al melanoma. Post meno ausal leed ng as the ma n com la nt o at ents th ag nal melanoma h le s ell ng or nodule or ul al melanoma. nl one at ent s al e and d sease ree among the ent re cohort. Med an o erall sur al o these at ents as 1 months th a standard de at on o 13.6. Med an d sease ree sur al as months th a standard de at on o .9. hree o these at ents had local recurrence and others had recurrence at d stant s te lung e ng the most common. Among e at ents n the metastat c grou lung as the most common s te o metastases ollo ed l er. Med an o erall sur al as onl 11 months th a standard de at on o 3. . onclus on ul o ag nal melanoma s an aggress e d sease th oor rognos s. Sur al outcomes are meager e en at ents resented th l m ted d sease. Ma or rognost c actors are stage of disease and lymph node status. Early diagnosis and surgical resection might extend o erall sur al
11 December 19 Young Doctor Session/Oral Presentation
Deepak Bose
urrent Pos t on th
601 Room M h necolog cal ncolog es dent De t o necolog cal ncolog eg onal ancer entre r andrum erala nd a December 19
ducat on M S D D ( )
th Professional Experiences (Top 5): 603 Room S ec al st n 3 ears Sen or es dent ( ) 1 ear December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
116 Role of Preoperative Evaluation and Prediction Models in Triaging Lymphadenectomy in Endometrial Cancers
Authors Dee a ose ema P Suchetha S Dhan a D nesh S aran th Preeth Ale amma Mathe A l at on De t o necolog cal ncolog De t o Surg cal ncolog De t o ostat st cs eg onal ancer entre r andrum erala
ntroduct on out ne l m hadenectom ma e an o ertreatment or endometr al cancer at ents. o re ent com l cat ons r s actors or l m h node metastas s should e dent ed to d st ngu sh the at ents ho m ght ene t more rom l m hadenectom than others. ne o the a ms o our stud as to assess the accurac o reo erat e d agnost c techn ues and relat onsh th nodal metastas s r s . he other o ect e as to e aluate the er ormance o r s models de sed rom actors resent n our stud o ulat on n red ct ng l m h node metastas s th res ect to an alread esta l shed model. Mater al Method A retros ect e stud as conducted on omen d agnosed th uterus con ned endometr al cancer and ho under ent surg cal stag ng th el c and or araaort c l m hadenectom rom our centre dur ng 1st ul 201 to 30th une 2019. Deta ls o preoperative myometrial infiltration extent on pelvic MRI and preoperative endometrial h stolog ere assessed. Per ormance o these d agnost c techn ues ere com ared th osto erat e m ometr al n as on and h stolog cal grades. s actors or nodal metastas s ere assessed us ng log st c regress on and t o r s models ere ro osed. he er ormance o these models ere com ared th that o model Stal erg that used r s actors such as grade 3 non endometr o d tumours and dee m ometr al n as on. esult 12 at ents ere ncluded n the stud . odal metastas s as seen n 1 . o at ents. he accurac o m ometr al n as on assessed reo erat e M as onl 9.3 h le preoperative diagnosis of high grade histology had an exactness of about 85.16%. Logistic regress on anal ses re ealed l m ho ascular n as on and non endometr o d h stolog to e significant risk factors, while tumour size >2cm, grade 3 and deep myometrial invasion were non s gn cant actors. s models em lo ng these actors re ealed sens t t o 9 9. s ec c t o . 69. and accurac o 63 1 h le the esta l shed“Stal erg”r s model elded sens t t o 3.6 s ec c t o 21.1 and accurac o 2 .91 . onclus ons Preo erat e M could not e cons dered to e an accurate measure o m ometr al n as on and hence could not e rel ed u on or gu d ng l m hadenectom . D rected r s models us ng s gn cant r s actors can etter red ct r s o nodal metastas s and thus a o d l m h node d ssect on n lo r s at ents. ur r s models had reasona l good sens t t n nodal metastas s red ct on and these models could e ut nto use a ter urther al dat on.
11 December 19 Young Doctor Session/Oral Presentation
Deepak Bose
urrent Pos t on th
601 Room M h necolog cal ncolog es dent De t o necolog cal ncolog eg onal ancer entre r andrum erala nd a December 19
ducat on M S D D ( )
th Professional Experiences (Top 5): 603 Room S ec al st n 3 ears Sen or es dent ( ) 1 ear December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
11 Prognostic Factors Affecting Outcomes of Surgically Treated Vulvar Malignancies – A Single Institution Experience
Authors ema P Suchetha S S aran th Dhan a D nesh Ale amma Mathe A l at on De t o necolog cal ncolog eg onal ancer entre r andrum erala nd a
ntroduct on o assess the cl n cal and h sto atholog cal eatures o surg call treated ul ar cancers actors go ern ng recurrence and to assess o erall and d sease ree sur al o ul ar cancers. Method etros ect e stud on omen ho under ent surg cal management a ter a d agnos s o ul ar neo lasms rom 1st anuar 2009 to 31st Decem er 2019 n our nst tut on. l n co atholog cal eatures treatment deta ls ollo u recurrence and sur al ere collected from medical records. Chi-square test and Fisher Exact test were used to compare categor cal data. s actors ere assessed us ng log st c regress on model. erall and d sease ree sur al ere calculated us ng the a lan Me er method. esult 1 at ents under ent surger n our centre or ul ar neo lasms dur ng the stud er od. these 33 (62 ) ere ul ar cancers o S h stolog o F stages A (9.1 ) (30.3 ) (1 .2 ) A (6.1 ) (9.1 ) (1 .2 ) (9.1 ). Most common procedure performed was radical local vulvar excision (58.8%), of which 66% required ngu no emoral node d ssect on. ecurrences ere seen n 1 o 33 at ents o h ch 2.6 had local 26.3 gro n and 21 had d stant recurrences. Factors such as h stolog cal grade, FIGO stage, lesion laterality, tumour size, node involvement and tumour margins ere not s gn cant n r s or recurrence. o e er ad u ant rad at on thera n nd cated cases s gn cantl reduced recurrences com ared to at ents ho d d not underta e the nd cated rad othera . Mult ar ate anal s s d d not eld an s gn cant rognost c actors. W th a med an ollo u o 0 months. ear o erall sur al as 6 and d sease ree sur al o . onclus on ur cohort o ul ar cancer at ents had a recurrence rate o 2. and o erall sur al o 76%. Major prognostic factors affecting recurrence were tumour size, stage, margin and nodal status although non s gn cant and ad u ant rad at on thera e ng s gn cant.
119 December 19 Young Doctor Session/Oral Presentation
Pallavi Verma
urrent Pos t on M. h Fello ( naecolog c ncolog ) at All nd a nst tute th
601 Room o Med cal Sc ences (A MS) sh esh December 19
ducat on M S D MS ( stetr cs naecolog ) F.MAS (Fello sh n M n mal access surger )
th Professional Experiences (Top 5): 603 Room 1. F rst ran ghest Percentage and cert cate o honour n MD ( stetr cs naecolog ) 2. F rst ran and cert cate o honour n hthalmolog n M S 3. ert cate o honour n Med c ne n M S . est a er a ard n con erence o Armed Forces nd a n 201 5. First rank in study leave and subspeciality entrance exam of Armed Forces India December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
120 Peripheral Primitive Neuroectodermal Tumor of Pelvis in Pregnancy: A Case Report
Authors Dr. Palla erma1 Dr. Amr ta aura 2 Dr. Pan a umar arg3 Dr. Am t Sehra at Dr. Shal n a aram Dr. a a hatur ed 6 Dr. Sand an ho dhur Dr. Parm ta ar A l at on M. h naecolog c ncolog ello and corres ond ng author1 Ass stant Pro essor stetr cs naecolog 2 Add t onal Pro essor(Surg cal ncolog )3 Ass stant Pro essor (Med cal ncolog ) Pro essor and ead o d s on o naecolog c ncolog Pro essor and ead o stetr cs naecolog 6 M. h nae ncolog Fello at All nd a nst tute o Med cal Sc ences(A MS) sh esh nd a
ac ground Pr m t e neuroectodermal tumors (P ) are h ghl mal gnant neo lasms com osed o small round cells o the neuroe thel al or g n and elong to same tumor am l as ng sarcoma. o ma n t es o P nclude central and er heral ased on locat on and cell o or g n. he t cal locat ons o P s are around the s eletal s stem ut the can ar se rom an so t t ssue. ere e re ort a rare el c so t t ssue P d agnosed dur ng regnanc . ect e n resent re ort e descr e o stetr c and oncolog cal outcome o a rare case o er heral P n a emale o 30 ee s gestat on th mult modal management. nter ent on and outcome 23 ears old lad re orted to our centre at 30 ee s o pregnancy with recurrent left adnexal mass. She underwent laparotomy for left adnexal mass at local hos tal h ch as re orted as mal gnant round cell tumor (P ) h sto atholog call . Pat ent as lost to ollo u a ter surger and de elo ed recurrence. At our centre, patient was evaluated by imaging and repeat biopsy from adnexal mass, which showed PNET. Patient and relatives were explained about grave prognosis and neoadjuvant chemothera ut the re used n e o regnanc . She under ent elect e class cal cesarean sect on and del ered health a at 36 ee s gestat on. ntrao erat el a large friable mass of 15x10 cm size occupying whole of lower pelvic region left side, infiltrating er toneum el c and a dom nal all along th mult le metastat c de os ts ere seen o er uterus and omentum. and F S stud o o s s ec men re ealed strong d use os t e or D99 n tumor cells and os t e or chromosome 22 12 gene rearrangement suggest e o ng s sarcoma. She as lanned or s stem c chemothera ollo ed assessment or res dual d sease. She rece ed 6 c cles o A reg men ( ncr st ne Act nom c n D clo hos ham de) and 1 c cle o ( os am de to os de). Pat ent had res dual d sease n a dom nal all and ar etal er toneum. She under ent wide local excision of residual disease with mesh based abdominoplasty. Her final h sto atholog con rmed ng sarcoma th resected marg ns negat e. She as g en ad u ant chemothera ( ). She s under regular ollo u . onclus on P s h ghl aggress e and un ersal gu del nes n regnanc are not a l ca le due to rarity of disease. 5-year survival of localized disease is 50–60%, while relapsed and metastat c at ents ha e ear sur al less than 20 . n ad anced stage A ollo ed com lete tumor resect on and ad u ant thera s est oss le management a roach n order to m ro e sur al and ual t o l e.
121 December 19 Young Doctor Session/Oral Presentation
Anandita
urrent Pos t on th
601 Room Mch es dent De artment o g necolog cal oncolog Amr ta nst tute o med cal sc ences och December 19
ducat on M S D
th Professional Experiences (Top 5): 603 Room A ter ostgraduat on 1 ear and 6 months sen or res denc n delh go ernemt hos tal n o stetr cs and g necolog December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
122 Comparison of Effect of postoperative coffee / tea consumption on gastrointestinal function after abdominal surgery
Authors Dr. Anand ta Dr. Anu ama D de artment o g necolog cal oncolog A MS
ntroduct on Postoperative ileus is the most common, frustrating and one of the expected complication o ntra a dom nal surger . he atho h s olog o osto erat e leus s mult actor al. o ee and tea are the most common e erages used orld de. o ee st mulates motor act t o the large ntest ne th n a e m nutes a ter nta e and the he gastro net c e ects o lac tea on gastro ntest nal mot l t ere stud ed oth n o and n tro. en though the mechan sm o act on o co ee s not ull no n currentl a a la le l terature demonstrates a s gn cant m ro ement n gastro ntest nal mot l t thout ha ng an m act on osto erat e mor d t . o th s o ular e erage. A m o th s stud s to com are the e ect o co ee tea on osto erat e gastro ntest nal unct on. Method h s s a s ngle nst tut onal lot stud carr ed out at a teach ng hos tal n south nd a. Stud er od as rom 1 ul 2020 to 30 o em er 2020. Pat ents undergo ng la arotom or en gn and mal gnant d seases n the de artment o g necolog cal oncolog ere ncluded n the stud . he at ent re u r ng s ta and ntest nal resect on anastomos s were excluded . ethical clearance from the ethical committee of the hospital obtained. n ormed consent ta en orm the at ents. Pr mar o ect e as to com are the t me to rst latus n osto erat e at ents et een co ee and tea consum t on and secondar o ect es to com are the t me to rst de ecat on tolerance o rst sol d ood and length o hos tal sta et een the 2 grou s. Post surger once the P status o the at ent as over, then on randomization basis, black tea or black coffee 100 ml was given two times a da th 0 mg o ca e ne n a cu o co ee and 0 mg ca e ne n a cu o tea. esult 0 at ents ere ta en 20 n each grou . n co ee grou mean t me to rst latus as 20 hours com ared to 32 hours n tea grou and alue (0.000 ). me to rst stool and tolerance o sol d ood as 3 and 32 hours n co ee grou res ect el and 3 and hours n tea grou res ect el alue e ng s gn cant n oth grou s.Posto erat e sta as hours n co ee grou and 6 hours n tea grou . P alue (0.0 ). he more content o ca e ne n a cu o co ee than tea must ha e een contr uted to the more gastro net c e ect o co ee. onclus ons he at ents th Posto erat e co ee consum t on had earl return o gastro ntest nal unct on as com ared to tea consum t on. And hence to loo nto the e ect on postoperative hospital stay, randomized control trail with large sample size can be conducted.
123 December 19 Young Doctor Session/Oral Presentation
Madhavi Dokku
urrent Pos t on th
601 Room Mch neconcolog es dent Amr ta nst tute o Med cal Sc ences and esearch entre December 19
ducat on S P SP A F nal ear M neconcolog res dent Amr ta nst tute o med cal sc ences erala.
th P S AD A M.S (2010 2013) Med t nst tute Med cal Sc ences ollege 603 Room han ur. AD A M S (2002 200 ) S S Med cal ollege Maha oo nagar
Professional Experiences (Top 5): Fello o he Assoc at on o M n mal Access Surgeons o nd a (FMAS) December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
12 Outcomes of Medical Management of Atypical Endometrial Hyperplasia Treated at Single Institution
Authors Madha Do u Anu ama a an a u A l at on De t o necolog cal ncolog
ntroduct on At cal ndometr al h er las a s a remal gnant les on o uterus th h gh r s o progression or coexistence with endometrial carcinoma. he o t mal treatment re u res remo al o uterus and o ar es ut ll result n loss o ert l t h ch s not acce ted all. ut ho e er there are no consensus on the deal med cal management rotocol hence ar ng reg mens are used n cl n cal ract ces. A m o the resent stud s to assess the res onse rate to med cal management and also to loo nto outcomes o med cal management n at ents th n ert l t as ell as the most common reg men assoc ated th regress on n th s grou o at ents. Mater al and Methods h s s a s ngle nst tut on retros ect e anal s s th data retr e ed rom electron c med cal records. Stud er od as rom anuar 201 to anuar 2020. All at ents th at cal endometr al h er las a undergo ng med cal management ere ncluded. Pat ents th endometr al carc noma undergo ng med cal management and at cal h er las a undergo ng surgery without medical management were excluded. Statistical analysis was done with IBM SPSS 20. (SPSS nc h cago SA). o o ta n assoc at on o categor cal ar a les ch s uare test as a l ed cons der ng P alue o 0.0 as stat st call s gn cant. esults Dur ng th s er od 320 at ents had at cal h er las a o the endometr um out o h ch 19 t nto the nclus on cr ter a. Pat ents th m ss ng ollo u data and no re eat o s after medical management were excluded from the analysis. 134 patients were included for final analysis. The most common progesterone used was medroxy progesterone acetate. egress on as seen n 10 at ents and o erall res onse rate as 9. . es onse rate o recommended rogesterone s other rogesterone reg mens ere assessed and the treatment res onse as not stat st call s gn cant (χ2 0.06 3 0.9 ). n su grou anal s s o 10 at ents th n ert l t the treatment res onse rate as 100 . Megestrol acetate 0 mg D or 3 months as the most common reg men used. hree at ents conce ed ollo ng n ert l t treatment dur ng a mean ollo u er od o 2 months and the conce t on rates as 30 . onclus on t seems the e cac o an rogesterone thera a ears s m lar and reg men ar at on s seen n cl n cal ract ces. Megestrol 0 mg D or a m n mum er od o 3 months as most common reg men assoc ated th res onse n at ents th n ert l t . here s need or ros ect e stud es to determ ne the o t mal management n at cal endometr al h er las a es ec all n n ert l t grou .
12 December 19 Young Doctor Session/Oral Presentation
Sue-Jar Chen
urrent Pos t on th
601 Room Fello necolog c ncolog Mac a Memor al os tal a an December 19
ducat on M.D a e Med cal n ers t ( M )
th Professional Experiences (Top 5): 603 Room 201 201 es dent De artment o stetr cs and necolog Mac a Memor al. os tal a an 201 2019 h e es dent De artment o stetr cs and necolog Mac a Memor al. os tal a an 2019 t ll no Fello necolog c ncolog De artment o stetr cs and necolog December 20 Mac a Memor al os tal a an th 601 Room December 20 December 20 th th 603 Room 603 Room
126 Can Chemotherapy Effectively Control the Metastatic Lymph Node in Epithelial Ovarian Cancer?: An Analysis of the Recurrent Pattern
Authors Sue ar hen1 uh heng ang1, Tze-Chien Chen1 en ue hen1 h a Su Weng1 h h ong hang1 2 A l at on De artment o stetr cs and necolog Mac a Memor al os tal1 Mac a Med cal ollege2
ac ground he e cac o chemothera on metastat c l m h node n e thel al o ar an cancer s st ll contro ers al. h s stud a med to n est gate the s te o treatment a lure and cl n cal outcome n e thel al o ar an cancer at ents ho n t all resented th l m h node n ol ement. Methods and esults A retros ect e cohort stud as conducted o omen d agnosed th ad anced ( nternat onal Federat on o necolog and stetr cs stage ) e thel al o ar an cancer th no n l m h node n ol ement status rom 200 to 201 at Mac a memor al hos tal ho ere treated th r mar c toreduct e surger ollo ed lat num ased ad u ant chemothera . Med cal records ere re e ed to assess or the locat on o rst recurrence. Anal s s o s tes o treatment a lure and n t al nodal status as er ormed. A total o 11 omen ere dent ed. these 6 ( .3 ) had n t all l m h node n ol ement and 3 (6 .2 ) o them recurred h le the rate o recurrence n at ents thout n t all nodal n ol ement as 2.0 . D str ut on o h stolog su t e rate o o t mal de ul ng and mean num er o remo ed nodes dur ng r mar c toreduct e surger ere s m lar et een the t o grou s. reatment a lure n l m h node as ound n 1 (26.9 ) at ents th n t all l m h node n ol ement and onl n 6 (12.0 ) at ents thout n t all nodal n ol ement ( 0.04). The rate of isolated lymph node relapse (without extranodal treatment failure) was also s gn cantl h gher n at ents th n t all l m h node n ol ement (13. ersus 2.0 n at ents thout n t all l m h node n ol ement 0.0 ). ntra er toneal treatment a lure and d stant rela se ere s m lar n re uenc et een the t o grou s ( ntra er toneal a lure 3 .3 ersus 3 .0 and d stant rela se 2 . ersus 22.0 ). here as no s gn cant d erence n med an rogress on ree sur al and o erall sur al n at ents th n t all l m h node n ol ement ersus those thout n t all nodal metastas s (PFS 1 .0 and 13.0 months S 6.0 and 2.0 months res ect el ). onclus on n our stud the rate o treatment a lure n l m h node and solated l m h node rela se oth a eared to e more re uent n at ents th n t all nodal n ol ement h le the rate o ntra er toneal d sease or d stant rela se ere s m lar among at ents th or thout n t all l m h node metastas s. hemothera seems to e less e ect el n nodal metastat c d sease than n the ntra er toneal or d stant d sease. o e er no s gn cant d erence as o ser ed n the rogress on or o erall sur al et een the t o grou s.
12 December 19 Young Doctor Session/Oral Presentation
Anjana JS
urrent Pos t on th
601 Room Mch student December 19
ducat on M S MD stetr cs and necolog
th Professional Experiences (Top 5): 603 Room Sen or res dent o stetr cs and g necolog or 2 ears December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
12 Outcome of Advanced Malignant Germ Cell Tumor Ovary After Neoadjuvant Chemotherapy and Surgery
Authors An ana S Suchetha S ema P Franc s Dhan a D nesh S aran th As n umar Ale amma Mathe A l at on De t o necolog cal ncolog
ntroduct on Mal gnant erm cell tumours (M s) are rare tumours that account or 2 3 o all o ar an cancers. he generall occur n adolescents and oung omen o re roduct e age grou . Fert l t s ar ng surger hene er eas le th or thout ad u ant chemothera s the standard treatment a roach. ront ert l t s ar ng surger ma not e eas le n at ents th ad anced stage d sease due to oor er ormance status large tumour load lateral o ar an d sease or large tumours n ltrat ng the uterus. eoad u ant chemothera ( A ) ollo ed conser at e surger m ght e cons dered or such at ents. h s stud a med to anal se the outcome o at ents th ad anced mal gnant germ cell tumour o ar ho under ent A ollo ed surger and to assess the menstrual and re roduct e unct on n those at ents ho under ent conser at e surger . Mater al Method Data rom 2 at ents ho under ent de ul ng surger ollo ng neoad u ant chemothera or ad anced germ cell tumour o ar rom anuar 200 to March 2019 ere collected and anal sed. esult he med an ollo u er od as 6 months (range to 133 months). he med an age as 16. ears (range to 31 ears). ent our ( . ) at ents under ent ert l t s ar ng surger . o at ents o ted or h sterectom and lateral sal ngo oo horectom as the had com leted the r am l and another t o under ent lateral sal ngo oo horectom or res dual d sease. A com lete atholog cal res onse rate as seen n 2 ( 9.3 ) at ents. o at ents ere lost to ollo u one o hom as regnant at the t me o the last ollo u . ne at ent ho n t all resented th stage D sgerm noma d ed 6 months a ter surger due to d sease recurrence. the rema n ng at ents 1 re orted menstruat on ollo ng treatment. o at ents ere d agnosed th r mar amenorrhoea and 2 are st ll remenarchal. hree at ents tr ed or regnanc and had a total o regnanc es. onclus ons When o t mal c toreduct on s not eas le A ollo ed nter al c toreduct on m ght e cons dered n at ents th ad anced mal gnant germ cell tumour. eoad u ant chemothera ma es com lete c toreduct on oss le n these at ents h le reser ng ert l t and s assoc ated th a good re roduct e outcome.
129 December 19 Young Doctor Session/Oral Presentation
Anjana JS
urrent Pos t on th
601 Room Mch student December 19
ducat on M S MD stetr cs and necolog
th Professional Experiences (Top 5): 603 Room Sen or res dent o stetr cs and g necolog or 2 ears December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
130 Correlation Between Cervical Cytology, Colposcopic Biopsy and Final Histopathology After LEEP in Patients With CIN - A Single Institution Experience
Authors An ana S ema P Suchetha S Dhan a D nesh S aran th A l at on De t o necolog cal ncolog
ntroduct on er cal cancer s a otent all re enta le d sease due to ts long re n as e stage. W th e ect e screen ng the nc dence o cer cal cancer has decreased n de elo ed countr es h le n de elo ng countr es l e nd a the urden o the d sease s st ll h gh. n nd a cer cal cancer s the second most re uentl detected cancer among omen.). n 2012 Amer can Soc et or ol osco and er cal Patholog (AS P) recommended e ther immediate excision of the transformation zone or colposcopy and biopsy for non-pregnant omen aged 2 ears or older th S . We conducted th s retros ect e stud to assess the correlat on et een cer cal c tolog col osco c o s and nal h stolog n at ents who underwent Loop electrosurgical excision procedure at our institution. Mater al Method h s s a retros ect e aud t o at ents ho under ent P at our nst tut on rom anuar 201 to Se tem er 2019. Data as collected rom med cal records a out at ent demogra h cs cl n cal s m toms col osco c nd ngs c tolog and h sto atholog cal re orts. he correlat on as assessed a a stat st cs. esult A total o 1 at ents under ent P dur ng th s t me er od. he mean age o at ents n th s stud as rs (2 2 rs). tolog re orts cons sted o S ( . ) S (1 .3 ) Squamous cell carcinoma (4.8%), atypical squamous cells cannot exclude HSIL (ASC-H) (3.4%) and at cal s uamous cells o undeterm ned s gn cance (AS S) (2 ). er cal o s h sto atholog as 3 (61.9 ) 2 (12.9 ) 1 (13.6 ) carc noma (2 ) and normal ( . ). P h sto atholog sho ed 2 3 (66 ) 1 (1 .3 ) n as e carc noma (6. ) and normal (12.9 ). Around 0 o at ents th h gh grade c tolog had 2 and h gher les ons n P s ec mens. t as also noted that n at ents th h gh grade cer cal c tolog there as a su stant al agreement et een col osco c o s re ort and P h stolog ( a a 0.60 alue 0.001). onclus ons ol osco c o s sho ed su stant al agreement th nal h sto atholog a ter P n at ents th AS S c tolog .
131 December 19 Young Doctor Session/Oral Presentation
Sarita Kumari
urrent Pos t on th
601 Room Fello n naecolog c oncolog D s on o naecolog c ncolog De artment o stetr cs and naecolog All nd a nst tute o Med cal Sc ences e Delh December 19
ducat on M S MD M. h Sen or res dent (academ c) D s on o necolog c ncolog De artment o stetr cs and necolog A MS e Delh
th Professional Experiences (Top 5): 603 Room Presentat ons Poster resentat on t tled“ ar an cancer mas uerad ng as cer cal carc noma a d agnost c d lemma” n th or sho o As an Soc et o necolog c ncolog n e u l c o orea n August 201 . Awards: First prize for slogan for FIGO-FOGSI cervical cancer elimination initiative 2020 Second runner n a er resentat on at A n o em er 201 December 20 Pu l cat ons a) umar S De a D Dadh al Perumal . orrelat on o etal lood essel Do ler measurements with fetal anaemia among Rhesus isoimmunized pregnancies after two ntrauter ne trans us ons. nt necol stet. 2019 1 6(2) 21 222. ) umar S. naecolog c cancer care dur ng D 19 andem c n nd a a soc al med a th
601 Room sur e . ancer e orts. 2020 3 e12 0. htt s do .org 10.1002 cnr2.12 0 c) umar S Sharma . ecurrent mmature teratoma n a ear old th maturat on n su se uent la arotom es and a gra e course. uro ean ournal o naecolog cal ncolog 2020 1( ) 13 16. d) umar S umar S Meena S nghal S. ru en erg umour th ccult astr c Pr mar December 20 December 20 n a 20 ear ld Present ng th Amenorrhea as n t al S m tom. l n ncol. 2020 1 . th th 603 Room 603 Room
132 Role of Cancer Testis Antigen POTE-E in Preoperative Diagnosis of Epithelial Ovarian Tumors: A Pilot Study
Authors umar S1 hatla 1 Sharma A2 Mathur S3 Perumal 1 Meena 1 umar umar S1 A l at on 1D s on o naecolog c ncolog De artment o stetr cs and naecolog 2De artment o ochem str 3De artment o Patholog and De artment o Med cal ncolog All nd a nst tute o Med cal Sc ences e Delh nd a
ac ground ar an cancer s the th rd most common mal gnanc n nd an omen. lo all there ere 29 1 ne cases and 1 99 deaths n 201 and As a had the h ghest reg onal incidence and mortality. Only 16% cases of Epithelial ovarian cancer (EOC) are localized at resentat on and earl d agnos s ecomes essent al or etter sur al. A12 has een the est tumour mar er ut s ele ated onl n 0 n earl stages. era et al descr ed the identification of a novel gene family POTE, which is selectively expressed in prostate, test s o ar and lacenta as ell as n rostate cancer. Anal ses us ng cD As rom cancer samples showed that POTE is frequently expressed in ovarian cancer. Methods and esults Aim of our study was to study the expression of POTE-E antigen in EOC, correlate the expression with clinico-pathological characteristics and evaluate its potential as a tumour omar er. A total o 12 omen ere recru ted ros ect el 0 n grou ( ) 0 n grou ( en gn o ar an d sease) and 2 n grou (health controls) a ter ul ll ng inclusion and exclusion criteria. Serum POTE-E values were obtained for all three groups. Serum A12 as o ta ned n grou s and . Med an age o omen n grou s and as 0 and 3 ears res ect el . n grou s and 92.0 and 6.0 cases had ele ated A12 res ect el . here as stat st call s gn cant d erence n med an serum alues et een t o grou s ( .001). A cut o o 132. ml and A o 0. 2 had a sens t t o 0.0 and s ec c t o 0.0 to d st ngu sh et een and en gn o ar an d sease ( .000). Med an alue o serum P ar ed s gn cantl among three grou s ( .000). At a cut o o 92. g ml and A o 0.99 serum P had a sens t t o 96.0 and s ec c t o 100.0 to d st ngu sh and health controls ( .000). At a cut o o 323. g ml and A o 0. 93 serum P had a sens t t o 6 .0 and s ec c t o 2.0 to d st ngu sh et een and en gn o ar an d sease ( .000). Serum alues d d not ar s gn cantl et een stage ( . 00) and grade ( .602) o tumour. onclus on n th s rel m nar stud on a no el tumour mar er e ound that serum P has a good d agnost c accurac to d st ngu sh et een en gn o ar an tumour and health controls, however further validation in larger sample size is required.
133 December 19 Young Doctor Session/Oral Presentation
AMULYA B
urrent Pos t on th
601 Room Ass stant Pro essor n Sa thag r nst tute o med cal sc ences December 19
ducat on M S MD F WS P APA S P
Professional Experiences (Top 5):
th S S D A S M D A A A A A A A 1 A 9 603 Room M S A A A P A SP A D A AD M S ASS S A P F SS A SAP A S F M D A S S A A 1 A M S W DA . December 20 th 601 Room December 20 December 20 th th 603 Room 603 Room
13 Case Series of Non Epithelial Ovarian Cancers
Authors oddu A A l at on De t o stetr cs and naecolog
ntroduct on on e thel al o ar an cancers com r se 10 1 o all o ar an cancers. one thel al ovarian cancers include malignancies of germ cell origin, sex cord–stromal cell origin, metastatic carcinomas to the ovary, and a variety of extremely rare ovarian cancers like sarcomas. Present ng a ser es o e cases o non e thel al o ar an cancers h ch ere adult granulosa cell tumour mal gnant rothel oma mal gnant germ cell tumor mal gnant mixed mullerian tumor of ovary and ovarian collision tumor. Mater als and methods A retros ect e stud as done at de artment o stetr cs and naecolog Sa thag r nst tute o med cal sc ences nd a. Data o o ar an cancer cases o erated rom 201 2020 as collected. ases o non e thel al o ar an cancers ere selected. esults F e cases o non e thel al o ar an cancers ere o ta ned rom the records. F rst case as ear old emale th carc noma o ar stage c ost 3 c cles o neoad u ant chemothera had ancer Ant gen ( A) 12 o 1000 un ts m ll l tre ( ml). She under ent nter al de ul ng and as d agnosed th o ar an coll s on tumor com r s ng o h gh grade serous c stadenocarc noma and mmature teratoma stage . Second case is a 24 year old unmarried girl presented with pain abdomen, left adnexal mass and raised lactate dehydrogenase(LDH) enzyme. Patient underwent total abdominal h sterectom ( A ) th lateral sal ngoo horectom ( S ) th omentectom and el c l m h node d ssect on(P D) n e o stage . sto atholog re ealed Mal gnant germ cell tumor ( ol sac d sgerm noma em r on c carc noma). h rd case as a 6 ear old female post hysterectomy presented with pain abdomen, 15 x 10 cm solid pelvic mass not separate from ovaries on imaging. Patient underwent explorative laparotomy+ovariotomy+ P D mesenter c l m h node sam l ng n racol c omentectom . sto atholog re ealed mal gnant rothel oma. Fourth case as 6 ear old emale ho resented th mass er abdomen. CT scan suggested 21 x 18 cm malignant ovarian mass, CA 125 was 275 U/ml. Patient underwent exploratory laparotomy+TAH+BSO+PLND+infracolic omentectomy. Post operative histopathology showed malignant mixed mullerian tumor. Patient expired after 1 month o surger due to des read metastas s. F th case as a 3 ear old emale th a n a domen s nce 2 months th r ght o ar an tumor on mag ng and A 12 o 111 ml. Pat ent under ent stag ng la arotom . sto atholog re ealed adult granulosa cell tumor stage A. onclus on on e thel al o ar an tumors are uncommon tumours resent ng at an ad anced stage. Management de ends on ade uate surg cal stag ng and h sto atholog .
13 Official Sponsor
臺灣阿斯特捷利康股份有限公司 百特醫療產品股份有限公司 AstraZeneca Taiwan Limited Baxter Healthcare Ltd.
美商默沙東藥廠股份有限公司台灣分公司 羅氏大藥廠股份有限公司 MSD Roche Products Ltd.
台灣武田藥品工業股份有限公司 台灣東洋藥品工業股份有限公司 Takeda Pharmaceutical Company Limited TTY Biopharm
136 Official Sponsor
13 13 139